
<html lang="en"     class="pb-page"  data-request-id="aad8e13f-c994-426e-97cc-36e886b30fcb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.5b00301;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2015.58.issue-18;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases" /></meta><meta name="dc.Creator" content="Luc J.  Farmer" /></meta><meta name="dc.Creator" content="Mark W.  Ledeboer" /></meta><meta name="dc.Creator" content="Thomas  Hoock" /></meta><meta name="dc.Creator" content="Michael J.  Arnost" /></meta><meta name="dc.Creator" content="Randy S.  Bethiel" /></meta><meta name="dc.Creator" content="Youssef L.  Bennani" /></meta><meta name="dc.Creator" content="James J.  Black" /></meta><meta name="dc.Creator" content="Christopher L.  Brummel" /></meta><meta name="dc.Creator" content="Ananthsrinivas  Chakilam" /></meta><meta name="dc.Creator" content="Warren A.  Dorsch" /></meta><meta name="dc.Creator" content="Bin  Fan" /></meta><meta name="dc.Creator" content="John E.  Cochran" /></meta><meta name="dc.Creator" content="Summer  Halas" /></meta><meta name="dc.Creator" content="Edmund M.  Harrington" /></meta><meta name="dc.Creator" content="James K.  Hogan" /></meta><meta name="dc.Creator" content="David  Howe" /></meta><meta name="dc.Creator" content="Hui  Huang" /></meta><meta name="dc.Creator" content="Dylan H.  Jacobs" /></meta><meta name="dc.Creator" content="Leena M.  Laitinen" /></meta><meta name="dc.Creator" content="Shengkai  Liao" /></meta><meta name="dc.Creator" content="Sudipta  Mahajan" /></meta><meta name="dc.Creator" content="Valerie  Marone" /></meta><meta name="dc.Creator" content="Gabriel  Martinez-Botella" /></meta><meta name="dc.Creator" content="Pamela  McCarthy" /></meta><meta name="dc.Creator" content="David  Messersmith" /></meta><meta name="dc.Creator" content="Mark  Namchuk" /></meta><meta name="dc.Creator" content="Luke  Oh" /></meta><meta name="dc.Creator" content="Marina S.  Penney" /></meta><meta name="dc.Creator" content="Albert C.  Pierce" /></meta><meta name="dc.Creator" content="Scott A.  Raybuck" /></meta><meta name="dc.Creator" content="Arthur  Rugg" /></meta><meta name="dc.Creator" content="Francesco G.  Salituro" /></meta><meta name="dc.Creator" content="Kumkum  Saxena" /></meta><meta name="dc.Creator" content="Dean  Shannon" /></meta><meta name="dc.Creator" content="Dina  Shlyakter" /></meta><meta name="dc.Creator" content="Lora  Swenson" /></meta><meta name="dc.Creator" content="Shi-Kai  Tian" /></meta><meta name="dc.Creator" content="Christopher  Town" /></meta><meta name="dc.Creator" content="Jian  Wang" /></meta><meta name="dc.Creator" content="Tiansheng  Wang" /></meta><meta name="dc.Creator" content="M. Woods  Wannamaker" /></meta><meta name="dc.Creator" content="Raymond J.  Winquist" /></meta><meta name="dc.Creator" content="Harmon J.  Zuccola" /></meta><meta name="dc.Description" content="While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), whic..." /></meta><meta name="Description" content="While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), whic..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 10, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00301" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00301" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00301" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00301" /></link>
        
    
    

<title>Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00301" /></meta><meta property="og:title" content="Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0012.jpeg" /></meta><meta property="og:description" content="While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00301"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00301">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00301&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00301&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00301&amp;href=/doi/10.1021/acs.jmedchem.5b00301" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 7195-7216</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b00602" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b00293" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luc+J.++Farmer">Luc J. Farmer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+W.++Ledeboer">Mark W. Ledeboer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Hoock">Thomas Hoock</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Arnost">Michael J. Arnost</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Randy+S.++Bethiel">Randy S. Bethiel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Youssef+L.++Bennani">Youssef L. Bennani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+J.++Black">James J. Black</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+L.++Brummel">Christopher L. Brummel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ananthsrinivas++Chakilam">Ananthsrinivas Chakilam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Warren+A.++Dorsch">Warren A. Dorsch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Fan">Bin Fan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+E.++Cochran">John E. Cochran</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Summer++Halas">Summer Halas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edmund+M.++Harrington">Edmund M. Harrington</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+K.++Hogan">James K. Hogan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Howe">David Howe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Huang">Hui Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dylan+H.++Jacobs">Dylan H. Jacobs</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leena+M.++Laitinen">Leena M. Laitinen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shengkai++Liao">Shengkai Liao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sudipta++Mahajan">Sudipta Mahajan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Valerie++Marone">Valerie Marone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gabriel++Martinez-Botella">Gabriel Martinez-Botella</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pamela++McCarthy">Pamela McCarthy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Messersmith">David Messersmith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Namchuk">Mark Namchuk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luke++Oh">Luke Oh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina+S.++Penney">Marina S. Penney</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Albert+C.++Pierce">Albert C. Pierce</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+A.++Raybuck">Scott A. Raybuck</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arthur++Rugg">Arthur Rugg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesco+G.++Salituro">Francesco G. Salituro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kumkum++Saxena">Kumkum Saxena</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean++Shannon">Dean Shannon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dina++Shlyakter">Dina Shlyakter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lora++Swenson">Lora Swenson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shi-Kai++Tian">Shi-Kai Tian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Town">Christopher Town</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Wang">Jian Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tiansheng++Wang">Tiansheng Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M.+Woods++Wannamaker">M. Woods Wannamaker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Raymond+J.++Winquist">Raymond J. Winquist</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Harmon+J.++Zuccola">Harmon J. Zuccola</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Vertex Pharmaceuticals (Canada) Inc., 275 Armand-Frappier, Laval, Québec H7V 4A7, Canada</span></div><div class="corresp-info"><strong>*</strong>Phone: 450-680-4656. Fax: 450-978-7972. E-mail: <a href="/cdn-cgi/l/email-protection#0b677e68546d6a79666e794b7d797f7325686466"><span class="__cf_email__" data-cfemail="7f130a1c20191e0d121a0d3f090d0b07511c1012">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone: 617-341-6309. Fax: 617-444-7825. E-mail: <a href="/cdn-cgi/l/email-protection#f994988b92a6959c9d9c9b969c8bb98f8b8d81d79a9694"><span class="__cf_email__" data-cfemail="88e5e9fae3d7e4edecedeae7edfac8fefafcf0a6ebe7e5">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00301&amp;href=/doi/10.1021%2Facs.jmedchem.5b00301" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 7195–7216</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 31, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 February 2015</li><li><span class="item_label"><b>Published</b> online</span>10 September 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 September 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00301" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00301</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7195%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLuc%2BJ.%2BFarmer%252C%2BMark%2BW.%2BLedeboer%252C%2BThomas%2BHoock%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D18%26contentID%3Dacs.jmedchem.5b00301%26title%3DDiscovery%2Bof%2BVX-509%2B%2528Decernotinib%2529%253A%2BA%2BPotent%2Band%2BSelective%2BJanus%2BKinase%2B3%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7216%26publicationDate%3DSeptember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00301"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5486</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">50</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00301" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Luc&quot;,&quot;last_name&quot;:&quot;J. Farmer&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;W. Ledeboer&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Hoock&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Arnost&quot;},{&quot;first_name&quot;:&quot;Randy&quot;,&quot;last_name&quot;:&quot;S. Bethiel&quot;},{&quot;first_name&quot;:&quot;Youssef&quot;,&quot;last_name&quot;:&quot;L. Bennani&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;J. Black&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;L. Brummel&quot;},{&quot;first_name&quot;:&quot;Ananthsrinivas&quot;,&quot;last_name&quot;:&quot;Chakilam&quot;},{&quot;first_name&quot;:&quot;Warren&quot;,&quot;last_name&quot;:&quot;A. Dorsch&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;E. Cochran&quot;},{&quot;first_name&quot;:&quot;Summer&quot;,&quot;last_name&quot;:&quot;Halas&quot;},{&quot;first_name&quot;:&quot;Edmund&quot;,&quot;last_name&quot;:&quot;M. Harrington&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;K. Hogan&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Howe&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Dylan&quot;,&quot;last_name&quot;:&quot;H. Jacobs&quot;},{&quot;first_name&quot;:&quot;Leena&quot;,&quot;last_name&quot;:&quot;M. Laitinen&quot;},{&quot;first_name&quot;:&quot;Shengkai&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Sudipta&quot;,&quot;last_name&quot;:&quot;Mahajan&quot;},{&quot;first_name&quot;:&quot;Valerie&quot;,&quot;last_name&quot;:&quot;Marone&quot;},{&quot;first_name&quot;:&quot;Gabriel&quot;,&quot;last_name&quot;:&quot;Martinez-Botella&quot;},{&quot;first_name&quot;:&quot;Pamela&quot;,&quot;last_name&quot;:&quot;McCarthy&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Messersmith&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Namchuk&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;Oh&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;S. Penney&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;C. Pierce&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;A. Raybuck&quot;},{&quot;first_name&quot;:&quot;Arthur&quot;,&quot;last_name&quot;:&quot;Rugg&quot;},{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;G. Salituro&quot;},{&quot;first_name&quot;:&quot;Kumkum&quot;,&quot;last_name&quot;:&quot;Saxena&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;Shannon&quot;},{&quot;first_name&quot;:&quot;Dina&quot;,&quot;last_name&quot;:&quot;Shlyakter&quot;},{&quot;first_name&quot;:&quot;Lora&quot;,&quot;last_name&quot;:&quot;Swenson&quot;},{&quot;first_name&quot;:&quot;Shi-Kai&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Town&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tiansheng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Woods Wannamaker&quot;},{&quot;first_name&quot;:&quot;Raymond&quot;,&quot;last_name&quot;:&quot;J. Winquist&quot;},{&quot;first_name&quot;:&quot;Harmon&quot;,&quot;last_name&quot;:&quot;J. Zuccola&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;7195-7216&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00301&quot;},&quot;abstract&quot;:&quot;While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00301&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00301" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00301&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00301" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00301&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00301" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00301&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00301&amp;href=/doi/10.1021/acs.jmedchem.5b00301" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00301" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00301" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00301%26sid%3Dliteratum%253Aachs%26pmid%3D26230873%26genre%3Darticle%26aulast%3DFarmer%26date%3D2015%26atitle%3DDiscovery%2Bof%2BVX-509%2B%2528Decernotinib%2529%253A%2BA%2BPotent%2Band%2BSelective%2BJanus%2BKinase%2B3%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D18%26spage%3D7195%26epage%3D7216%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/jmcmar.2015.58.issue-18/20150924/jmcmar.2015.58.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (<i>K</i><sub>i</sub>) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus kinase family of protein kinases consists of four members: JAK1, JAK2, JAK3, and TYK2. JAK3 expression is largely restricted to lymphocytes, which are cells central to the uncontrolled immune response associated with many diseases, including rheumatoid arthritis (RA).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> In these cells, JAK3 is constrained physically and functionally to only the common γ chain, which is shared by receptors for interleukin (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21).<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a> Observations from genetic studies of mice and humans with loss of JAK3 function demonstrate that JAK3 is an essential component of cell signaling that underlies immune response/function (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8-11)</a> Conversely, while JAK3 expression and function is restricted to the immune system, the other JAKs are much more broadly expressed and utilized in a variety of cells and organs. Therefore, a potent and selective JAK3 inhibitor would be an attractive candidate molecule for the treatment of a variety of autoimmune diseases.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> Inhibition of other JAK isoforms could potentially increase the chances of unwanted safety and tolerability issues without adding any additional activity for controlling immune-mediated disease.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20">(14-20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0014.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. JAK-STAT signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Thus, over the past decade there have been extensive efforts to identify and design novel transformative small-molecule JAK inhibitors with varied profiles of subtype selectivity to address unmet medical needs such as transplant rejection, RA, cancers, and other autoimmune diseases (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> Flanagan et al. have reported on tofacitinib (Xeljanz) as the first orally available JAK1/JAK3 inhibitor to be clinically approved for RA.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Ruxolitinib, a JAK1/JAK2 subtype selective inhibitor, was first to be approved for the treatment of myelofibrosis under the trade name Jakafi.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Baricitinib, a JAK1/2 inhibitor, and filgotinib, a JAK1 selective inhibitor, are currently in clinical trials for RA.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0015.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selected clinically approved or experimental JAK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this paper we report on the lead optimization process that led to the identification of decernotinib (VX-509), an orally available, selective inhibitor of JAK3 for the treatment of autoimmune diseases.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> To date, this is the only selective JAK3 inhibitor that has been evaluated in clinical studies of RA, and data from this clinical program have demonstrated that selective inhibition of JAK3 is sufficient for significant clinical response.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12120" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12120" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our effort to discover potent and selective small-molecule JAK3 inhibitors, we conducted a high-throughput screen of our in-house compound collections for their affinities to bind JAK3. Compounds with confirmed JAK3 inhibitory activity were then screened for selectivity against a small panel of kinases. Our JAK kinase assays were performed using a truncated form of the protein including only the active kinase domain. This was done primarily because the full-length protein was difficult to produce and does not remain stable in solution, making its utility as an enzyme screening reagent limited. It is clear from our assays and published work that the isolated kinase domains of the various JAK isotypes do not accurately measure the relative potency and selectivity of small-molecule inhibitors in cells.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> The context of other JAK protein domains and the microenvironment at the subplasma membrane in the cell significantly affect these relative data. To assess JAK isoform selectivity, we extended our enzymatic data set on isolated JAK kinase domains with a number of cell-based assays to provide data points from more biologically relevant systems.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We first investigated the ability of our compounds to inhibit STAT-5 phosphorylation by blocking the JAK3/1-STAT5 cascade in IL-2-stimulated HT-2 cells. Likewise, the ability to block the JAK2-mediated phosphorylation of STAT5 was assessed in GMCSF- stimulated TF-1 cells. This provided a measure of selectivity for inhibition of JAK3/1-mediated vs JAK2-mediated signaling in cells.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Furthermore, assaying IFN-α-mediated STAT2 translocation to the nucleus in HeLa cells, which is dependent on JAK1 and TYK2, provides useful counterscreening data to establish each compound’s specificity against these additional JAK isoforms.</div><div class="NLM_p">One of the more promising classes of compounds resulting from our JAK3 screen was the diaminotriazole class represented by <b>1</b>. While optimizing this class of compounds, a parallel screening effort was maintained to identify additional structurally diverse inhibitors of JAK3 from other ongoing kinase inhibitor programs, including SYK, FLT3, and AURA. As part of this latter strategy, a variety of known kinase inhibitor structures were compared with the crystal structure of <b>1</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). From this approach a different chemotype (<b>2</b>) was identified based on the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (7-azaindole). The superposition of the crystal co-complexes of JAK2–<b>1</b> and ERK2–<b>2</b> showed that the <i>exo-</i> primary amino group of the triazole and the NH of the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine core are closely aligned, as are the nitrogen hydrogen bond acceptors of the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine and triazole. This overlay provided a basis for replacement of the anilinoaminotriazole hinge binding element of <b>1</b> with a smaller 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine hinge binding element. Although the vectors from the triazole and 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine do not overlay perfectly, they are similar enough to suggest that the anilinopyrimidine of <b>1</b> might form a similar set of interactions on the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine core. JAK2 was used as a surrogate for JAK3 because of difficulty in handling this protein and due to the close sequence homology of the ATP binding sites of JAK2 and JAK3. As such, the JAK2 co-complex should provide a reasonable approximation for binding of these compounds with the JAK3 isoform.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0016.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>1</b> and <b>2</b> overlaid in the JAK2 structure. Superposition created by overlaying the hinge regions of the ERK2 and JAK2 crystal structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our overlay also suggested that a 1,3-disubstitution pattern in the central core pyrimidine ring of <b>1</b> would position the phenyl group more optimally. The resulting 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-based hybrid compound <b>3</b> was prepared and exhibited moderate potency. Compound <b>3</b> became the starting point for further exploration of this class of JAK3 inhibitors. With a minimal survey to explore the amine-linked side chain, we identified benzylamine-derived 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>4</b> with good affinity for JAK3 and a <i>K</i><sub>i</sub> of 14 nM. From the outset we desired compounds with a clean selectivity profile against the kinome to avoid unwanted side effects. In particular, we needed to avoid binding to additional kinases with potential for undesirable pharmacologic activity. Despite its potent FLT3 inhibition, compound <b>4</b> was used as the prototype for the central ring variations with the goal to further improve potency as well as selectivity against FLT3, SYK, and AURA. Changing the 4,6-pyrimidinyl moiety to 2,6- and 2,4-pyrimidinyl led to a decrease in affinity for JAK3, as exemplified by compounds <b>5</b> and <b>6</b>, respectively. However, 2,4-pyrimidinyl regioisomer <b>6</b> exhibited the best selectivity against FLT3 (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The addition of a 5-chloro atom on the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine ring led to an overall improvement in potency for JAK3 as seen for <b>7</b> and <b>8</b>. The replacement of the pyrimidine central core with a pyridine ring in compound <b>9</b> led to an activity profile similar to that for analogue <b>5</b>. Replacing the central heteroaryl ring with a phenyl ring gave a significant drop in affinity for JAK3 as exemplified with analogue <b>10</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Central Core Ring Variations<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0007.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">JAK3 <i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">JAK2 <i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">SYK <i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">FLT3 <i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center">AURA <i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center">HT-2/IL-2 IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.035</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char="."><0.06</td><td class="colsep0 rowsep0" align="left"> >0.8</td><td class="colsep0 rowsep0" align="left">9.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>5</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">0.096</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">>3.33</td><td class="colsep0 rowsep0" align="char" char="."><0.06</td><td class="colsep0 rowsep0" align="left">0.38</td><td class="colsep0 rowsep0" align="left"> >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">0.38</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="char" char=".">>3.33</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="left">CCl</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char="."><0.06</td><td class="colsep0 rowsep0" align="left">0.062</td><td class="colsep0 rowsep0" align="left">5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="left">CCl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">>3.33</td><td class="colsep0 rowsep0" align="char" char="."><0.06</td><td class="colsep0 rowsep0" align="left">0.02</td><td class="colsep0 rowsep0" align="left"> >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="left">CCl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">0.055</td><td class="colsep0 rowsep0" align="char" char=".">0.07</td><td class="colsep0 rowsep0" align="char" char=".">>3.33</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left"> >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="left">CCl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">0.078</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr></tbody></table></div></div><div class="NLM_p">Most of the compounds exhibited FLT3 activity and had limited or poor cellular activity in the JAK3/1 HT-2 assay. Compound <b>6</b> was the least potent inhibitor of JAK3 in this set, yet it exhibited only modest potency for FLT3, and poor affinity for both SYK and AURA. As a result, compound <b>6</b> was the only regioisomer considered for further exploration. To follow up on compound <b>6</b>, we identified additional potent analogues with a small set of compounds containing N-linked small branched or cyclic alkyl groups. Several examples containing hydrogen bond donor and acceptor groups were also examined. These results are presented in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Side Chain Variations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0008.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0009.gif" alt="" id="fx3" /></img><div></div></div><div class="NLM_p">In general, derivatives with small, branched alkyl groups (<b>11</b>), and cycloalkyl groups (<b>12</b>), were well tolerated as these compounds exhibited good affinity for JAK3, yet in most cases they lacked adequate selectivity versus FLT3 (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Alkylation of the amine nitrogen on compound <b>13</b>, as shown in <b>15</b>, led to a 10-fold decrease in JAK3 inhibition. From the X-ray structural data for related JAK3 inhibitors, it appears unlikely that the aniline NH acts as a hydrogen bond donor to the protein. The introduction of the <i>N</i>-methyl in combination with the adjacent F causes the alkyl substituent to twist out of plane relative to the pyrimidine ring, leading to what we believe to be a modestly less favorable binding conformation. Incorporation of polar atoms was well tolerated and led to improved potency in some cases (<b>16</b> and <b>19</b>). However, addition of strongly basic amines as in compounds <b>17</b> and <b>20</b> did not provide the same enhancements in affinity. Among these analogues, piperazine amide derivative <b>21</b> was the most potent example in our HT-2 cellular assay, with an IC<sub>50</sub> of 2.1 μM, and exhibited a modest 21-fold selectivity vs AURA. Most examples showed reasonable selectivity against SYK and, in the case of <b>21</b>, AURA as well (>20-fold). Finally, in this exercise no appreciable selectivity was achieved versus FLT3 for any of the compounds while also retaining potency in the cell.</div><div class="NLM_p"><i>N</i>-Acetylpiperazine-based compound <b>21</b> was the most active in our HT-2 cell assay, and it contained an amide moiety in the side chain. We found that a related compound (<b>22)</b> from our AURA program, bearing an amide-containing side chain with our preferred core, also exhibited good binding affinity for JAK3 (<i>K</i><sub>i</sub> = 2 nM). More importantly, in our IL-2-driven HT-2 cell assay (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), compound <b>22</b> exhibited an IC<sub>50</sub> of 0.074 μM. To understand the binding of this compound, analysis of the X-ray co-complex of <b>22</b> and JAK2 indicated a different orientation of the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine at the hinge than was anticipated in the original design concept from <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> (see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> also). While both orientations would accept a hydrogen bond from the backbone NH of Leu 932, the orientation of <b>22</b> anticipated from the ERK2 structure would have the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine NH donating a hydrogen bond to the backbone carbonyl of Glu 930. Instead, the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine NH of <b>22</b> is donating a hydrogen bond to the carbonyl oxygen of Leu 932 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). While unexpected, this difference in binding modes is not too surprising given the significant structural differences between compounds <b>2</b> and <b>22</b> and given that the compounds are complexed to different kinases. Interestingly, the amide of <b>22</b> does not appear to be involved in H bonding to the JAK2 protein.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. 5-Substituted 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine with Amino Acid Side Chain Variations<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0010.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0011.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All compounds showed <i>K</i><sub>i</sub> > 4 uM for SYK.</p></div></div><div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0017.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure co-complex of <b>22</b> in JAK2. Hinge hydrogen bonds to Leu 932 highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Relative to earlier 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine derivatives, <b>22</b> exhibited excellent selectivity against SYK (<i>K</i><sub>i</sub> > 4 μM) and provided a good selectivity window against FLT3 as well as JAK2 as reflected by the more relevant cellular end points (HT-2 vs TF-1). To minimize potential off-target activity of our JAK3 inhibitors, further improvements in selectivity were still desired, particularly for AURA, while maintaining the promising selectivity profile exhibited by <b>22</b>. Thus, a series of amino acid-containing analogues, capped with a trifluoroethyl amide, were prepared, and the results are summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Examples containing amides capped with −NHMe, −NEt, or −NMeEt were also assessed, but these were all less selective for FLT3 and were often accompanied by significant loss of cell potency (data not shown). As such, we chose to focus on amides containing the trifluoroethyl group.</div><div class="NLM_p">Many natural and unnatural amino acid-based analogues were explored. As demonstrated by compounds <b>23</b>, <b>24</b>, and <b>27</b>, smaller and larger amino acids such as glycine, norvaline, and methionine were all tolerated and maintained good enzyme affinity for JAK3 with retention of selectivity for SYK. However, the structure–activity relationship (SAR) with respect to cellular potency for these compounds was quite sensitive to variation of the side chain.</div><div class="NLM_p">In the natural (<i>S</i>)-configuration, the amino acid variations largely failed to significantly reduce AURA affinity. Only methylserine-derived <b>26</b> showed modestly improved selectivity against AURA (20-fold), but because of its very weak potency in our HT-2 cell assay, this compound did not meet the requirements for further investigation. The rigid proline-based analogue <b>28</b> exhibited favorable selectivity against both SYK and FLT3, but no improvement in selectivity against AURA was observed. A homologated version of <b>22</b> containing a β-alanine group as in <b>29</b> exhibited poorer JAK3 affinity as well as 150-fold reduction of cellular potency. Inversion of the absolute stereochemistry of (<i>S</i>)-<b>22</b> (compound (<i>R</i>)-<b>30</b>) did not show any significant improvement in the overall profile relative to its enantiomer, while an 18-fold loss of cellular potency was observed. Interestingly, the desfluoropyrimidyl analogue <b>31</b> with the same (<i>R</i>)-configuration exhibited a selectivity profile similar to that of <b>30</b> and improved cellular potency (HT-2 IC<sub>50</sub> = 1.3 μM vs 0.11 μM). Compounds bearing unnatural amino acids with sp and sp<sup>2</sup> character, such as analogues <b>33</b>, <b>36</b>, and <b>37</b>, did not show selectivity against AURA. These compounds also exhibited weak cellular activities. Fortunately, incorporation of bigger unnatural hydrophobic amino acid side chains, such as (<i>R</i>)-norvaline (<b>32</b>), (<i>R</i>)-valine (<b>34</b>), and (<i>R</i>)-leucine (<b>35</b>), led to a significant improvement in selectivity versus AURA. A couple of these compounds, <b>34</b> and <b>32</b>, also retained good discrimination against SYK and FLT3 and displayed potent JAK3-mediated cellular activity in our HT-2 assay with IC<sub>50</sub> = 0.11 and 0.22 μM, respectively. It is interesting to note that differences in enzyme affinity do not always translate to potent cellular activity. This may be attributed to subtle differences in the affinity of our compounds for the truncated JAK kinase enzyme domains versus full-length enzymes present in the cells.</div><div class="NLM_p">A brief survey of substituents at the C-5 position of the (<i>R</i>/<i>S</i>)-alanine-based 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine indicated that smaller substituents such as H, F, or OMe (compounds <b>38</b>–<b>41</b>) were all tolerated for JAK3 binding activity with good selectivity, but lacked the potency that the 5-chloro analogue <b>22</b> displayed in the HT-2 cellular assay. Incorporation of larger C-5 substituents such as carbamates or amides provided compounds with modest enzyme activity and cellular potency at best (data not shown), and compounds of this type were not pursued further. Changing the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (azaindole) core to a deazapurine core (CH → N) led to a complete or partial loss of potency in the HT-2 assay for compound <b>42</b> and diminished activity for compound <b>46</b>. Taken together, these results suggest that polar groups with available lone pairs at this C-5 position are less optimal for potency.</div><div class="NLM_p">With the hope that we could retain the positive aspect of compounds <b>22</b> and <b>31</b> (HT-2 cell potency) as well as <b>30</b> (AURA selectivity), we prepared a series of compounds with germinal substitution, as exemplified by <b>43</b> to <b>49</b>. Both <b>43</b> and <b>44</b> retained the cellular activity as was seen for both the (<i>S</i>)- and (<i>R</i>)-alanine derivatives <b>22</b> and <b>31</b>, with <i>des</i>fluoropyrimidine <b>43</b> being the most potent (HT-2 IC<sub>50</sub> = 0.058 μM). However, the selectivity with respect to AURA was modest overall.</div><div class="NLM_p">Since the addition of a methyl group on the glycine side chain of <b>23</b> with the (<i>R</i>)-stereochemistry, as in (<i>R</i>)-<b>31</b>, improved selectivity vs AURA (<b>23</b> vs <b>31</b>), we employed a similar strategy to follow up on <b>43</b> by increasing the steric bulk of the germinal (<i>R</i>)-substituent. Thus, the (<i>R</i>)-2-amino-2-methylbutanoic acid-based compound (<i>R</i>)-<b>45</b> was prepared and tested for its affinity in our kinase panel and cellular assays. A similar level of cellular potency (HT-2 IC<sub>50</sub> = 0.081 μM) was observed for (<i>R</i>)-<b>45</b>, but more importantly, a dramatic increase in selectivity against AURA (<i>K</i><sub>i</sub> = 0.620 μM) was achieved. As expected from previous results, its enantiomer, (<i>S</i>)-<b>47</b>, was 10-fold less selective for AURA (<i>K</i><sub>i</sub> = 0.070 μM). Furthermore, optimization at the 5-position of the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine core, as shown for compounds VX-509 and <b>48</b>, led to the most kinase-selective analogues of the series with excellent cellular potencies (HT-2 IC<sub>50</sub> < 0.1 μM).</div><div class="NLM_p">Interestingly, the crystal structure of <b>44</b> revealed that the orientation of the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine hinge binding element was flipped relative to <b>22</b> to give the same orientation as <b>2</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Given the relatively modest structural differences between <b>44</b> and <b>22</b>, this significant change in binding mode was unexpected. However, as shown in the structure of VX-509, these significant binding mode changes between structurally very similar compounds were fairly common with this compound class (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). This phenomenon of flipping binding modes for closely related compounds obviously complicated the interpretation of the SAR. Given the interesting binding behavior of these compounds in JAK2, a separate paper is in preparation to address the topic.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0018.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of <b>44</b> in JAK2. Hinge hydrogen bonds to Leu 932 and Glu 930 highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structure of VX-509 in JAK2. Hinge hydrogen bonds to Leu 932 highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With promising candidates in hand, we decided to investigate JAK isotype selectivity further. At the outset of our efforts, we were concerned about mitigating JAK2-mediated pharmacological effects.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Significant hematopoietic consequences were expected (e.g., anemia) with potent JAK2 inhibition. Therefore, we sought to optimize JAK isotypes selectivity, with a particular emphasis on JAK3 versus JAK2. In our enzyme binding studies using isolated active kinase domains, selectivity for JAK3 versus JAK2 was typically less than 10-fold for most of the compounds made in this optimization process. Given the high degree of structural similarity in the ATP binding pockets of JAK2 and JAK3 (identical except for JAK3 Cys 909 vs JAK2 Ser 936 and JAK3 Ala 966 vs JAK2 Gly 993), our observations are consistent with the expectation that the potential for JAK3 vs JAK2 selectivity would be limited. Furthermore, it is known that other domains of the JAK kinases have some degree of regulatory function for the kinase, and we had indications from cellular data sets that the selectivity window between JAK3 and JAK2 was greater in cellular assays.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Thus, this limited JAK3/JAK2 enzymatic selectivity might be explained by the fact that truncated isolated protein kinase domains were used for <i>K</i><sub>i</sub> determinations. This does not fully account for the subtle structural differences in the full-length proteins, particularly in the context of their natural microenvironment, when bound to the γ chain of the IL-2 family of cytokine receptors in cells. Thus, we chose to emphasize JAK isotype selectivity characterization in the more physiologically relevant biologic systems with the hope of minimizing off-target JAK2 inhibition. Comparison of inhibition of the JAK3/1- or JAK2-mediated phosphorylation of STAT5 in HT-2 or TF-1 cells following brief stimulation with IL-2 or GMCSF, respectively, provided a useful selectivity ratio for the compounds. Furthermore, assessment of selectivity against JAK1/TYK2 was obtained by counterscreening our compounds in HeLa cells stimulated with IFN-α and measuring inhibition of STAT2 translocation to the nucleus. Results from the HeLa assays show that VX-509 has an IC<sub>50</sub> of >10 μM, demonstrating a high degree of selectivity against these additional JAK isoforms. However, a more relevant predictor of in vivo selectivity was also needed. To confirm and expand upon these findings, primary human and mouse cell assays were used. Specifically, T-cell proliferative response in mixed lymphocyte reactions (MLRs), IL-2-stimulated T-cell blast assays from isolated peripheral blood mononuclear cells (JAK3/JAK1 signaling pathway), erythroid colony formation assays (CFU-E) from human bone marrow after stimulation with erythropoietin (JAK2 signaling pathway), and IL-6 stimulation of human whole blood (JAK1/JAK2/TYK2 signaling pathway) were used to assess JAK isotype selectivity ratios in a more physiologically relevant manner (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Enzyme (<i>K</i><sub>i</sub> nM ± SD, <i>n</i>), Cell-Based Potency (IC<sub>50</sub> nM ± SD, <i>n</i>), and Selectivity (ratio)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">JAK isoform involved</th><th class="colsep0 rowsep0" align="center">VX-509</th><th class="colsep0 rowsep0" align="center"><b>44</b></th><th class="colsep0 rowsep0" align="center"><b>34</b></th><th class="colsep0 rowsep0" align="center"><b>43</b></th><th class="colsep0 rowsep0" align="center"><b>45</b></th><th class="colsep0 rowsep0" align="center">tofacitinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">2 ± 0.7, 5</td><td class="colsep0 rowsep0" align="left">1 ± 0.07, 10</td><td class="colsep0 rowsep0" align="left">1 ± 0.09, 5</td><td class="colsep0 rowsep0" align="left">1 ± 0.3, 10</td><td class="colsep0 rowsep0" align="left">3 ± 2, 3</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.07, 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="left">11 ± 0, 1</td><td class="colsep0 rowsep0" align="left">3 ± 0, 1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2 ± 0, 1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">3 ± 0.4, 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">13 ± 0, 4</td><td class="colsep0 rowsep0" align="left">2 ± 0.5, 12</td><td class="colsep0 rowsep0" align="left">4 ± 009, 6</td><td class="colsep0 rowsep0" align="left">1 ± 0.5, 12</td><td class="colsep0 rowsep0" align="left">2 ± 1, 5</td><td class="colsep0 rowsep0" align="left">1 ± 0.9, 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYK2</td><td class="colsep0 rowsep0" align="left">TYK2</td><td class="colsep0 rowsep0" align="left">11 ± 2, 2</td><td class="colsep0 rowsep0" align="left">10 ± 0, 1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">11 ± 0, 1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">11 ± 0, 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT-2/IL-2/P-STAT5</td><td class="colsep0 rowsep0" align="left">JAK3/1</td><td class="colsep0 rowsep0" align="left">99 ± 50, 4</td><td class="colsep0 rowsep0" align="left">90 ± 30, 10</td><td class="colsep0 rowsep0" align="left">112 ± 70, 5</td><td class="colsep0 rowsep0" align="left">58 ± 40, 5</td><td class="colsep0 rowsep0" align="left">81 ± 70, 2</td><td class="colsep0 rowsep0" align="left">30 ± 20, 72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TF-1/GMCSF/P-STAT5</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">2600 ± 1664, 4</td><td class="colsep0 rowsep0" align="left">1060 ± 600, 9</td><td class="colsep0 rowsep0" align="left">2927 ± 1350, 7</td><td class="colsep0 rowsep0" align="left">409 ± 142, 6</td><td class="colsep0 rowsep0" align="left">651 ± 13, 2</td><td class="colsep0 rowsep0" align="left">190 ± 137, 35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse two-way MLR</td><td class="colsep0 rowsep0" align="left">JAK3/1</td><td class="colsep0 rowsep0" align="left">170 ± 100, 4</td><td class="colsep0 rowsep0" align="left">160 ± 110, 3</td><td class="colsep0 rowsep0" align="left">280, 1</td><td class="colsep0 rowsep0" align="left">170 ± 70, 2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">60, 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">primary human IL-2 T-cell blast</td><td class="colsep0 rowsep0" align="left">JAK3/1</td><td class="colsep0 rowsep0" align="left">240 ± 180, 2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">130 ± 28, 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human WB/IL-6/P-STAT3</td><td class="colsep0 rowsep0" align="left">JAK1/2 TYK2</td><td class="colsep0 rowsep0" align="left">>11200 ± 1896, 9</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">666 ± 253, 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human CFU-E, 3 U/mL EPO<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">7700 ± 6100, 2</td><td class="colsep0 rowsep0" align="left">6100 ± 3400, 2</td><td class="colsep0 rowsep0" align="left">5400 ± 2000, 2</td><td class="colsep0 rowsep0" align="left">2500 ± 2200, 2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">380 ± 160, 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human CFU-E, 0.3 U/mL EPO</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">5300 ± 740, 2</td><td class="colsep0 rowsep0" align="left">3600 ± 1200, 2</td><td class="colsep0 rowsep0" align="left">3000 ± 1000, 2</td><td class="colsep0 rowsep0" align="left">1700 ± 325, 2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">320 ± 150, 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HeLa IFN-α STAT2</td><td class="colsep0 rowsep0" align="left">JAK1/TYK2</td><td class="colsep0 rowsep0" align="left">11900 ± 3650, 3</td><td class="colsep0 rowsep0" align="left"> >20000, 1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2800 ± 2000, 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CFU-E/MLR (3 U/mL EPO)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">45.3</td><td class="colsep0 rowsep0" align="left">38.1</td><td class="colsep0 rowsep0" align="left">22.1</td><td class="colsep0 rowsep0" align="left">10.6</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CFU-E/MLR (0.3 U/mL EPO)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">31.3</td><td class="colsep0 rowsep0" align="left">22.5</td><td class="colsep0 rowsep0" align="left">14.2</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TF-1/HT-2 ratio</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">EPO = erythropoietin.</p></div></div></div><div class="NLM_p">The selectivity ratios of JAK3-mediated versus JAK2-mediated end points (TF-1/HT-2) were superior to that of binding selectivity for all the above compounds tested, ranging from 7- to 26-fold. The three most selective compounds, <b>44</b>, VX-509, and <b>34</b>, were further evaluated for their functional activity in primary human cell-based assays dependent on either JAK3 or JAK2, namely, the MLR and CFU-E assays. Analogues <b>44</b> and VX-509 exhibited robust selectivity windows between JAK3- and JAK2-dependent cell assays, with 38-fold and 45-fold selectivity, respectively, in favor of JAK3 (CFU- E/MLR). As a clinical benchmark reference, tofacitinib was similarly evaluated for selectivity in our assays. Tofacitinib proved to be generally less selective in this assessment with selectivity ratios of 6- and 7-fold (TF-1/HT-2) and (CFU-E/MLR), respectively. In these assays, the superior selectivity for compound VX-509 against JAK2 with respect to tofacitinib was consistent with the results obtained for the TF-1/HT-2 ratios. Additionally, VX-509 demonstrated a lack of activity against an IL-6 stimulated primary human whole blood phospho-STAT3 assay (>11.2 μM; <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), whereas tofacitinib revealed an IC<sub>50</sub> point of 666 nM. These data further solidify the characterization of VX-509 as a selective JAK3 inhibitor and, in contrast to tofacitinib, VX-509 lacks appreciable activity against JAK1. Finally, VX-509 was evaluated along with tofacitinib in a primary human IL-2 T-cell blast proliferation assay, which provided an additional functional measure of the ability of compounds to inhibit JAK3 activity. Both compounds showed similar potency with IC<sub>50</sub> values at 0.14 and 0.15 μM, respectively.</div><div class="NLM_p">During our lead optimization process, we routinely determined the pharmacokinetic parameters for potent and selective compounds following a single iv bolus dose to Sprague–Dawley (SD) rats. The results for the most promising analogues are summarized in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. While compound <b>44</b> exhibited the lowest clearance coupled with an acceptable <i>T</i><sub>1/2</sub>, VX-509 also demonstrated reasonable exposure, with a moderate clearance and extended <i>T</i><sub>1/2</sub> of 5.1 h. In addition, VX-509 had a superior kinase selectivity profile (particularly against JAK2 and AURA) relative to <b>44</b>. On the basis of these promising results, VX-509 was selected for further evaluation.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameter Determinations in Sprague–Dawley Rats (Single iv Bolus Dose)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">DN-AUC<sub>inf</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> [(h μg)/mL]</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>dss</sub> (L/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">36.2</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">1.76</td><td class="colsep0 rowsep0" align="char" char=".">9.45</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">39.7</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">0.60</td><td class="colsep0 rowsep0" align="char" char=".">41.1</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VX-509</td><td class="colsep0 rowsep0" align="char" char=".">0.98</td><td class="colsep0 rowsep0" align="char" char=".">0.74</td><td class="colsep0 rowsep0" align="char" char=".">24.3</td><td class="colsep0 rowsep0" align="char" char=".">5.57</td><td class="colsep0 rowsep0" align="char" char=".">4.98</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">The AUCINF values are normalized to a 1 mg/kg dose.</p></div></div></div><div class="NLM_p">In vitro profiling indicated that VX-509 was moderately to extensively metabolized in liver microsomes and S9 fractions in the mouse, rat, dog, monkey, and human (<a class="ref internalNav" href="#tbl6" aria-label="Tables 6">Tables 6</a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). This suggested that the contributions to drug clearance from non-CYP-mediated metabolic pathways was minimal.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mean <i>T</i><sub>1/2</sub> and Predicted Hepatic Clearance for VX-509 at an Initial Concentration of 1 μM in Liver Microsomes after Incubation at 37 °C</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">mean <i>T</i><sub>1/2</sub> (±SD) and mean predicted hepatic clearances (±SD)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char="±">predicted hepatic clearance (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 7.9</td><td class="colsep0 rowsep0" align="char" char="±">69 ± 6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char="±">34 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 0.2</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Mean <i>T</i><sub>1/2</sub> and Predicted Hepatic Clearance for VX-509 at an Initial Concentration of 1 μM in Liver S9 after Incubation at 37 °C</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">mean <i>T</i><sub>1/2</sub> (±SD) and mean predicted hepatic clearances (±SD)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char="±">predicted hepatic clearance (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1.01</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char="±">36 ± 3.4</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 5.4</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 0.9</td></tr></tbody></table></div></div><div class="NLM_p">Other properties that favored selection of VX-509 included its high permeability in human colon carcinoma (Caco-2) cell monolayer assays, indicating potential for good oral absorption, and demonstration that it was a weak efflux pump protein substrate to P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) with efflux ratios ranging between 2 and 3. Although the efflux ratios were small for P-gp and BCRP, more than 50% reduction of these efflux ratios in the presence of standard inhibitors was used to classify them as weak substrates. In addition, the hERG IC<sub>50</sub> value for VX-509 was determined to be 51.9 μM, and its solubility was found to be 6.38 μg/mL in water.</div><div class="NLM_p">Preclinical pharmacokinetics (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>A) of VX-509 was investigated in multiple species. Following a nominal 1 mg/kg intravenous dose to rats and monkeys, plasma clearances were moderate at 24.3 and 21.7 mL/min/kg, respectively; the volume of distribution at the steady state (Vdss) ranged from 1.7 to 5.0 L/kg. In dogs, the clearance and Vdss values were significantly lower at 4.17 mL/min/kg and 0.4 L/kg, respectively. These lower values in dogs might be explained, at least in part, by differences in aldehyde oxidase-mediated metabolism in that species (results to be published elsewhere). The percentage of VX-509 (1 μM) bound to plasma proteins was 89%, 93%, 99%, 80%, and 81% in mouse, rat, dog, monkey, and human plasma, respectively. Consistent with its high permeability and low to moderate clearance, VX-509 exhibited high oral bioavailability in both rats and dogs (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>B).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Mean Pharmacokinetic Parameters for VX-509</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center">(A) Single iv Bolus Dose</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">DN-AUC<sub>inf</sub><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> [(h μg)/mL]</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vdss (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">0.98</td><td class="colsep0 rowsep0" align="char" char=".">0.74</td><td class="colsep0 rowsep0" align="char" char=".">24.3</td><td class="colsep0 rowsep0" align="char" char=".">4.98</td><td class="colsep0 rowsep0" align="char" char=".">5.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">0.88</td><td class="colsep0 rowsep0" align="char" char=".">4.06</td><td class="colsep0 rowsep0" align="char" char=".">4.17</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">1.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">0.88</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td><td class="colsep0 rowsep0" align="char" char=".">21.7</td><td class="colsep0 rowsep0" align="char" char=".">1.65</td><td class="colsep0 rowsep0" align="char" char=".">1.28</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="7" align="center">(B) Single Oral Dose</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">DN-AUC<sub>inf</sub><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> [(h μg)/mL]</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μg/mg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">10.7</td><td class="colsep0 rowsep0" align="char" char=".">6.75</td><td class="colsep0 rowsep0" align="char" char=".">1.73</td><td class="colsep0 rowsep0" align="char" char=".">1.50</td><td class="colsep0 rowsep0" align="char" char=".">5.87</td><td class="colsep0 rowsep0" align="char" char=".">91.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">9.65</td><td class="colsep0 rowsep0" align="char" char=".">44.6</td><td class="colsep0 rowsep0" align="char" char=".">7.46</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">5.82</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">The AUCINF values are normalized to a 10 mg/kg dose.</p></div></div></div><div class="NLM_p">Comparison of the estimated hepatic clearance values from liver microsomes in rats, dogs, and monkeys (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, 38, 24, and 38 mL/min/kg, respectively) with clearance values obtained in vivo (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>, 24.3, 4.2, and 21.7 mL/min/kg, respectively) showed that clearance was overestimated on the basis of in vitro data and suggested that VX-509 might exhibit acceptable clearance in humans. Due to its favorable potency, selectivity, and pharmacokinetic profile, VX-509 was selected for assessment of its potential for in vivo efficacy in JAK3-mediated models of disease. Thus, VX-509 efficacy was evaluated in vivo in the rat host versus graft (HvG) model (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). HvG response was elicited by the injection of allogeneic cells isolated from Dark Agouti rat spleen into the footpad of the host Lewis rat. The HvG reaction is primarily a T-cell-mediated response, in which host T-cells recognize major histocompatibility complex (MHC) antigens presented by the antigen presenting cells on the graft cells. The graft cells migrate to the host local popletial lymph node (PLN) and induce an immune response leading to hyperplasia of the lymph node. The enlargement of host PLN peaks at day 4, and the weight difference (Δ) between contralateral (nongrafted) and ipsilateral (grafted) PLNs was the efficacy assessment. Concomitantly, ex vivo analysis of T-cell activation of CD25 in whole blood from dosed animals was also evaluated as a biomarker of JAK3 activity.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose-dependent inhibition of popletial lymph node (PLN) hyperplasia by VX-509 in the rat HvG model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">VX-509 was evaluated at oral doses of 10 mg/kg bid, 25 mg/kg bid, 50 mg/kg bid, or 100 mg/kg qd. Cyclosporin A was administered orally as a reference compound at a dose of 6 mg/kg qd. PLNs were collected at termination. For ex vivo CD25 biomarker analysis, terminal blood samples at 1 and 14 h (trough) postdose were used. VX-509 demonstrated statistically significant, dose-dependent inhibition on PLN hyperplasia as determined by Δ measurement, which is the weight difference between the grafted and nongrafted PLNs. As illustrated in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>, VX-509 at 50 mg/kg bid or 100 mg/kg qd was significantly efficacious, inhibiting 66% (<i>p</i> = 0.019) and 94% (<i>p</i> < 0.01) of the PLN hyperplasia, respectively, relative to cyclosporin A (CsA). There was a partial but nonsignificant inhibition (50%, <i>p</i> = 0.101) for the 25 mg/kg bid group relative to CsA. Tofacitnib, when evaluated in the HvG model, also demonstrated statistically significant inhibition of PLN hyperplasia. The compound inhibited the PLN hyperplasia by 87% at 20 mg/kg tid, 88% at 20 mg/kg bid, or 100% at 60 mg/kg bid as compared to CsA (100%) (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf" class="ext-link">Supporting Information Figure 13</a>). There was significant reduction of the CD25 expression by tofacitinib at 1 h postdose in all groups tested (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf" class="ext-link">Supporting Information Figure 14</a>).</div><div class="NLM_p">Terminal whole blood samples at 1 and 14 h postdose were analyzed using ex vivo 4β-phorbol 12-myristate 13-acetate (PMA) and anti-CD28 antibody-stimulated CD25 expression. In the absence of stimulation with PMA and anti-CD28 antibody, CD25 expression in CD3 (+) T-cells was below 5%, whereas CD25 expression reached approximately 85% within 24 h after stimulation. There was significant reduction of CD25 expression by VX-509 at 1 h postdose in all of the dose groups tested: 59% (<i>p</i> < 0.01) inhibition at 10 mg/kg bid, 51% (<i>p</i> < 0.01) inhibition at 25 mg/kg bid, 71% (<i>p</i> < 0.01) inhibition at 50 mg/kg bid, and 92% (<i>p</i> < 0.01) inhibition at 100 mg/kg qd. There was also significant reduction (66%, <i>p</i> < 0.01) in CD25 expression in the 100 mg/kg qd group at the trough (23 h postdose) (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>), supporting the potential for a qd dosing regimen in clinical studies. In this study, VX-509 exhibited significant dose-dependent immunosuppressive activity. Ex vivo whole blood analysis of CD25 expression demonstrates that VX-509 effectively attenuated T-cell activation at 1 h postdose.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose-dependent decrease in ex vivo stimulated biomarker CD25 by VX-509 in the rat HvG model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the potency, its unique selectivity profile favoring JAK3 as determined using cellular assays, the pharmacokinetic profile, and its efficacy in preclinical pharmacologic models of aberrant immune function, VX-509 appears to have potential clinical utility for treatment of a variety of immune-based diseases, and results from clinical studies will be reported in due course.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Synthesis</h3><div class="NLM_p">Synthesis of final compounds relied on ready access to common 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine and deazapurine boronates <b>50</b>. These key intermediates were all similarly prepared according to the general route outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) NaH, TsCl, THF; (b) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (c) bis(pinacolato)diboron, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, 1,4-dioxane.</p></p></figure><div class="NLM_p"><i>N</i>-Tosyl protection starting from known intermediates <b>A</b>, followed by bromination at C-3, enabled efficient preparation of the 3-bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine or deazapurines <b>C</b>. Treatment with bis(pinacolato)diboron and palladium tetrakis(triphenylphosphine) provided the desired Suzuki coupling partners, intermediates <b>50a</b>–<b>e</b>.</div><div class="NLM_p">The syntheses of analogues containing the benzylamine group and with central core ring variations in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> were achieved via the general route described in <a class="ref internalNav" href="#sch2a" aria-label="Scheme 2">Scheme 2</a>. The sequence involved Suzuki coupling of protected boronates <b>50a,b</b> with suitably substituted aryl halides followed by deprotection as shown in <a class="ref internalNav" href="#sch2a" aria-label="Scheme 2">Scheme 2</a>a. Thus, SnAr displacement of suitable dihalopyrimidine regioisomers with benzylamine provided halo-coupling partners <b>51a</b>,<b>b</b> and <b>52</b> in moderate to good yields. Suzuki coupling under standard conditions was followed by removal of the tosyl group under basic conditions to provide compounds <b>4</b>, <b>6</b>, and <b>7</b>, as well as pyridine-derived analogues <b>9</b>. The corresponding phenyl analogue <b>10</b> was accessed using commercial <i>N</i>-benzyl-3-bromoaniline following the same sequence. Compounds <b>11</b>–<b>21</b> were prepared most conveniently by the same sequence starting from either 2,4-dichloropyrimidine or 2,4-dichloro-5-fluoropyrimidine and the corresponding amines. Thus, chloride displacement followed by Suzuki coupling and tosyl deprotection delivered compounds <b>11–21</b>.</div><figure id="sch2a" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0005.jpeg" id="GRAPHIC-d4011e3113-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=sch2a"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions for part a: (a) PhCH<sub>2</sub>NH<sub>2</sub>, DIPEA, THF, reflux, 1–2 h or IPA, 90 °, (54–79%); (b) PhCH<sub>2</sub>NH<sub>2</sub>, neat (79%); (c) PhCH<sub>2</sub>NH<sub>2</sub>, 150 °C (microwave) (40–55%); (d) (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, reflux; (ii) NaO<i>t</i>Bu, 130–160 °C, 10–20 min (microwave) (25–89%). Conditions for part b: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, reflux (51%; X = CCl); (b) Oxone, CH<sub>3</sub>OH–H<sub>2</sub>O (1:1) (32%; X = CCl); (c) (i) PhCH<sub>2</sub>NH<sub>2</sub>, EtOH, reflux, 16 h (94%; X = CCl); (ii) 3 N NaOH, CH<sub>3</sub>OH (75%; X = CCl) or NaO<i>t</i>Bu, 130–160 °C, 10–20 min (microwave).</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch2a" aria-label="Scheme 2">Scheme 2</a>b describes the chemistry to gain access to compounds <b>5</b> and <b>8</b>. Interemediates <b>53</b> and <b>54</b> were prepared in moderate yield via Suzuki coupling of boronic esters <b>50a</b> and <b>50b</b> with 4-chloro-2-(methylthio)pyrimidine followed by oxidation of <b>53</b> to provide the corresponding sulfones <b>54</b>. This sequence allowed for facile SnAr displacement with benzylamine to obtain, after detosylation, the desired analogues <b>5</b> and <b>8</b>.</div><div class="NLM_p">The syntheses of amino acid-based compounds <b>22</b>–<b>49</b> depicted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> were accomplished in a five-step protocol from commercially available <i>N</i>-Boc amino acids <b>M</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The requisite amide cap was installed via the coupling of <b>M</b> with 2,2,2-trifluoroethylamine hydrochloride under standard conditions using either HATU or EDC/HOBt to furnish, after Boc deprotection with CH<sub>2</sub>Cl<sub>2</sub>–TFA, the corresponding amides <b>N</b> in good overall yield. N-arylation with 2,4-dichloropyrimidine, 2,4-dichloro-5-fluoropyrimidine, or 2,4-dichlorotriazine provided the desired coupling partners <b>Q</b> for assembly of the final compounds. Finally, Pd-mediated Suzuki coupling of <b>Q</b> with <b>50a</b>–<b>e</b> delivered, after removal of the tosyl protecting group using basic conditions, the desired analogues <b>22</b>–<b>49</b> in moderate to good yield.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) HATU or EDC, HOBt, DIEA, DMF, CF<sub>3</sub>CH<sub>2</sub>NH<sub>2</sub>–HCl, rt (60–92%); (b) 1:1 TFA–CH<sub>2</sub>Cl<sub>2</sub> or 2 M HCl, Et<sub>2</sub>O–CH<sub>3</sub>OH (quantitative); (c) DIEA, IPA or THF (29–80%); (d) (i) <b>50a</b>–<b>e</b>, 2 M Na<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DME, 150 °C, 10 min (microwave) or reflux; 16 h; (ii) LiOH, THF, H<sub>2</sub>O, rt or CH<sub>3</sub>OH, 25% NaOCH<sub>3</sub> in CH<sub>3</sub>OH, 60 °C, 1 h (30–65%, two steps).</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Protein Preparation</h3><div class="NLM_p">The human JAK3 kinase domain (A815–E1124) was cloned by PCR from a previously isolated full-length JAK3 cDNA (GenBank accession number <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=AAD22741">AAD22741</a>) and inserted into pBEV10 (a custom shuttle vector for insect cell expression via the baculovirus polyhedrin promoter). The expressed protein contains a thrombin-cleavable N-terminal hexahistidine tag. For production, Sf9 insect cells grown to 2 × 10<sup>6</sup> cells/mL in Excell-405 medium (JRH Biosciences, Lenexa, KS) were infected with virus at a multiplicity of infection (MOI) of 2.5 and incubated for 72–96 h at 27 °C. Frozen cell paste was thawed in 5–10 volumes of buffer A (50 mM HEPES, pH 8.0, 500 mM NaCl, 20% (v/v) glycerol, 0.2% Tween 20 (v/v), 0.05% (v/v) mM β-mercaptoethanol, 5 mM imidazole) containing 1 mM PMSF, 5 mg/mL leupeptin, 3 mM benzamidine, and 625 units/L Benzonase (EMD Millipore, Bellerica, MA) and mechanically lysed in a microfluidizer (Microfluidics, Newton, MA). The lysate was clarified by centrifugation at 54000<i>g</i> for 1 h, and JAK3 was purified by nickel metal affinity resin (Sigma-Aldrich, St. Louis, MO) followed by sizing in buffer B (50 mM HEPES, pH 8.0, 500 mM NaCl, 20% (v/v) glycerol, 0.05% (w/v) octyl β-glucopyranoside, and 5 mM DTT) using an HR 16/60 Superdex-75 size exclusion column (GE Healthsciences, Piscataway, NJ). The final protein concentration was quantified using a molar extinction coefficient of 39 440 L mol<sup>–1</sup> cm<sup>–1</sup> calculated from the protein sequence. Purified JAK3 protein was stored at −80 °C in small aliquots until further use.</div><div class="NLM_p">The human JAK2 kinase domain (T842–G1132) (Swiss-Prot entry <a href="https://O60674" class="ext-link">O60674</a>) and SYK full-length protein (Genbank accession number <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=L28824">L28824</a>) were cloned, expressed, and purified in a manner similar to that for the JAK3 kinase domain. For JAK2, the final purified material was activated at 0.5–1 mg/mL using 5 mM ATP and 20 mM MgCl<sub>2</sub> for 1 h at 25 °C followed by a desalting step in buffer B. A molar extinction coefficient of 38 975 L mol<sup>–1</sup> cm<sup>–1</sup> was used for determining the protein concentration. For SYK, the activation step was performed at 0.1 mg/mL for 16 h at 4 °C. A molar extinction coefficient of 111 660 L mol<sup>–1</sup> cm<sup>–1</sup> was used for determining the protein concentration of SYK. For crystallography, the JAK2 protein was prepared as previously described.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">The human FLT3 kinase domain (H564–V958) was expressed and purified as previously described.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The protein was activated at 0.1 mg/mL using 2.5 mM ATP and 5 mM MgCl<sub>2</sub> for 16 h at 4 °C followed by a desalting step, and the protein concentration was determined using a molar extinction coefficient of 66 280 L mol<sup>–1</sup> cm<sup>–1</sup>.</div><div class="NLM_p last">Recombinant AURA (1–403) was expressed as a N-terminal, His6-tagged fusion protein using a baculovirus expression system (FastBac, Gibco BRL). The protein was purified by using affinity chromatography using Ni–NTA agarose, followed by size exclusion using a Superdex 200 26/60 column (Amersham Biosciences).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Kinase Inhibition Assay</h3><div class="NLM_p last">Inhibition of kinase activity was assessed using a standard enzyme-coupled system or a radiometric, phosphocellulose–peptide capture assay as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Crystallization and Structure Determination</h3><div class="NLM_p last">Crystals of JAK2 were obtained as described previously.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Briefly, the kinase domain of JAK2 was concentrated to 10 mg/mL. Crystals were grown by hanging-drop vapor diffusion in 24-well plates using repeated seeding. The reservoir contained 0.5 mL of 1.7 to 2.1 M <span class="smallcaps smallerCapital">dl</span>-malic acid, pH 7.0, and 2 mM dithiothreitol. The crystallization drop contained 0.5 μL of protein containing 1 mM compound dissolved in DMSO + 0.5 μL of resevoir solution + 0.5 μL of water. The crystals were transferred to a drop containing crystallization buffer that was 25% glycerol and then flash frozen in liquid nitrogen. Data were collected at the Advanced Light Source. Images were processed with autoPROC.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The structure was solved by difference Fourier methods using a previously determined structure, and refinement and model building were performed with BUSTER<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and COOT,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> respectively (see the <a href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf" class="ext-link">Supporting Information</a> for data collection and refinement statistics).</div></div><div id="sec3_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> HT-2/IL-2 Assay (JAK3-Mediated Cell Assay)</h3><div class="NLM_p last">HT-2 cells were deprived of growth factors for 4 h at 37 °C. The cells were plated in 96-well plates at a density of 2.5 × 10<sup>5</sup> cells per well (50 μL of a 5 × 10<sup>6</sup> cells/mL stock). VX-509 solution was plated in triplicate, in columns, at a final concentration ranging from 10 μM to 4.5 nM. Two columns of cells were plated with DMSO as the proliferation control. The cells were incubated at 37 °C for 1 h, after which cells in the VX-509 columns and in one of the control columns were stimulated with IL-2 for 20 min at 37 °C. The second column of control cells was not stimulated and served as the negative control. The plates were centrifuged at 500<i>g</i> for 5 min, and the supernatant was aspirated. the cells were fixed with 4% formaldehyde for 10 min at room temperature. The plates were centrifuged, and the supernatant was aspirated. The cells were then permeabilized by incubation in 90% methanol for 30 min at 4 °C. The plates were centrifuged at 500<i>g</i> for 5 min, and the supernatant was aspirated. The plates were washed by adding phosphate-buffered saline (PBS) and immediately centrifuging at 500<i>g</i> for 5 min, after which the supernatant was aspirated. The cells were stained with a 1:10 dilution of anti-phospho-STAT5 PE antibody for 45 min on a shaker at room temperature. The cells were then washed by adding PBS, centrifuging the plates for 5 min at 500<i>g</i>, and aspirating the supernatant. The cells were resuspended in PBS, and STAT-5 phosphorylation was quantified on a Guava PCA 96 FACS reader (Millipore). The half-maximal inhibitory concentration (IC<sub>50</sub>) of VX-509 was determined using Softmax pro software.</div></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> TF-1/GMCSF (JAK2-Mediated Cell Assay)</h3><div class="NLM_p last">TF-1 cells were deprived of growth factors for 4 h at 37 °C. The cells were plated in 96-well plates at a density of 2.5 × 10<sup>5</sup> cells per well (50 μL of a 5 × 10<sup>6</sup> cells/mL stock). VX-509 solution was plated in triplicate, in columns, at a final concentration ranging from 10 μM to 4.5 nM. Two columns of cells were plated with DMSO as the proliferation control. The cells were incubated at 37 °C for 1 h, after which cells in the VX-509 columns and in one of the control columns were stimulated with GMCSF for 15 min at 37 °C. The second column of control cells was not stimulated and served as the negative control. The plates were centrifuged at 500<i>g</i> for 5 min, and the supernatant was aspirated. The cells were fixed with 4% formaldehyde for 10 min at room temperature. The plates were centrifuged, and the supernatant was aspirated. The cells were then permeabilized by incubation in 90% methanol for 30 min at 4 °C. The plates were centrifuged at 500<i>g</i> for 5 min, and the supernatant was aspirated. The plates were washed by adding PBS and immediately centrifuging at 500<i>g</i> for 5 min, after which the supernatant was aspirated. The cells were stained with a 1:10 dilution of anti-phospho-STAT-5 PE antibody for 45 min on a shaker at room temperature. The cells were then washed by adding PBS, centrifuging the plates for 5 min at 500<i>g</i>, and aspirating the supernatant. The cells were resuspended in PBS, and STAT-5 phosphorylation was quantified on a Guava PCA 96 FACS reader (Millipore). The half-maximal inhibitory concentration (IC<sub>50</sub>) of VX-509 was determined using Softmax pro software.</div></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Mouse TWO-Way MLR from <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a></h3><div class="NLM_p last">Spleens from 8–10 week old female mice (CBA and BALB/c, Jackson Laboratories) were used to isolate splenocytes. The splenocytes from each strain of mouse were plated at a density of 1.8 × 10<sup>5</sup> cells per well in 96-well plates, in total 3.6 × 10<sup>5</sup> cells per well. The VX-509 dilutions were added to the wells; two rows were plated with DMSO alone and served as the proliferation controls for the assay. The plates were incubated at 37 °C in a CO<sub>2</sub> incubator for 4 days. On day 5, 20 μCi/mL methyl-<sup>3</sup>H-thymidine was added to each well. After 7 h, the cells were harvested onto Betaplate double filters using a TOMTEC Harvester 96. The filters were dried for 1 h, and then 20 mL of scintillation fluid was added per filter. The filters were analyzed for radioactive counts on a PerkinElmer-Wallace β counter (1205 Betaplate β liquid scintillation counter). Data were analyzed to generate an IC<sub>50</sub> value using Softmax pro software.</div></div><div id="sec3_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> STAT-2 Nuclear Translocation Assay</h3><div class="NLM_p last">HeLa cells were plated in a 96-well plate at a density of 5 × 10<sup>3</sup> cells per well. The plates were incubated at 37 °C for 18 h (overnight) in a CO<sub>2</sub> incubator. VX-509 was added to the plates at a final concentration ranging from 4.5 nM to 10 μM, and the plates were placed in a CO<sub>2</sub> incubator at 37 °C for 1 h. The cells were then stimulated with IFN-α and incubated for 45 min at 37 °C in a CO<sub>2</sub> incubator (medium only for negative control plates). The plates were processed according to the protocol from the Cellomics STAT2 activation HitKit and screened using the ArrayScan II HCS system (Beckman Coulter, Fullerton, CA). Data were analyzed using Softmax pro software to generate an IC<sub>50</sub> value for VX-509.</div></div><div id="sec3_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> IL-2-Stimulated Human T-Cell Blast Proliferation Assay</h3><div class="NLM_p last">Whole blood samples from healthy volunteers were used to collect PBMCs, which were plated in T75 tissue culture flasks at a density of 1 × 10<sup>6</sup> cells/mL. The cells were stimulated with 10 μg/mL PHA at 37 °C for 72 h. After 72 h, the cells were detached from the flask by scraping, washed, and plated at a density of 1 × 10<sup>5</sup> cells per well in a 96-well plate. VX-509 (9.7 nM to 10 μM) was added, and the plates were incubated for 30 min at 37 °C followed by stimulation with human IL-2. In two rows, only DMSO was added; one row was not stimulated with IL-2, and one row was stimulated with IL-2 to serve as the proliferation control. The plates were incubated at 37 °C for 2 days. On day 2, the cells were pulsed with 20 μCi/mL methyl-<sup>3</sup>H-thymidine for 18–24 h and harvested onto filters for radiographic determination using a PerkinElmer-Wallace β counter (1205 Betaplate β Liquid Scintillation Counter). Data were analyzed to generate an IC<sub>50</sub> value using Softmax pro software.</div></div><div id="sec3_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Colony-Forming Unit Erythroid (CFU-E) Assay</h3><div class="NLM_p last">CFU-E assays were performed by StemCell Technologies (Vancouver, BC, Canada). Briefly, clonogenic progenitors from normal human bone marrow of the erythroid, myeloid, and multipotential lineages were plated in methylcellulose-based medium formulations containing 50 ng/mL SCF, 10 ng/mL GMCSF, 10 ng/mL IL-3, and either 3.0 or 0.3 U/mL EPO. VX-509 was added to produce final concentrations between 0.01 and 10 μM. Solvent control cultures, as well as standard controls, were also made for each medium formulation. The cultures were performed in triplicate at 1 × 10<sup>4</sup> cells per culture. Following 14 days in culture, the colonies were assessed and classified on the basis of size and cell and colony morphology.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Liver Microsome and S9 Fraction Stability Assays</h3><div class="NLM_p">In the liver microsomal stability experiments, 1 or 10 μM VX-509 was incubated with liver microsomes from the mouse, rat, dog, monkey, or human at a final protein concentration of 0.5 mg/mL and 50 μg of alamethicin/mg of microsomal protein. The reactions were initiated upon the addition of cofactors, either nicotinamide adenine dinucleotide phosphate (NADPH; 2 mM final concentration) to evaluate the role of NADPH-dependent metabolic pathways or NADPH (2 mM final concentration) and uridine diphosphate glucuronic acid (UDPGA; 5 mM final concentration) to evaluate the role of glucuronidation in the metabolism of VX-509 across species. No cofactors were added to the control reactions. The liver microsomal incubations were performed in triplicate. The reactions were terminated by protein precipitation using acetonitrile containing the analytical standard <i>N</i>-(1<i>H</i>-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]quinazolin-4-amine as the quenching reagent at 0, 5, 15, and 30 min. The samples were analyzed using liquid chromatography–tandem mass spectrometry (LC–MS/MS), and the percentage of VX-509 remaining based on the zero time point was determined.</div><div class="NLM_p last">In the liver S9 stability experiments, 1 or 10 μM VX-509 was incubated with liver S9 from the mouse, rat, dog, monkey, or human at a final protein concentration of 3.0 mg/mL. The reactions were initiated upon the addition of NADPH (2 mM final concentration) to evaluate the role of NADPH-dependent metabolic pathways. No cofactors were added to the control reactions. The liver S9 incubations were performed in triplicate. The reactions were terminated by protein precipitation using acetonitrile containing the analytical standard <i>N</i>-(1<i>H</i>-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]quinazolin-4-amine as the quenching reagent at 0, 5, 15, and 30 min. The samples were analyzed using LC–MS/MS, and the percentage of VX-509 remaining based on the zero time point was determined.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vivo Pharmacokinetic Studies</h3><div class="NLM_p last">Male Sprague–Dawley rat intravenous bolus/oral administration studies were conducted in-house, and beagle dog intravenous bolus/oral administration studies were conducted at Huntingdon Life Sciences, Eastmillstone, NJ. Male Sprague–Dawley rats (<i>n</i> = 3 per dose group) received single nominal intravenous doses of 1 mg/kg VX-509 solutions formulated in DMI–D5W–PG–EtOH (dimethylisosorbide (DMI), 5% dextrose in water (D5W), propylene glycol (PG), and ethanol (EtOH) in a ratio of 10:40:35:15). Blood samples (approximately 0.25 mL each) were collected via a carotid artery catheter predose and at 0.08, 0.17, 0.25, 0.50, 1.00, 2.00, 4.00, 6.00, 8.00, 12.00, and 24.00 h postdose.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Rat iv/po Studies</h3><div class="NLM_p last">Male Sprague–Dawley rats (<i>n</i> = 3 per dose group) were administered single nominal oral doses of 10 mg/kg VX-509 by gavage as a suspension formulated in 10% VitE TPGS (vitamin E <span class="smallcaps smallerCapital">d</span>-α-tocopheryl polyethylene glycol 1000 succinate). Blood samples were collected via carotid artery catheter prior to dosing and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 24.00, and 48.00 h postdose.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Dog iv/po Studies</h3><div class="NLM_p">One group of male beagle dogs (<i>n</i> = 3) was administered a single nominal intravenous dose of 1 mg/kg VX-509 as a solution formulated in propylene glycol 400 (PEG 400) and 5% dextrose in water (10:90, v/v) (PEG 400/D5W (10:90)). Blood samples (approximately 0.25 mL each) were collected via jugular, cephalic, or saphenous venipuncture at 0 h (predose) and 0.08, 0.17, 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 24.00, and 48.00 h postdose.</div><div class="NLM_p last">Male beagle dogs (<i>n</i> = 3 per dose group) were administered single nominal oral doses of 10 mg/kg VX-509 by gavage as a suspension formulated in 10% VitE TPGS. Blood samples were collected via jugular, cephalic, or saphenous venipuncture prior to dosing (predose) and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 24.00, and 48.00 h postdose.</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Blood Sample Collection and Plasma Sample Analysis</h3><div class="NLM_p last">Blood samples for the rat and dog pharmacokinetic studies were collected in tubes containing dipotassium EDTA and kept at approximately 4 °C. The plasma was separated and stored at approximately −70 °C until analysis. The plasma samples were analyzed using LC–MS/MS to determine VX-509 concentrations, with a lower limit of quantitation (LLOQ) of 1 ng/mL. The linear range of the assay was from 1 to 5000 ng/mL. VX-509 and the internal standard <i>N</i>-(1<i>H</i>-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]quinazolin-4-amine were extracted from the plasma, 100 μL each, by direct protein precipitation with acetonitrile (1:4 ratio of plasma to acetonitrile). After centrifugation, the supernatant extract (10 μL) was injected into the LC–MS/MS system. The HPLC portion of the system included a Waters Xterra MS C18 column (5 μm, 2.1 mm diameter × 50 mm length) eluted with a gradient mobile phase containing 10 mM ammonium acetate in water and acetonitrile. The analytes were detected by MS/MS with atmospheric pressure chemical ionization (APCI) in the mode of multiple reaction monitoring (MRM). Plasma concentration vs time data were subjected to noncompartmental pharmacokinetic (PK) analysis using WinNonlin Professional Edition software, version 5.1.1 (Pharsight Corp., Mountain View, CA).</div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Rat Host versus Graft (HvG) Model</h3><div class="NLM_p last">Male Lewis and Dark Agouti (DA) rats weighing 200–250 g (Harlan, Indianapolis, IN) were allowed to acclimate to the animal facility for 6 days, during which time they had ad libitum access to food and water. Spleen cells isolated from four DA male rats were pooled and γ-irradiated at 3000 cGy. A total of 40 male Lewis rats received injections into the right foot pad of 20 × 10<sup>6</sup> irradiated allogeneic spleen cells suspended in 100 μL of PBS. All treatments were initiated on day 0, 1 h prior to the injection of the graft cells. All groups were terminated on day 4. VX-509 was solubilized at 10, 25, 50, and 100 mg/kg as an aqueous solution in 10% VitE TPGS and 1% hydroxypropyl methylcellulose acetyl succinate (HPMC-AS). VX-509 was administered by oral gavage (po) once a day (qd) at 100 mg/kg or twice a day (bid, on a 10/14 h dosing schedule) at 10, 25, or 50 mg/kg/day for 4 days. CsA, an immunosuppressive drug used clinically, was used as a reference compound and was dosed at 6 mg/kg po, qd. VX-509 and CsA were administered in a dosing volume of 10 mL/kg. At study termination on day 4, the animals were sacrificed by CO<sub>2</sub> asphyxiation, and the popliteal lymph nodes were excised and weighed. The Δ weight difference between ipsilateral (right, grafted) and contralateral (left, nongrafted) popliteal lymph nodes was calculated and compared to the Δ values of the vehicle control and CsA-treated groups. Whole blood samples were collected via cardiac puncture and used for the ex vivo whole blood biomarker assay.</div></div><div id="sec3_9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Ex Vivo Whole Blood Biomarker Assay</h3><div class="NLM_p last">Whole blood was collected from Lewis rats via cardiac puncture in tubes containing lithium heparin (Vacutainer, BD, Franklin, NJ). The blood samples were plated at a volume of 100 μL (the final concentration of whole blood in the assay is 50%) in 96-well cluster tubes. Three wells per animal were stimulated with PMA at 100 ng/mL and rat anti-CD28 at a concentration of 10 μg/mL. Control medium was added to the other three wells (unstimulated). The final volume of the cluster tubes was 200 μL. The cluster tubes were incubated overnight at 37 °C in a CO<sub>2</sub> incubator. After 18–24 h of incubation, the cells were stained with anti-CD3 PE and anti-CD28 FITC for 30 min at room temperature. Lysis buffer (800 μL of 1× RBC, Sigma) was added to the plate, and the plate was incubated at room temperature for 10 min. The cluster plate was centrifuged, and the supernatant was aspirated. Lysis buffer (300 μL of 1× RBC) was added, and the plates were centrifuged. Once the supernatant was aspirated, the cell pellet was resuspended in 300 μL of PBS containing 1% formaldehyde. The samples were read on the FACS Calibur HTS reader. Data were analyzed using Flow Jo and Excel.</div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Compound Preparation and Characterization</h3><div class="NLM_p">All commercially available reagents and anhydrous solvents were used without further purification. Purity assessment for final compounds based on analytical HPLC: 4.6 mm × 50 mm Waters YMC Pro-C18, 5 μm column, 120A. Mobile phases are as follows: A, H<sub>2</sub>O with 0.2% formic acid; B, acetonitrile with 0.2% formic acid. Gradient: 10–90% B in 3 min with a 5 min run time. The flow rate was 1.5 mL/min. Unless specified otherwise, all compounds were ≥95% pure. Mass samples were analyzed on a Micro Mass ZQ, ZMD, Quattro LC, or Quatro II mass spectrometer operated in a single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using flow injection (FIA) or chromatography. The mobile phase for all mass analysis consisted of acetonitrile–water mixtures with either 0.2% formic acid or ammonium formate. <sup>1</sup>H NMR spectra were recorded using either a Bruker Avance 400 (400 MHz) or a Bruker Avance II-300 (300 MHz) instrument. Column chromatography was performed using Teledyne ISCO RediSep Normal Phase (35–70 μm) or RediSep Gold Normal Phase (25–40 μm) silica flash columns using a Teledyne ISCO Combiflash Companion or Combiflash Rf purification system. Preparative reversed-phase chromatography was carried out using a Gilson 215 liquid handler coupled to a UV–vis 156 Gilson detector and an Agilent Zorbax SB-C18 column, 21.2 mm × 100 mm. A linear gradient from 10% to 90% CH<sub>3</sub>CN in H<sub>2</sub>O over 10 min (0.1% trifluoroacetic acid) was used; the flow rate was 20 mL/min.</div><div class="NLM_p last">High-resolution mass spectrometry data were collected on a Thermo Scientfic QExactive mass spectrometer coupled to a Waters Acquity UPLC system. Samples were analyzed from a 100 μM DMSO solution with a 3 μL injection volume. The chromatographic column was a Waters Acquity CSH C18, 2.1 × 50 mm, 1.7 μm particle size. Gradient elution was employed using 0.1% formic acid in water as mobile phase A and 0.1% formic acid as mobile phase B. The gradient began at 10% B and increased to 60% B over 0.8 min and to 100% B over the next 0.2 min, followed by a 0.5 min re-equilibration at the initial conditions. The mass spectrometer was run in full MS mode, positive polarity, with the resolution set to 35 000. A heated electrospray source was used with settings of 3.5 kV and 400 °C.</div></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Preparation of 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine Intermediates (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h3><div id="sec3_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 5-Chloro-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>B</b>; X = CCl)</h4><div class="NLM_p last">A 22 L, four-necked, round-bottomed flask equipped with an overhead stirrer, dropping funnel, and thermocouple was charged with 3 L of anhydrous THF followed by 131.6 g (3.29 mol) of NaH and 582.8 g (3.06 mol) of <i>p</i>-toluenesulfonyl chloride. A solution of 467.5 g (3.06 mol) of <b>4</b> in 2 L of THF was added to the mixture via the dropping funnel. A significant exotherm was observed that was controlled by the rate of addition. The mixture was stirred at room temperature overnight, quenched with water, and extracted with EtOAc. The organic extract was dried (MgSO<sub>4</sub>) and evaporated in vacuo. The crude product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and filtered over a plug of silica gel. The plug was eluted with CH<sub>2</sub>Cl<sub>2</sub>, and the filtrate was evaporated in vacuo to afford 917 g (98%) of <b>5</b> as a light yellow solid: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 12.21 (s, 1H), 8.67 (s, 1H), 8.32 (t, 1H) 8.26 (dd, 2H), 8.0 (s, 1H), 7.47 (s, 1H), 3.78 (m, 2H), 1.59 (s, 6H).</div></div><div id="sec3_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-Bromo-5-chloro-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>C</b>; X = CCl)</h4><div class="NLM_p last">A 22 L, four-necked, round-bottomed flask equipped with an overhead stirrer, dropping funnel, and thermocouple was charged with 855.6 g (2.79 mol) of <b>5</b> and 5 L of CH<sub>2</sub>Cl<sub>2</sub>. Bromine (290 mL, 5.64 mol) was added via the dropping funnel. An exotherm was observed during the addition, and an orange solid precipitated. The mixture was stirred overnight and washed with aqueous NaHSO<sub>3</sub>. The organic solution was dried (MgSO<sub>4</sub>) and filtered over a plug of silica gel. The plug was eluted with CH<sub>2</sub>Cl<sub>2</sub>, and the filtrate was evaporated in vacuo to afford 1047 g (97%) of <b>6</b> as an off-white solid: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.38 (d, 1H), 8.08 (d, 2H), 7.76 (d, 1H), 7.28 (d, 2H), 2.39 (s, 3H).</div></div><div id="sec3_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 5-Chloro-3-(4,,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>50b</b>; X = CCl)</h4><div class="NLM_p last">A 22 L, four-necked, round-bottomed flask equipped with an overhead stirrer and thermocouple was charged with 1074 g (2.79 mol) of <b>6</b> and 6 L of 1,4-dioxane. Bispinacol diboron (1030 g, 4.06 mol) was added along with 812 g (8.27 mol) of KOAc. The mixture was deoxygenated for 2 h with a stream of nitrogen, and 185 g (160 mmol) of Pd(PPh<sub>3</sub>)<sub>4</sub> was added along with 200 mL of distilled water. The mixture was heated to 95 °C overnight. The reaction was cooled and filtered over Celite. The Celite was washed with EtOAc, and the filtrate was evaporated in vacuo. The crude product mixture was dissolved in EtOAc and filtered over a plug of Florisil. The plug was eluted with EtOAc, and the filtrate was evaporated in vacuo. The solid was slurried with hexane and filtered. The filter cake was washed with hexane and dried to afford 984 g (82%) of <b>50b</b> as a gray solid: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.31 (d, 1H), 8.13 (m, 2H), 8.05 (d, 2H), 2.38 (s, 3H), 1.38 (s, 12H).</div></div><div id="sec3_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Data for 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>50a</b>; X = CH):</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.17 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 8.12 (s, 1H), 8.10–8.04 (d, <i>J</i> = 8.1 Hz, 2H), 7.24 (d, <i>J</i> = 8.1 Hz, 2H), 7.17 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 2.34 (s, 3H), 1.34 (s, 12H).</div></div><div id="sec3_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Data for 5-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>50c</b>; X = CF):</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (dd, <i>J</i> = 2.7, 1.3 Hz, 1H), 8.11 (s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (dd, <i>J</i> = 8.4, 2.7 Hz, 2H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 2.32 (s, 3H), 1.29 (s, 12H).</div></div><div id="sec3_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Data for 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>50d</b>; X = COCH<sub>3</sub>):</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.13 (d, <i>J</i> = 2.8 Hz, 1H), 8.08 (s, 1H), 8.06–8.00 (d, <i>J</i> = 8.0 Hz, 2H), 7.63 (d, <i>J</i> = 2.8 Hz, 1H), 7.28–7.20 (d, <i>J</i> = 8.0 Hz, 2H), 3.86 (s, 3H), 2.34 (s, 3H), 1.33 (s, 12H).</div></div><div id="sec3_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Data for 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>50e</b>; X = N):</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.07 (s, 1H), 8.96 (s, 1H), 8.10 (s, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 2H), 7.43 (d, <i>J</i> = 8.0 hZ, 2H), 2.33 (s, 3H), 1.30 (s, 12H).</div></div></div><div id="sec3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Preparation of Compounds from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> (<a class="ref internalNav" href="#sch2a" aria-label="Scheme 2">Scheme 2</a>a)</h3><div id="sec3_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Benzyl(2-chloropyridin-4-yl)amine (<b>51a</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloropyrimidine (0.15 g, 1.0 mmol) and benzylamine (0.109 mL, 1.0 mmol) in THF was added DIPEA (0.526 mL, 3.0 mmol), and the reaction mixture was heated at reflux for 2 h, resulting in the formation of a 4:1 mixture of regioisomers (desired vs undesired) by TLC (5% CH<sub>3</sub>OH–CH<sub>2</sub>Cl<sub>2</sub>). The reaction was concentrated in vacuo to an oil that was then subjected to flash chromatography (2% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to provide 120 mg (54%) of the desired product <b>51a</b>: <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 4.95 (br s, 2H), 6.6 (d, 1H), 7.2 (m, 1H), 7.3–7.5 (m, 5H), 8.0 (d, 1H), 8.3 (d, 1H), 8.4 (s, 1H), 8.55 (d, 1H); LC–MS [M + H]<sup>+</sup>= 220.</div></div><div id="sec3_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Benzyl[2-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3-yl)-pyrimidin-4-yl]amine (<b>6</b>)</h4><div class="NLM_p last">A solution of <b>50a</b> (0.36 g, 0.09 mmol), <b>51a</b> (0.028 g, 0.108 mmol), 2 M Na<sub>2</sub>CO<sub>3</sub> (0.108 mL, 0.271 mmol), and catalytic PdCl<sub>2</sub> in 1 mL of DMSO was heated in the microwave at 160 °C for 5 min, resulting in conversion to the tosylated intermediate product. NaO<i>t</i>Bu (0.026 g, 0.271 mmol) was added, and the reaction mixture was heated in the microwave for 5 min at 160 °C, resulting in complete conversion to product. The reaction was filtered and purified by preparative HPLC, giving 0.0032 g of <b>6</b> as a white solid in 11% yield: <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 4.95 (br s, 2H), 6.6 (d, 1H), 7.2 (, 1H), 7.3–7.5 (m, 5H), 8.0 (d, 1H), 8.3 (d, 1H), 8.4 (s, 1H), 8.55 (d, 1H); LC–MS [M + H]<sup>+</sup> = 302.0; HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>15</sub>N<sub>5</sub> + H<sup>+</sup>) 302.1400221, found 302.13962 with a deviation of only 1.33 ppm.</div></div><div id="sec3_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Benzyl(6-chloro-pyrimidin-4-yl)amine (<b>51b</b>)</h4><div class="NLM_p last">Benzylamine (0.697 mL, 6.76 mmol) was added to 4,6-dichloropyrimidine (l.0 g, 6.76 mmol) neat, causing a vigorous reaction and color change. The reaction was slowly diluted with methylene chloride, resulting in a white precipitate. Triethylamine (1 mL) was added, and TLC indicated conversion to product (5% CH<sub>3</sub>OH–CH<sub>2</sub>Cl<sub>2</sub>). The reaction was loaded directly onto silica and purified (2% CH<sub>3</sub>OH–CH<sub>2</sub>Cl<sub>2</sub>), giving 1.17 g (5.32 mmol) of <b>51b</b> as a yellow wax in 79% yield.</div></div><div id="sec3_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-Benzyl-6-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-amine (<b>4</b>)</h4><div class="NLM_p last">Final product <b>4</b> was formed as described for <b>6,</b> giving 0.012 g of a white solid: <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 4.8 (s, 2H), 7.05 (s, 1H), 7.2–7.6 (m, 6H), 8.2 (s, 1H), 8.4 (m, 2H), 8.55 (s, 1H); LC–MS [M + H]<sup>+</sup> = 302; HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>15</sub>N<sub>5</sub> + H<sup>+</sup>) 302.14002, found 302.13956 with a deviation of only 1.53 ppm.</div></div><div id="sec3_12_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-Benzyl-6-(5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-amine (<b>7</b>)</h4><div class="NLM_p last">Final product <b>7</b> was formed as described for <b>6</b>, giving 0.010 g of a white solid: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.7 (br s, 2H), 8.4 (br s, 2H), 8.3 (s, 1H), 7.4 (m, 5H), 4.8 (s, 2H); LC–MS [M + H]<sup>+</sup> = 335.9; <i>t</i><sub>R</sub> = 2.4 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_12_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-Benzyl-6-bromopyridin-2-amine (<b>52</b>)</h4><div class="NLM_p last">This compound is commercially available from several sources. However, the compound was conveniently prepared as described here. A microwave vial was charged with benzylamine (700 mg, 5 mmol) and 2,6-dibromopyridine (238 mg, 1 mmol). The reaction mixture was stirred in the microwave at 150 °C three times for 10 min each. The reaction mixture was diluted with diethyl ether (50 mL) and washed with 10% aqueous citric acid, saturated aqueous sodium bicarbonate, and brine. The organic phase was dried over magnesium sulfate and, after filtration, concentrated in vacuo to afford the title compound (300 mg, 100% yield) as an oil, which was used without further characterization: LC–MS [M + H]<sup>+</sup> = 264.</div></div><div id="sec3_12_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-Benzyl-6-(5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyridin-2-amine (<b>9</b>)</h4><div class="NLM_p last">A microwave vial was charged with <i>N</i>-benzyl-6-bromopyridin-2-amine (300 mg, 1 mmol), 5-chloro-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-1-(tolyl-4-sulfonyl)-1<i>H</i>-[2,3-<i>b</i>]pyridine (<b>50b</b>) (215 mg, 0.5 mmol), tetrakis(triphenylphosphine) palladium (60 mg, 0.05 mmol), 2 M sodium hydroxide (0.75 mL), and dimethoxyethane (5 mL). The suspension was degassed with nitrogen. The reaction mixture was stirred in the microwave at 130 °C for 10 min. It was then diluted with ethyl acetate (60 mL), washed with brine twice, dried over magnesium sulfate, and, after filtration, concentrated in vacuo. The compound was purified by flash chromatography (eluent petroleum ether/ethyl acetate, 60:40) to afford 50 mg of the tosyl-protected title compound. This residue was taken up in a mixture of methanol and tetrahydrofuran (1:3), and 1 M sodium hydroxide solution (1 mL) was added to the reaction mixture, which was then stirred at room temperature for 3 h. The reaction mixture was then concentrated in vacuo, and the residue was triturated with methanol. The suspension was filtered to afford the title compound (35 mg, 10%): <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>CN) δ 10.55 (s, 1H), 8.38 (m, 1H), 8.30 (m, 2H), 7.89 (t, 1H), 7.41 (m, 4H), 7.34 (m, 1H), 7.12 (d, 1H), 6.73 (d, 1H), 4.7–5.7 (s, 4H) 4.60 (s, 2H); LC–MS [M + H]<sup>+</sup> = 335; <i>t</i><sub>R</sub> = 4.1 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>19</sub>H<sub>15</sub>ClN<sub>4</sub> + H<sup>+</sup>) 335.10580, found 335.10515 with a deviation of only 1.94 ppm.</div></div><div id="sec3_12_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-Benzyl-3-(5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline (<b>10</b>)</h4><div class="NLM_p last">Final product <b>10</b> was formed as described for <b>6</b> starting from commercially available <i>N</i>-benzyl-3-bromoaniline (160 mg, 73%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.04 (s, 1H), 8.23 (d, <i>J</i> = 2.3 Hz, 1H), 8.06 (d, <i>J</i> = 2.3 Hz, 1H), 7.81 (d, <i>J</i> = 2.6 Hz, 1H), 7.41 (d, <i>J</i> = 7.0 Hz, 2H), 7.35 (dd, <i>J</i> = 10.3, 4.8 Hz, 2H), 7.24 (t, <i>J</i> = 7.3 Hz, 1H), 7.10 (t, <i>J</i> = 7.8 Hz, 1H), 6.90 (t, <i>J</i> = 1.8 Hz, 1H), 6.84 (d, <i>J</i> = 7.7 Hz, 1H), 6.51 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 6.33 (t, <i>J</i> = 6.0 Hz, 1H), 4.34 (d, <i>J</i> = 5 0.9 Hz, 2H); LC–MS [M + H]<sup>+</sup> = 333.8; <i>t</i><sub>R</sub> = 2.4 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div></div><div id="sec3_12_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Preparation Compounds from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> (<a class="ref internalNav" href="#sch2a" aria-label="Scheme 2">Scheme 2</a>b)</h3><div id="sec3_12_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-(2-(Methylthio)pyrimidin-4-yl)-1-(tolyl-4-sulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>53a</b>; X = CH)</h4><div class="NLM_p last">A mixture of boronic ester <b>50a</b> (900 mg, 0.0023 mmol) and 4-chloro-2-(methylthio)pyridine (341 mg, 0.0068 mmol) in 20 mL of DME was refluxed under nitrogen for 18 h. The mixture was diluted with ethyl acetate, and the organic layer was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The residue was subjected to flash chromatography (40% EtOAc in hexanes) to give 460 mg (51%) of the desired product <b>53a</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.8 (d, 1H), 8.7 (d, 2H), 8.4 (s, 1H), 8.1 (d, 2H), 7.2 (m, 4H), 2.6 (s, 3H), 2.3 (s, 3H).</div></div><div id="sec3_12_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-(2-(Methylsulfonyl)pyrimidin-4-yl)-1-(tolyl-4-sulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>54a</b>)</h4><div class="NLM_p last">The above pyrimidine <b>53a</b> (460 mg, 0.0012 mmol) was dissolved in 20 mL of methanol–water (1:1). Then Oxone (2.14 g, 0.0035 mmol) was added, and the reaction was refluxed for 18 h. The methanol was removed in vacuo, and the aqueous phase was extracted with ethyl acetate. The organic phase was washed with water amd brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The residue was subjected to flash chromatography (40% EtOAc in hexanes) to give 160 mg (32%) of the desired product <b>54a</b>, which was used without further purification: LC–MS [M + H]<sup>+</sup> = 428.9</div></div><div id="sec3_12_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Benzyl[4-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-2-yl]amine (<b>5</b>)</h4><div class="NLM_p last">A solution of <b>54a</b> (20 mg, 0.047 mmol) and benzylamine (0.007 mL, 0.061 mmol) in 1 mL of ethanol was heated in a sealed tube at 80 °C for 18 h. The solvent was removed in vacuo, and the crude product was purified by preparative TLC (50% EtOAc/50% hexanes) to give 20 mg of intermediate product, which was deprotected with 2 mL of 3 N NaOH in methanol for 4 h. To evaporate to dryness, 2 mL of 3 N HCl was added. Reversed-phase HPLC (20–70% CH<sub>3</sub>CN–water with 0.1% TFA (20 mL/min)) gave 10 mg (75%) of the desired product <b>5</b>: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.7 (br s, 1H), 8.4 (br s, 1H), 8.25 (d, 1H), 8.1 (d, 1H), 7.4 (m, 2H), 7.25 (m, 3H), 7.2 (br s, 1H), 7.15 (br s, 1H), 4.7 (br s, 2H); LC–MS [M + H]<sup>+</sup> = 302.14.</div></div><div id="sec3_12_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-Benzyl-4-(5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-2-amine (<b>8</b>)</h4><div class="NLM_p last">The compound was prepared according to the above procedure for compound <b>5</b> using <i>N</i>-benzyl-4-(5-chloro-1<i>H</i>-pyrrolo[5,4-<i>b</i>]pyridin-3-yl)pyrimidin-2-amine (trifluoroacetic acid) (51 mg, 0.1097 mmol, 49.14%): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.62 (br s, 1H), 8.60 (s, 1H), 8.29 (d, <i>J</i> = 2.2 Hz, 1H), 8.07 (d, <i>J</i> = 6.5 Hz, 1H), 7.47 (d, <i>J</i> = 7.6 Hz, 2H), 7.43–7.32 (m, 3H), 7.29 (t, <i>J</i> = 7.1 Hz, 1H), 4.83 (s, 2H); LC–MS [M + H]<sup>+</sup> = 335.9; <i>t</i><sub>R</sub> = 2.6 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>14</sub>ClN<sub>5</sub> + H<sup>+</sup>) 336.10104, found 336.10051 with a deviation of only 1.61 ppm.</div></div></div><div id="sec3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Preparation os Compounds from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> (<a class="ref internalNav" href="#sch2a" aria-label="Scheme 2">Scheme 2</a>a)</h3><div id="sec3_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoro-<i>N</i>-isopropylpyrimidin-4-amine (<b>11</b>)</h4><div class="NLM_p">A solution of 2-isopropylamine (0.27 mL, 3.12 mmol), 2,4-dichloro-5-fluoropyrimidine (518 mg, 3.12 mmol), and DIPEA (0.790 mL, 4.6 mmol) in 2 mL of 2-propanol was heated at 90 °C in a sealed tube overnight. The solution was allowed to cool, and the volatiles were removed in vacuo. The residue was dissolved in ethyl acetate, washed twice with water, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to provide a brown oil that was used directly for the next step.</div><div class="NLM_p last">A microwave vial was charged with 2-chloro-5-fluoro-<i>N</i>-isopropylpyrimidin-4-amine (85 mg, 0.45 mmol) from the previous step, 5-chloro-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1-(tolyl-4-sulfonyl)-1<i>H</i>-[2,3-<i>b</i>]pyridine (<b>50b</b>) (146 mg, 0.347 mmol), tetrakis(triphenylphosphine)palladium (39 mg, 0.035 mmol), 2 M K<sub>2</sub>CO<sub>3</sub> (0.52 mL), and dimethoxyethane (4 mL). The suspension was degassed with nitrogen. The reaction mixture was stirred in the microwave at 130 °C for 15 min. The compound was purified by flash chromatography (0–45% ethyl acetate/hexanes) to afford the tosyl-protected title compound. This residue was taken up in a mixture (5 mL) of methanol and tetrahydrofuran (1:3), and a 2 M sodium hydroxide solution (1 mL) was added to the reaction mixture, which was then stirred at room temperature for 2 h. Trituration from TFA/acetonitrile provided after filtration 30 mg (28%, two steps) of the desired product <b>11</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.79–12.42 (m, 1H), 8.63 (d, <i>J</i> = 2.4 Hz, 1H), 8.45–8.09 (m, 3H), 4.43 (dq, <i>J</i> = 13.4, 6.6 Hz, 1H), 1.29 (d, <i>J</i> = 6.6 Hz, 6H); <sup>13</sup>C NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 148.04, 142.35, 131.89, 129.04, 124.61, 119.27, 43.36, 22.49; LC–MS [M + H]<sup>+</sup> = 306.46; <i>t</i><sub>R</sub> = 4.8 min (1–99% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>14</sub>H<sub>13</sub>ClFN<sub>5</sub> + H<sup>+</sup>) 306.091628, found 306.09043 with a deviation of only 3.91 ppm.</div></div><div id="sec3_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-<i>N</i>-cyclopropyl-5-fluoropyrimidin-4-amine (<b>12</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using cyclopropylamine as the starting material, to provide 50 mg of an off-white solid: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.16 (s, exchanged with D<sub>2</sub>O, 1H), 9.07 (d, <i>J</i> = 2.0 Hz, 1H), 8.30 (d, <i>J</i> = 2.4 Hz, 1H), 8.17 (d, <i>J</i> = 2.4 Hz, addition of D<sub>2</sub>O changed d to s, 1H), 8.07 (d, <i>J</i> = 3.6 Hz, 1H), 5.28 (s, exchanged with D<sub>2</sub>O, 1H), 2.98–2.95 (m, 1H), 1.05–1.00 (q, 2H), 0.75–0.71 (m, 2H); HRMS [M + H]<sup>+</sup> calcd for (C<sub>14</sub>H<sub>11</sub>ClFN<sub>5</sub> + H<sup>+</sup>) 335.1058008, found 335.10515 with a deviation of only 1.94 ppm.</div></div><div id="sec3_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-<i>N</i>-cyclohexyl-5-fluoropyrimidin-4-amine (<b>13</b>)</h4><div class="NLM_p last">The itle compound was prepared according to the procedure detailed for <b>11</b>, using cyclohexylamine as the starting material, to provide 30 mg (25%, two steps) of the desired product <b>13</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.85 (1H, m), 1.48 (4H, m), 1.68 (1H, d), 1.81 (2H, m), 2.04 (2H, m), 4.03 (1H, m), 7.49 (1H, d), 8.13 (1H, s), 8.19 (1H, s), 8.29 (1H, s), 8.73 (1H, s), 12.21 (1H, s); LC–MS [M + H]<sup>+</sup> = 346.43; <i>t</i><sub>R</sub> = 5.25 min (10–100% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-<i>N</i>-cyclohexylpyrimidin-4-amine (<b>14</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using cyclohexylamine as the starting material, to provide 18.4 mg of a white solid: <sup>1</sup>H NMR (300 MHz, CDCl3) δ 10.84 (s, 1 H), 8.91 (d, <i>J</i> = 2.2 Hz, 1 H), 8.29–8.14 (m, 3 H), 6.13 (d, <i>J</i> = 5.9 Hz, 1 H), 4.96 (s, 1 H), 3.86 (s, 1 H), 2.15–1.48 (m, 10 H); LC–MS [M + H]<sup>+</sup> = 328.2; <i>t</i><sub>R</sub> = 2.07 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>18</sub>ClN<sub>5</sub> + H<sup>+</sup>) 328.13235, found 328.13112 with a deviation of only 3.75 ppm.</div></div><div id="sec3_13_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-<i>N</i>-cyclohexyl-5-fluoro-<i>N</i>-methylpyrimidin-4-amine (<b>15</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using <i>N</i>-methylcyclohexylamine as the starting material, to provide 18.4 mg of a white solid: <sup>1</sup>H NMR (300 MHz, CDCl3) δ 10.02 (br s, 1H), 8.81 (d, 1H), 8.31 (d, 1H), 8.29 (br s, 1H), 8.07 (d, 1H), 4.58 (m, 1H), 3.17 (d, 3H), 1.94–1.51 (m, 10 H); LC–MS [M + H]<sup>+</sup> = 360.2; <i>t</i><sub>R</sub> = 3.18 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_13_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoro-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)pyrimidin-4-amine (<b>16</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using tetrahydro-2<i>H</i>-pyran-4-amine as the starting material, to provide, after chromatography of the final product (0–100% ethyl acetate/hexanes), 55 mg (27%, two steps) of the desired product <b>16</b> as an off-white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.79–12.42 (m, 1H), 8.63 (d, <i>J</i> = 2.4 Hz, 1H), 8.45–8.09 (m, 3H), 4.43 (dq, <i>J</i> = 13.4, 6.6 Hz, 1H), 1.29 (d, <i>J</i> = 6.6 Hz, 6H); ES<sup>+</sup> = 348.68; <i>t</i><sub>R</sub> = 4.42 min (10–100% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>16</sub>H<sub>15</sub>ClFN<sub>5</sub>O + H<sup>+</sup>) 348.102193, found 348.10078 with a deviation of only 4.06 ppm.</div></div><div id="sec3_13_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoro-<i>N</i>-(piperidin-4-yl)pyrimidin-4-amine (<b>17</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using <i>tert</i>-butyl 4-aminopiperidine-1-carboxylate as the starting material, to provide, after the removal of Boc with TFA/CH<sub>2</sub>Cl<sub>2</sub> at rt for 2 h, the crude desired product. Reversed-phase preparative chromatography (10–80% CH<sub>3</sub>CN–water with 0.1% TFA) purification of the final product gave 20 mg (36%, two steps) of the desired product <b>17</b> as an off-white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.67 (2H, m), 1.96 (2H, d), 3.49 (2H, t), 3.96 (2H, d), 4.30 (1H, m), 7.62 (1H, d), 8.18 (1H, s), 8.22 (1H, s), 8.29 (1H, s), 8.72 (1H, s), 12.36 (1H, s); LC–MS [M + H]<sup>+</sup> = 347.4; <i>t</i><sub>R</sub> = 3.5 min (10–100% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>16</sub>H<sub>16</sub>ClFN<sub>6</sub> + H<sup>+</sup>) 347.118177, found 347.11708 with a deviation of only 3.16 ppm.</div></div><div id="sec3_13_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-<i>N</i>-(cyclohexylmethyl)-5-fluoropyrimidin-4-amine (<b>18</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using cyclohexylmethanamine as the starting material, to provide, after chromatography of the final product (0–100% EtOAc/hexanes), 60 mg (29%, two steps) of the desired product <b>18</b> as an off-white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.81–12.50 (m, 1H), 8.66 (d, <i>J</i> = 2.6 Hz, 1H), 8.45–8.25 (m, 3H), 3.39 (t, <i>J</i> = 6.5 Hz, 2H), 2.0–1.41 (m, 6H), 1.30–0.82 (m, 5H). <sup>13</sup>C NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 147.72, 142.38, 128.91, 124.88, 119.44, 42.20, 37.11, 31.37, 26.72, 26.01; LC–MS [M + H]<sup>+</sup> = 360.46; <i>t</i><sub>R</sub> = 5.39 min (10–100% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>19</sub>ClFN<sub>5</sub> + H<sup>+</sup>) 360.138578, found 360.13722 with a deviation of only 3.77 ppm.</div></div><div id="sec3_13_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoro-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-4-yl)methyl)pyrimidin-4-amine (<b>19</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using (tetrahydro-2<i>H</i>-pyran-4-yl)methanamine as the starting material, to provide, after chromatography of the final product (0–100% EtOAc/hexanes), 19 mg (14%, two steps) of the desired product <b>19</b> as a yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.31 (d, <i>J</i> = 2.2 Hz, 1H), 8.70 (dd, <i>J</i> = 2.4, 1.0 Hz, 1H), 8.25 (dd, <i>J</i> = 2.5, 1.0 Hz, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 8.11 (dd, <i>J</i> = 4.0, 0.9 Hz, 1H), 7.78 (t, <i>J</i> = 5.8 Hz, 1H), 3.84 (d, <i>J</i> = 9.5 Hz, 2H), 3.38 (t, <i>J</i> = 6.5 Hz, 2H), 3.23 (d, <i>J</i> = 11.1 Hz, 2H), 1.69 (d, <i>J</i> = 12.5 Hz, 2H), 1.25 (dd, <i>J</i> = 12.6, 4.4 Hz, 2H); LC–MS [M + H]<sup>+</sup> = 361.0; <i>t</i><sub>R</sub> = 4.5 min (10–100% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>17</sub>ClFN<sub>5</sub>O + H<sup>+</sup>) 362.117843, found 362.11669 with a deviation of only 3.18 ppm.</div></div><div id="sec3_13_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoro-<i>N</i>-((1-methylpiperidin-4-yl)methyl)pyrimidin-4-amine (<b>20</b>)</h4><div class="NLM_p last">The title compound was prepared according to the procedure detailed for <b>11</b>, using (1-methylpiperidin-4-yl)methanamine as the starting material, to provide, after chromatography of the final product (0–100% ethyl acetate/hexanes), 10 mg (10%, two steps) of the desired product <b>20</b> as a yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.14–1.24 (2H, m), 1.75–1.80 (5H, m), 2.11 (3H, s), 2.75 (2H, d), 3.40 (2H, t), 7.80 (1H, t), 8.13 (1H, d), 8.20 (1H, s), 8.28 (1H, d), 8.73 (1H, d), 12.35 (1H, s); LC–MS [M + H]<sup>+</sup> = 375.0; <i>t</i><sub>R</sub> = 3.95 min (10–100% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>20</sub>ClFN<sub>6</sub> + H<sup>+</sup>) 375.149477, found 375.14795 with a deviation of only 4.07 ppm.</div></div><div id="sec3_13_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)-2-methylpropan-1-ol (<b>21</b>)</h4><div class="NLM_p">A solution of (2<i>S</i>,6<i>R</i>)-2,6-dimethylpiperazine (1.2 g, 10 mmol), 2,4-dichloropyrimidine (1.49 g, 10 mmol), and DIPEA (3.5 mL) in 3.5 mL of 2-propanol was heated to reflux for 3 h. The solution was allowed to cool, and the volatiles were removed in vacuo. The residue was suspended in ethyl acetate (100 mL), heated with 10 mL of acetic anhydride and 3 mL of <i>N</i>-methylmorpholine, and stirred overnight at room temperature. The reaction mixture was washed with satd NaHCO<sub>3</sub> and then brine and the organic phase dried with Na<sub>2</sub>SO<sub>4</sub>. The organic phase was concentrated in vacuo to give 2.3 g of a crude gummy solid that was subjected to chromatography (5% CH<sub>3</sub>OH–CH<sub>2</sub>Cl<sub>2</sub>), providing 0.58 g of the desired intermediate, which was used directly for the next step.</div><div class="NLM_p last">A microwave vial was charged with 1-((2<i>S</i>,6<i>R</i>)-4-(2-chloropyrimidin-4-yl)-2,6-dimethylpiperazin-1-yl)ethan-1-one (32 mg, 0.13 mmol) from the previous step, 5-chloro-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-l-(tolyl-4-sulfonyl)-1<i>H</i>-[2,3-<i>b</i>]pyridine (<b>50b</b>) (43 mg, 0.10 mmol), tetrakis(triphenylphosphine)palladium (20 mg, 0.025 mmol), 2 M K<sub>2</sub>CO<sub>3</sub> (0.5 mL), and dimethoxyethane (4 mL). The suspension was degassed with nitrogen. The reaction mixture was stirred in the microwave at 140 °C for 20 min. The compound was filtered over Celite and concentrated to afford the tosyl-protected title compound. This residue was dissolved in a mixture 3 mL of THF and 1 mL of 1 M lithium hydroxide solution, which was then microwaved at 150 °C for 5 min. Chromatography (30–100% ethyl acetate/hexanes) provided 12 mg (30%, two steps) of the desired product <b>21</b> as a white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.68 (d, <i>J</i> = 2.2 Hz, 1H), 8.50 (s, 1H), 8.40 (d, <i>J</i> = 2.3 Hz, 1H), 8.17 (d, <i>J</i> = 7.6 Hz, 1H), 7.08 (d, <i>J</i> = 7.5 Hz, 1H), 3.58 (br s, 4H), 2.22 (s, 3H), 1.36 (br s, 6H); ES<sup>+</sup> = 385.1; <i>t</i><sub>R</sub> = 1.6 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>19</sub>H<sub>21</sub>ClN<sub>6</sub>O + H<sup>+</sup>) 385.153814, found 385.15248 with a deviation of only 3.46 ppm.</div></div></div><div id="sec3_14_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Representative Procedures for the Synthesis of Compounds in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>  (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>)</h3><div id="sec3_14_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Synthesis of 2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>44</b>)</h4><div id="sec3_14_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> <i>tert</i>-Butyl 2-(2,2,2-Trifluoroethylcarbamoyl)propan-2-ylcarbamate</h5><div class="NLM_p last">Boc-<i>N</i>-2-methylpropanoic acid (<b>M</b>) (aa (amino acid) = C(CH<sub>3</sub>)<sub>2</sub>) (14.6 g, 72.1 mmol), HATU (27.4 g, 72.1 mmol), diisopropylethylamine (18.8 mL, 108.1 mmol), and trifluoroethylamine hydrochloride (14.6 g, 108.1 mmol) were dissolved in 100 mL of DMF, and the solution was stirred at rt for 16 h. The reaction mixture was poured into water (1 L), and the pH was adjusted to 4 with 1 N HCl. The aqueous phase was extracted with MBTE (2 × 1 L), and the combined organic phases were washed with satd NaHCO<sub>3</sub>, water, and brine. The organic layer was dried Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to provide 15.11 g (78%) of a white solid that was used directly for the next step: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 3.90–3.80 (m, 2H), 1.41 (s, 9H), 1.40 (s, 6H).</div></div><div id="sec3_14_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 2-Amino-<i>N</i>-(2,2,2-trifluoroethyl)-2-methylpropanamide (<b>N</b>)</h5><div class="NLM_p last">The white solid Boc-amide (15.11 g) was dissolved in 75 mL of CH<sub>2</sub>Cl<sub>2</sub>. A 37 mL volume of TFA was slowly added, and the reaction mixture was stirred for 1 h at rt. The reaction mixture was concentrated in vacuo to an oil that was diluted with 100 mL of ether and evaporated to dryness to remove the residual TFA. Two more dissolution/evaporation cycles were necessary to remove excess TFA and provided the desired amine peptide <b>N</b> quantitatively as the TFA salt. This intermediate was used directly for the next step: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 3.96 (q, <i>J</i> = 9.3 Hz, 2H), 1.58 (s, 6H).</div></div><div id="sec3_14_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 2-(2-Chloro-5-fluoropyrimidin-4-ylamino)-<i>N</i>-(2,2,2-trifluoroethyl)-2-methylpropanamide (<b>Q</b>; Z = CF)</h5><div class="NLM_p last">Amine <b>N</b> (12.37 g, 44 mmol) and DIEA (38 mL, 220 mmol) were dissolved in 125 mL of DMF. 5-Fluoro-2,4-dichloropyrimidine (7.4 g, 44 mmol) was then added, and the reaction mixture was stirred at rt for 8 h. The reaction mixture was poured into water (600 mL) and extracted with MBTE (2 × 200 mL) after adjustment of the pH to 4–5 with 1 N HCl. The combined organics were washed with water and brine, dried, filtered, and concentrated in vacuo to a crude solid. The residue was subjected to chromatography on the ISCO (120 g column; gradient 0–80% EtOAc in hexanes) to provide 4.38 g (32%) of the desired product <b>Q</b> (Z = CF): H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.97 (d, <i>J</i> = 3.4 Hz, 1H), 3.83 (q, <i>J</i> = 9.3 Hz, 2H), 1.60 (s, 6H); LC–MS [M + H]<sup>+</sup> = 315.07; <i>t</i><sub>R</sub> = 0.65 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec20" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 2-(2-(5-Chloro-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)propanamide</h5><div class="NLM_p last">A 1 L, four-necked, round-bottomed flask was charged with 11.86 g (27.4 mmol) of <b>50b</b>, 8.54 g (27.1 mmol) of <b>Q</b> (Z = CF), 200 mL of DME, and 100 mL of 2 M Na<sub>2</sub>CO<sub>3</sub>. The mixture was degassed with a stream of nitrogen gas for 20 min, and 2.19 g (1.89 mmol) of Pd(PPh<sub>3</sub>)<sub>4</sub> was added. The mixture was heated to reflux overnight, cooled, diluted with water, and extracted with EtOAc. The organic extract was dried (MgSO<sub>4</sub>) and evaporated in vacuo. The crude product was triturated with MBTE to afford 10.48 g (66%) of the desired coupled product as an off-white solid: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.69 (d, 1H), 8.42 (s, 1H), 8.37 (d, 1H), 8.18 (d, 1H) 8.08 (d, 2H), 6.57 (br t, 1H), 5.40 (s, 1H), 3.95 (m, 1H), 2.38 (s, 3H), 1.73 (s, 6H).</div></div><div id="sec3_14_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 2-(2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>44</b>)</h5><div class="NLM_p last">A 5 L four-necked, round-bottomed flask equipped with an overhead stirrer was charged with 350.1 g (598 mmol) of 2-(2-(5-chloro-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)propanamide, 2 L of THF, and then 1 L of water. To this mixture was added 130.3 g (3.10 mol) of LiOH. The mixture was stirred at room temperature overnight, acidified with 1 N HCl, and extracted with EtOAc. The extract was washed with satd aq NaHCO<sub>3</sub>, dried (MgSO<sub>4</sub>), and filtered over a plug of silica gel. The plug was eluted with 25% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>, and the filtrate was evaporated in vacuo to afford 199.6 g (77%) of <b>9</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.29 (d, <i>J</i> = 2.8 Hz, 1H), 8.65 (dd, <i>J</i> = 2.4, 0.5 Hz, 1H), 8.36 (t, <i>J</i> = 6.4 Hz, 1H), 8.30–8.15 (m, 2H), 8.02 (d, <i>J</i> = 2.8 Hz, 1H), 7.62 (s, 1H), 3.79–3.67 (m, 2H), 1.53 (s, 6H); <sup>13</sup>C NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.56, 150.88, 147.69, 141.73, 131.26, 129.39, 124.33, 119.27, 57.29, 25.61; LC–MS [M + H]<sup>+</sup> = 441.2; <i>t</i><sub>R</sub> = 2.46 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_14_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (<i>S</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>22</b>)</h5><div class="NLM_p">To a stirred solution of Boc-alanine <b>M</b> (aa = <span class="smallcaps smallerCapital">l</span>-Ala; 3.8 g, 0.02 mol), EDC (4.63 g, 0.024 mol), HOBt (4.0 g, 0.026 mol), and DIEA (10.5 mL, 0.06 mol) in 100 mL of CH<sub>2</sub>Cl<sub>2</sub> was added trifluoroethylamine hydrochloride (2.92 g, 0.022 mol). The reaction mixture was stirred for 16 h. It was concentrated to dryness, redissolved in EtOAc, and washed successively with 0.5 N HC1, a saturated aqueous solution of NaHCO<sub>3</sub>, and brine. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to give 5.4 g (98%) of a white solid, which was used directly for the next step.</div><div class="NLM_p">The white solid (5.32 g, 0.0197 mol) was treated with a 1:1 mixture of CH<sub>2</sub>Cl<sub>2</sub>/TFA at rt for 45 min. Concentration to dryness gave the intermediate amine <b>N</b> as the TFA salt, which was used directly in the next step without further purification. A mixture of 5-fluoro-2,4-dichloropyrimidine (3.28 g, 0.0197 mol), the crude amine <b>N</b> (5.25 g, 0.0197 mol), and DIEA (10.27 mL, 0.059 mol) were stirred in 2-propanol at rt for 16 h. The reaction mixture was concentrated in vacuo, redissolved in EtOAc, and washed successively with 0.5 N HCl, a saturated aqueous solution of NaHCO<sub>3</sub>, and brine. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to give a crude oil that was subjected to chromatography (50% EtOAc/50% hexanes) to yield the desired compound <b>Q</b> (Z = CF), which was used directly for the next step.</div><div class="NLM_p">A mixture of 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine boronate <b>50b</b> (X = CCl) (150 mg, 0.33 mmol, <b>Q</b> (Z = CF, 150 mg, 0.5 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (30 mg, 0.026 mmol), and sodium carbonate (2 M, 600 μL) in 4 mL of DME was microwaved at 140 °C for 30 min. The reaction mixture was filtered through a short pad of silica gel with 30% EtOAc/70% hexanes as the eluent to provide, after concentration to dryness, the crude intermediate, which was used directly for the next step.</div><div class="NLM_p last">The crude intermediate was dissolved in 5 mL of dry methanol, and 1 mL of sodium methoxide in methanol 25% was added. The reaction mixture was stirred at 60 °C for 1 h and quenched with 6 N HC1 (800 μL). The mixture was concentrated in vacuo and purified by reversed-phase HPLC (10–60% CH<sub>3</sub>CN–water with 0.5% TFA) to provide 40 mg (27%; from <b>50b</b>) of <b>22</b>: <sup>1</sup>H (DMSO-<i>d</i><sub>6</sub>) δ 12.4 (br s, 1H), 8.8 (t, 1H), 8.7 (s, 1H), 8.3 (s, 2H), 8.2 (s, 1H), 7.9 (br s, 1H), 4.7 (q, 1H), 4.0 (m, 2H), 1.3 (d, 3H); LC–MS [M + H]<sup>+</sup> = 416.19; <i>t</i><sub>R</sub> = 2.3 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>16</sub>H<sub>13</sub>ClF<sub>4</sub>N<sub>6</sub>O + H<sup>+</sup>) 417.084826, found 417.08344 with a deviation of only 3.32 ppm.</div></div><div id="sec3_14_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)acetamide (<b>23</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-glycine <b>M</b> (aa = Gly) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50a</b> (X = CCl) to provide 5.8 mg of <b>23</b> as a white solid: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.97 (s, 1H), 9.30 (br s, 1H), 8.92 (s, 1H), 8.61 (s, 1H), 8.56 (s, 1H), 8.40 (d, <i>J</i> = 2.3 Hz, 1H), 8.19 (d, <i>J</i> = 2.1 Hz, 1H), 6.71 (s, 1H), 4.32 (s, 2H), 4.01–3.94 (m, 2H); LC–MS [M + H]<sup>+</sup> = 385.1; <i>t</i><sub>R</sub> = 1.6 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_14_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> (<i>S</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)pentanamide (<b>24</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-norvaline <b>M</b> (aa = (<i>S</i>)-Nor) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 17.4 mg of <b>24</b> as a white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 12.4 ppm (s, 1H), 8.8 (t, 1H), 8.7 (s, 1H), 8.3 (m, 3H), 7.8 (br s, 1H), 4.6 (q, 1H), 3.8–4.0 (m, 2H), 1.8 (m, 2H), 1.3–1.5 (m, 2H), 0.9 (t, 3H); LC–MS [M + H]<sup>+</sup> = 445.1; <i>t</i><sub>R</sub> = 2.7 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>17</sub>ClF<sub>4</sub>N<sub>6</sub>O + H<sup>+</sup>) 445.1161262, found 445.1149 with a deviation of only 2.75 ppm.</div></div><div id="sec3_14_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> (<i>S</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-3-hydroxy-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>25</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-serine <b>M</b> (aa = (<i>S</i>)-Ser) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (where X = CCl) to provide 3.0 mg of <b>25</b> as a white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.85 and 8.80 (2s, 1H), 8.25–8.13 (m, 3 H), 7.12 (d, 1H), 4.63 (dd, 1H), 3.98 (d, 2H), 3.96–3.34 (m, 2H); LC–MS [M + H]<sup>+</sup> = 414.7; <i>t</i><sub>R</sub> = 1.7 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>16</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>) 415.0891625, found 415.08823 with a deviation of only 2.25 ppm.</div></div><div id="sec3_14_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> (<i>S</i>)-2-((2-(5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-3-methoxy-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>26</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-methoxyserine <b>M</b> (aa = (<i>S</i>)-C(H)CH<sub>2</sub>OCH<sub>3</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (where X = CCl) to provide 4.5 mg of <b>26</b> as a white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 3.41 (s, 3H), 3.73–4.01 (m, 4H), 5.01 (br s, 1H), 7.32 (br s, 1H), 8.29 (s, 1H), 8.40 (d, 1H), 8.45 (d, 1H), 8.65 (d, 1H); LC–MS [M + H]<sup>+</sup> = 429.1; <i>t</i><sub>R</sub> = 1.9 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>) 429.1048126, found 429.10387 with a deviation of only 2.20 ppm.</div></div><div id="sec3_14_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-3-(methylthio)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>27</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-methylcysteine <b>M</b> (aa = (<i>S</i>)-C(H)CH<sub>2</sub>SCH<sub>3</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 12 mg of <b>27</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.8 (br m, 1H), 8.85 (m, 1H), 8.8 (m, 1H), 8.65 (s, 1H), 8.3 (d, 1H), 8.25 (1H), 7.75 (br m, 1H), 7.3 (d, 1H), 4.85 (m, 1H), 3.9 (m, 2H), 3.0 (d, 2H), 2.2 (s, 3H); LC–MS [M + H]<sup>+</sup> = 449.9; <i>t</i><sub>R</sub> = 2.2 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>6</sub>OS + H<sup>+</sup>) 445.08196, found 445.08093 with a deviation of only 2.23 ppm.</div></div><div id="sec3_14_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> (<i>S</i>)-1-(2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)-<i>N</i>-(2,2,2-trifluoroethyl)pyrrolidine-2-carboxamide (<b>28</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-<span class="smallcaps smallerCapital">l</span>-proline <b>M</b> (aa = (<i>S</i>)-Pro) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 12.3 mg of <b>28</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.4 (br s, 1H), 8.7 (dd, 1H), 8.65 (s, 1H), 8.25 (m, 2H), 8.2 (m, 1H), 4.8 (d, 1H), 4.0–3.8 (m, 4H), 2.3 (m, 1H), 2.05–1.9 (m, 3H); LC–MS [M + H]<sup>+</sup> = 442.9; <i>t</i><sub>R</sub> = 2.2 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>15</sub>ClF<sub>4</sub>N<sub>6</sub>O + H<sup>+</sup>) 443.10047, found 443.09942 with a deviation of only 2.38 ppm.</div></div><div id="sec3_14_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> (<i>S</i>)-3-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>29</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-(<i>S</i>)-aminobutanoic acid <b>M</b> (aa = (<i>S</i>)-C(H)MeCH<sub>2</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 1.5 mg of <b>29</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.5 (br s, 1H), 8.8 (s, 1H), 8.7 (t, 1H), 8.3 (s, 1H), 8.2 (m, 1H), 4.8 (sept, 1H), 3.9 (m, 2H), 2.7 (dd, 2H), 1.25 (d, 3H); LC–MS [M + H]<sup>+</sup> = 430.9; <i>t</i><sub>R</sub> = 2.0 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>15</sub>ClF<sub>4</sub>N<sub>6</sub>O + H<sup>+</sup>) 431.1004762, found 431.09945 with a deviation of only 2.38 ppm.</div></div><div id="sec3_14_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>30</b>)</h5><div class="NLM_p last">This compound was prepared from unnatural Boc-(<i>R</i>)-alanine <b>M</b> (aa = (<i>R</i>)-C(H)Me) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = Cl) to provide 15 mg of <b>30</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.70 (dd, 1H), 8.65 (s, 1H), 8.28 (m, 2H), 8.20 (m, 1H), 7.90 (m, 1H), 4.62 (m, 1H), 3.88 (m, 2H), 1.41 (d, 3H); LC–MS [M + H]<sup>+</sup> = 417.0; <i>t</i><sub>R</sub> = 2.4 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>16</sub>H<sub>13</sub>ClF<sub>4</sub>N<sub>6</sub>O + H<sup>+</sup>) 417.0848261, found 417.0838 with a deviation of only 2.46 ppm.</div></div><div id="sec3_14_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>31</b>)</h5><div class="NLM_p last">This compound was prepared from unnatural Boc-(<i>R</i>)-alanine <b>M</b> (aa = (<i>R</i>)-C(H)Me) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 11 mg of <b>31</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (m, 1H), 8.60 (m, 2H), 8.32 (s, 1H), 8.18 (m, 1H), 6.65 (m, 1H), 6.72 (m, 1H), 4.80 (m, 1H), 4.00 (m, 2H), 1.42 (d, 3H); LC–MS [M + H]<sup>+</sup> = 399.0; <i>t</i><sub>R</sub> = 1.7 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>16</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 399.094248, found 399.09351 with a deviation of only 1.85 ppm.</div></div><div id="sec3_14_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)pentanamide (<b>32</b>)</h5><div class="NLM_p last">This compound was prepared from unnatural norvaline <b>M</b> (aa = (<i>R</i>)-C(H)<i>n</i>Pr) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 10.4 mg of <b>32</b> as a white solid: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.0 ppm (br s, 1H), 9.0 (s, 1H), 8.6 (d, 2H), 8.4 (s, 1H), 8.2 (d, 1H), 6.7 (s, 1H), 4.8 (s, 1H), 3.8–4.2 (m, 3H), 1.9 (m, 2H), 1.4–1.5 (m, 2H), 0.9 (t, 3H); LC–MS [M + H]<sup>+</sup> = 427.1; <i>t</i><sub>R</sub> = 1.9 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 427.1255481, found 427.12418 with a deviation of only 3.20 ppm.</div></div><div id="sec3_14_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)pent-4-ynamide (<b>33</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-propargylglycine <b>M</b> (aa = (<i>R</i>)-C(H)CH<sub>2</sub>CHCH) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (Z = Cl) to provide 4.5 mg of <b>33</b> as a white solid: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.95 (br s, 1H), 9.07 (s, 1H), 8.63 (s, 1H), 8.60 (s, 1H), 8.40 (d, <i>J</i> = 2.1 Hz, 1H), 8.20 (s, 1H), 6.75 (s, 1H), 4.99 (s, 1H), 4.05–3.83 (m, 2H), 2.98 (t, <i>J</i> = 2.4 Hz, 1H), 2.80 (d, <i>J</i> = 7.3 Hz, 2H); LC–MS [M + H]<sup>+</sup> = 423.0; <i>t</i><sub>R</sub> = 1.8 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 423.094248, found 423.09315 with a deviation of only 2.60 ppm.</div></div><div id="sec3_14_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> (<i>S</i>)-2-((5-Fluoro-2-(5-fluoro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>38</b>)</h5><div class="NLM_p last">This compound was prepared as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and 5-fluoro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50c</b> (X = CF) to provide 27 mg of <b>38</b> as a white amorphous solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.5 (br s, 1H), 8.9 (t, 1H), 8.4 (d, 1H), 8.2 (m, 2H), 8.2 (br s, 1H), 4.8 (q, 1H), 4.0 (m, 2H), 1.5 (d, 3H); LC–MS [M + H]<sup>+</sup> = 401.0; <i>t</i><sub>R</sub> = 2.0 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>16</sub>H<sub>13</sub>F<sub>5</sub>N<sub>6</sub>O + H<sup>+</sup>) 401.1143766, found 401.11368 with a deviation of only 1.73 ppm.</div></div><div id="sec3_14_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> (<i>S</i>)-2-((5-Fluoro-2-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>39</b>)</h5><div class="NLM_p last">This compound was prepared as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Y = CF) and 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50a</b> (X = CH) to provide 8.1 mg (28%, two steps) of <b>39</b> as a white amorphous solid: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.2 (br s, 1H), 8.8 (dd, 1H), 8.65 (d, 1H), 8.3 (m, 2H), 8.2 (s, 1H), 8.15 (br s, 1H), 7.2 (br s, 1H), 4.5 (m, 1H), 3.9 (m, 2H), 1.5 (d, 3H); LC–MS [M + H]<sup>+</sup> = 383.0; <i>t</i><sub>R</sub> = 1.6 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_14_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> (<i>S</i>)-2-((5-Fluoro-2-(5-methoxy-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>40</b>)</h5><div class="NLM_p last">This compound was prepared as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Y = CF) and 5-methoxy-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50d</b> (X = COMe) to provide 31 mg of <b>40</b> as a white amorphous solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.2 (br s, 1H), 8.7 (t, 1H), 8.4 (s, 1H), 8.2 (s, 1H), 8.1 (s, 1H), 8.0 (s, 1H), 4,8 (q, 1H), 3.9 (s, 3H), 3.85 (m, 2H), 1.15 (d, 3H); LC–MS [M + H]<sup>+</sup> = 412.9; <i>t</i><sub>R</sub> = 1.9 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>16</sub>F<sub>4</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>) 413.13436, found 413.13331 with a deviation of only 2.55 ppm.</div></div><div id="sec3_14_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> (<i>R</i>)-2-((5-Fluoro-2-(5-methoxy-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>41</b>)</h5><div class="NLM_p last">This compound was prepared from unnatural Boc-(<i>R</i>)-alanine <b>M</b> (aa = (<i>R</i>)-Ala) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and 5-methoxy-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50d</b> (X = COMe) to provide 8 mg of <b>41</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.66 (dd, 1H), 8.28 (m, 1H), 8.18 (s, 1H), 8.15 (m, 1H), 8.02 (m, 1H), 4.72 (m, 1H), 3.88 (s, 3H), 3.90 (m, 2H), 1.42 (d, 3H); LC–MS [M + H]<sup>+</sup> = 412.9; <i>t</i><sub>R</sub> = 1.8 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>16</sub>F<sub>4</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>) 413.1343631, found 413.13332 with a deviation of only 2.52 ppm.</div></div><div id="sec3_14_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> (<i>R</i>)-2-((5-Fluoro-2-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-5-yl)pyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>42</b>)</h5><div class="NLM_p last">This compound was prepared from unnatural Boc-alanine <b>M</b> (aa = (<i>R</i>)-Ala) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and deazapurine <b>50e</b> (X = N) to provide 35 mg of <b>42</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.65 (s, 1H), 8.96 (s, 1H), 8.76 (dd, 1H), 8.35 (s, 1H), 8.30 (d, 1H), 7.92 (d, 1H), 4.63 (m, 1H), 3.88 (m, 2H), 1.45 (d, 3H); LC–MS [M + H]<sup>+</sup> = 384; <i>t</i><sub>R</sub> = 2.0 min (5–45% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>15</sub>H<sub>13</sub>F<sub>4</sub>N<sub>7</sub>O + H<sup>+</sup>) 384.1190474, found 384.11844 with a deviation of only 1.58 ppm.</div></div></div><div id="sec3_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Synthesis of (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-3-methyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>34</b>)</h4><div id="sec3_14_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> <i>tert</i>-Butyl (<i>R</i>)-(1-((2,2,2-Trifluoroethyl)carbamoyl)-2-methylpropyl)carbamate (<b>N</b>)</h5><div class="NLM_p last">To a suspension of Boc-(<i>R</i>)-valine <b>M</b> (aa = (<i>R</i>)-C(H)CHMe<sub>2</sub>; 25 g, 0.115 mol), EDC (24.2 g, 0.127 mol), HOBT (4.65 g, 0.034 mol), and trifluoroethylamine hydrochloride (17.14 g, 0.127 mol) in 250 mL of THF at 0 °C was added triethylamine (35.2 mL, 0.253 mol), maintaining the temperature below 25 °C. The reaction mixture was stirred at rt for 16 h. It was quenched with 250 mL of water, and ethyl acetate (250 mL) was added, followed by acidification to pH 4 with 1 N HC. The layers were separated, and the aqueous layer was back-extracted with an additional 250 mL of EtOAc. The organics were combined, washed with satd NaHCO<sub>3</sub> and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to provide 33.53 g (98%) of monopeptide.</div></div><div id="sec3_14_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> (<i>R</i>)-2-Amino-<i>N</i>-(2,2,2-trifluoroethyl)-3-methylbutanamide</h5><div class="NLM_p last">Boc-(<i>R</i>)-valine amide <b>N</b> (33.53 g, 0.112 mol) was dissolved in 250 mL of CH<sub>2</sub>Cl<sub>2</sub>. A 30 mL volume of TFA was slowly added, and the reaction mixture was stirred for 16 h at rt. The reaction mixture was concentrated in vacuo to give an oil that was diluted with 300 mL of ether and evaporated to dryness to remove the residual TFA. Two more dissolution/evaporation cycles were necessary to remove most of the TFA and provided the desired amine peptide <b>N</b> quantitatively. This intermediate was used directly for the next step.</div></div><div id="sec3_14_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> (<i>R</i>)-2-((2-Chloropyrimidin-4-yl)amino)-<i>N</i>-(2,2,2-trifluoroethyl)-3-methylbutanamide (<b>Q</b>; Z = CH)</h5><div class="NLM_p last">Unprotected (<i>R</i>)-valine amide salt <b>N</b> (1.84 g, 6 mmol) was dissolved in 2-propanol (50 mL) and diisopropylethylamine (2.1 mL, 12.02 mmol). 2,4-Dichloropyrimidine (1.3 g, 6.01 mmol) was added, and the reaction mixture was heated at 90 °C for 16 h. The reaction mixture was cooled to rt, and the solvent was removed in vacuo to give a residue that was partitioned in a 1:1 mixture of EtOAc–water (200 mL). The pH was adjusted to 1 with 1 N HCl. Extraction was performed with EtOAc. The organic layer was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The oily solid was recrystallized in an MBTE–CH<sub>2</sub>Cl<sub>2</sub> mixture to provide 1.09 g (60%) of the desired product <b>Q</b> (Z = CH): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.82 (t, <i>J</i> = 5.8 Hz, 1H), 7.90 (d, <i>J</i> = 5.8 Hz, 1H), 6.59 (d, <i>J</i> = 5.8 Hz, 1H), 4.42 (d, <i>J</i> = 6.4 Hz, 1H), 4.09–3.92 (m, 1H), 3.90–3.73 (m, 1H), 2.14 (dq, <i>J</i> = 13.6, 6.8 Hz, 1H), 1.02 (dd, <i>J</i> = 6.7, 5.2 Hz, 6H); LC–MS [M + H]<sup>+</sup> = 310.95; <i>t</i><sub>R</sub> = 0.64 min (0–95% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_14_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-3-methyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>34</b>)</h5><div class="NLM_p last">This compound was prepared from boronic ester <b>50b</b> (X <b> = </b> CCl) and <b>Q</b> (Z = CH) as for compound <b>44</b> to provide 297.6 mg of the desired product <b>34</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (s, 1H), 8.78 (t, <i>J</i> = 6.3 Hz, 1H), 8.72 (s, 1H), 8.29 (s, 1H), 8.23 (d, <i>J</i> = 2.4 Hz, 1H), 8.08 (d, <i>J</i> = 5.9 Hz, 1H), 7.41 (d, <i>J</i> = 7.8 Hz, 1H), 6.45 (s, 1H), 4.52 (s, 1H), 3.99 (m, 1H), 3.90–3.70 (m, 1H), 2.08 (q, <i>J</i> = 6.8 Hz, 1H), 0.97 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.00, 161.97, 141.38, 131.89, 129.39, 123.82, 119.89, 119.55, 30.67, 19.65; LC–MS [M + H]<sup>+</sup> = 427.3; <i>t</i><sub>R</sub> = 1.88 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 427.125548, found 427.12388 with a deviation of only 3.90 ppm.</div></div><div id="sec3_14_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-4-methyl-<i>N</i>-(2,2,2-trifluoroethyl)pentanamide (<b>35</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-isoleucine <b>M</b> (aa = (<i>R</i>)-C(H)CH<sub>2</sub><i>i</i>Pr) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 13.7 mg of <b>35</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.0 ppm (br s, 1H), 9.0 (t, 1H), 8.7 (s, 2H), 8.4 (s, 1H), 8.1 (d, 1H), 6.6 (d, 1H), 4.8 (t, 1H), 3.8–4.2 (m, 4H), 1.7 (br s, 2H), 1.0 (d, 3H), 0.9 (d, 3H); LC–MS [M + H]<sup>+</sup> = 441.2; <i>t</i><sub>R</sub> = 2.0 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>19</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 441.1411981, found 441.14025 with a deviation of only 2.15 ppm.</div></div><div id="sec3_14_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-3-phenyl-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>36</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-phenylalanine <b>M</b> (aa = (<i>R</i>)-C(H)CH<sub>2</sub>Ph) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 13.5 mg of <b>36</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.0 ppm (br s, 1H), 9.2 ppm (t, 1H), 8.6 (s, 1H), 8.4 (s, 1H), 8.1 (d, 1H), 7.4 (d, 2H), 7.3 (t, 2H), 7.2 (d, 1H), 6.7 (d, 1H), 5.2 (t, 1H), 3.9–4.1 (m, 3H), 3.3 (m, 1H), 3.1 (t, 1H); LC–MS [M + H]<sup>+</sup> = 475.23; <i>t</i><sub>R</sub> = 2.0 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>22</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 475.12554, found 475.12478 with a deviation of only 1.62 ppm.</div></div><div id="sec3_14_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)-3-(1<i>H</i>-imidazol-4-yl)-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>37</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-histidine <b>M</b> (aa = (<i>R</i>)-His) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CF) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 60 mg of <b>37</b> as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.0 (s, 1H), 10.7 (s, 1H), 8.57 (s, 1H), 8.42 (s, 2H), 8.39 (s, 1H), 8.28 (d, 1H), 7.90 (m, 1H), 7.75 (d, 1H), 7.28 (s, 1H), 5.22 (m, 1H), 3.96 (m, 2H), 3.61 (m, 1H), 3.41 (m, 1H) (CD<sub>3</sub>CN); LC–MS [M + H]<sup>+</sup> = 483.0; <i>t</i><sub>R</sub> = 1.7 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>19</sub>H<sub>15</sub>ClF<sub>4</sub>N<sub>8</sub>O + H<sup>+</sup>) 483.10662, found 483.1059 with a deviation of only 1.50 ppm.</div></div><div id="sec3_14_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)propanamide (<b>43</b>)</h5><div class="NLM_p last">This compound was prepared from Boc-<i>N</i>-2-methylpropanoic acid <b>M</b> (aa = C(CH<sub>3</sub>)<sub>2</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 3.54 g of <b>43</b> as a white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.75 (d, <i>J</i> = 1.9 Hz, 1H), 8.55 (t, <i>J</i> = 5.9 Hz, 1H), 8.48 (s, 1H), 8.36 (d, <i>J</i> = 2.2 Hz, 1H), 8.06 (d, <i>J</i> = 7.2 Hz, 1H), 6.71 (d, <i>J</i> = 7.2 Hz, 1H), 3.85 (m, 2H), 1.75 (s, 6H) LCMS [<i>M</i> + <i>H</i>]<sup>+</sup> = 413.25; <i>t</i><sub>R</sub> = 1.86 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 413.10989, found 413.10834 with a deviation of only 3.77 ppm.</div></div><div id="sec3_14_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> (<i>R</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>45</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-methylbutanoic acid <b>M</b> (aa = (<i>R</i>)-C(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = Cl) to provide 13 mg of <b>45</b> as a white solid: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.96 (s, 1H), 9.00 (s, 1H), 8.69 (s, 1H), 8.56 (s, 2H), 8.37 (d, <i>J</i> = 1.6 Hz, 1H), 8.18 (d, <i>J</i> = 6.7 Hz, 1H), 6.72 (s, 1H), 3.80 (dd, <i>J</i> = 9.8, 16.6 Hz, 2H), 2.12–1.93 (m, 2H), 1.59 (s, 3H), 0.87 (t, <i>J</i> = 7.5 Hz, 3H), 0.00 (TMS); LC–MS [M + H]<sup>+</sup> = 427.1; <i>t</i><sub>R</sub> = 1.8 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 427.12554, found 427.12419 with a deviation of only 3.18 ppm.</div></div><div id="sec3_14_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> (<i>R</i>)-2-((2-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-5-yl)pyrimidin-4-yl)amino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>46</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-methylbutanoic acid <b>M</b> (aa = (<i>R</i>)-C(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and deazapurine <b>50e</b> (X = N) to provide 18 mg of <b>46</b> as a white solid: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.2 (br s, 1H), 9.57 (s, 1H), 8.98 (br s, 2H), 8.61 (br s, 2H), 8.23 (d, <i>J</i> = 6.8 Hz, 1H), 6.76 (s, 1H), 3.78 (br s, 2H), 2.13–2.07 (m, 1H), 1.97–1.93 (m, 1H), 1.59 (s, 3H), 0.88 (t, <i>J</i> = 7.5 Hz, 3H); LC–MS [M + H]<sup>+</sup> = 394.2; <i>t</i><sub>R</sub> = 1.2 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>N<sub>7</sub>O + H<sup>+</sup>) 394.15976, found 394.15877 with a deviation of only 2.53 ppm.</div></div><div id="sec3_14_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> (<i>R</i>)-2-((2-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (VX-509)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-methylbutanoic acid <b>M</b> (aa = (<i>R</i>)-C(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50a</b> (X = H) to provide 8 g of VX-509 as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.94 (d, <i>J</i> = 2.8 Hz, 1H), 8.68 (d, <i>J</i> = 7.8 Hz, 1H), 8.31–8.21 (m, 1H), 8.20 (dd, <i>J</i> = 4.7, 1.7 Hz, 1H), 8.09 (d, <i>J</i> = 5.9 Hz, 1H), 7.99 (d, <i>J</i> = 2.8 Hz, 1H), 7.26 (s, 1H), 7.10 (dd, <i>J</i> = 7.9, 4.7 Hz, 1H), 6.36 (s, 1H), 3.73 (ddd, <i>J</i> = 19.3, 9.6, 6.2 Hz, 1H), 2.04 (dd, <i>J</i> = 13.8, 7.3 Hz, 1H), 1.79 (dd, <i>J</i> = 13.8, 7.4 Hz, 1H), 0.78 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.47, 160.76, 149.51, 143.33, 130.55, 129.36, 118.44, 116.91, 114.93, 59.83, 21.95, 8.9; LC–MS [M + H]<sup>+</sup> = 393.3; <i>t</i><sub>R</sub> = 1.6 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA).</div></div><div id="sec3_14_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> (<i>S</i>)-2-((2-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>47</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>S</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-methylbutanoic acid <b>M</b> (aa = (<i>S</i>)-C(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50b</b> (X = CCl) to provide 5.1 mg of <b>47</b> as a white solid: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 8.83 (d, 1H), 8.26 (d, 1H), 8.22 (d, 1H), 8.13 (d, 1H), 7.20 (m, 1H), 6.38 (d, 1H), 6.00 (s, 1H), 3.88 (m, 1H), 3.77 (m, 1H), 1.95 (m, 2H), 1.57 (s, 3H), 0.91 (t, 3H) (CD<sub>3</sub>CN); LC–MS [M + H]<sup>+</sup> = 427.4; <i>t</i><sub>R</sub> = 1.8 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>18</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 427.12554, found 427.12399 with a deviation of only 3.65 ppm.</div></div><div id="sec3_14_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> (<i>R</i>)-2-((2-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrimidin-4-yl)amino)-2,3-dimethyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>48</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dimethylbutanoic acid <b>M</b> (aa = (<i>R</i>)-C(CH<sub>3</sub>)CH(CH<sub>3</sub>)<sub>2</sub>)) as for compound <b>44</b> using chloropyrimidine <b>Q</b> (Z = CH) and 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50a</b> (X = H) to provide 4.8 g of <b>48</b> as a white solid: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.89 (s, 1H), 8.79 (d, 1H), 8.27 (m, 1H), 8.19 (d, 1H), 8.10 (d, 1H), 7.18 (m, 2H), 6.49 (d, 1H), 5.80 (s, 1H), 3.97 (m, 1H), 3.59 (m, 1H), 1.53 (s, 3H), 1.02 (dd, 6H) (CD<sub>3</sub>CN); LC–MS [M + H]<sup>+</sup> = 405.5; <i>t</i><sub>R</sub> = 1.72 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>19</sub>H<sub>21</sub>F<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup>) 407.18017, found 407.17916 with a deviation of only 2.48 ppm.</div></div><div id="sec3_14_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> (<i>R</i>)-2-((4-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-1,3,5-triazin-2-yl)amino)-2-methyl-<i>N</i>-(2,2,2-trifluoroethyl)butanamide (<b>49</b>)</h5><div class="NLM_p last">This compound was prepared from (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-methylbutanoic acid <b>M</b> (aa = (<i>R</i>)-C(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>) as for compound <b>44</b> using 2,4-dichloro-1,3,5-triazine <b>Q</b> (Z = N) and 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>50a</b> (X = H) to provide 5.1 g of <b>49</b> as a white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 9.14 (m, 0.25H), 8.95 (d, <i>J</i> = 6.7 Hz, 0.66H), 8.59–8.41 (m, 3.64 H), 7.45 (m, 1H), 3.84 (m, 2H), 2.21–2.18 (m, 1H), 2.05–2.02 (m, 1H), 1.67 (m, 3H), 0.97 (t, <i>J</i> = 7.3 Hz, 3H); LC–MS [M + H]<sup>+</sup> = 394.1; <i>t</i><sub>R</sub> = 2.16 min (10–90% CH<sub>3</sub>CN–water with 0.1% TFA); HRMS [M + H]<sup>+</sup> calcd for (C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>N<sub>7</sub>O + H<sup>+</sup>) 394.15976, found 394.15858 with a deviation of only 3.02 ppm.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d4011e8365-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00301">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b00301" class="ext-link">10.1021/acs.jmedchem.5b00301</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Data collection and refinement statistics, <sup>1</sup>H and <sup>13</sup>C NMR spectra, VX-509 plasma and lymph node exposures, dose-dependent inhibition of PLN hyperplasia by tofacitanib, dose-dependent decrease in stimulated biomarker CD25 by tofacitinib, and VX-509 dog and rat concentration vs time plots (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Simplified molecular input line entry system (SMILES) notation (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf">jm5b00301_si_001.pdf (1.72 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_002.csv">jm5b00301_si_002.csv (5.03 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00301" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luc J. Farmer</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals (Canada) Inc., 275 Armand-Frappier, Laval, Québec H7V 4A7, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3a564f59655c5b48575f487a4c484e4214595557"><span class="__cf_email__" data-cfemail="600c15033f0601120d051220161214184e030f0d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark W. Ledeboer</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6a070b180135060f0e0f08050f182a1c181e1244090507"><span class="__cf_email__" data-cfemail="ef828e9d84b0838a8b8a8d808a9daf999d9b97c18c8082">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Hoock</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Arnost</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Randy S. Bethiel</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youssef L. Bennani</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals (Canada) Inc., 275 Armand-Frappier, Laval, Québec H7V 4A7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James J. Black</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher L. Brummel</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ananthsrinivas Chakilam</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Warren A. Dorsch</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Fan</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John E. Cochran</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Summer Halas</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edmund M. Harrington</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James K. Hogan</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Howe</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Huang</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dylan H. Jacobs</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leena M. Laitinen</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shengkai Liao</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sudipta Mahajan</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valerie Marone</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabriel Martinez-Botella</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pamela McCarthy</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Messersmith</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Namchuk</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke Oh</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina S. Penney</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert C. Pierce</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott A. Raybuck</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arthur Rugg</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco G. Salituro</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kumkum Saxena</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean Shannon</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dina Shlyakter</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lora Swenson</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shi-Kai Tian</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Town</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Wang</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tiansheng Wang</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Woods Wannamaker</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raymond J. Winquist</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harmon J. Zuccola</span> - <span class="hlFld-Affiliation affiliation">Vertex
Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d4011e8356-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i113">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21345" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21345" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank David Lauffer and Alex Aronov for identifying early hits from the 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine class with JAK3 potency, Kenny Bonnano and Jacque Zwahlen for protein expression and cloning, respectively, Dean Boyall, Simon Everitt, and Haley Binch for providing analogues from their previous kinase programs, and Bill Markland for help in determining the minimal significant ratios. Also, we thank Ralph Stearns for helpful discussion and suggestions and Michael Clark, Janek Szychowski, Constantin Yannopoulos, and Louis Vaillancourt for proofreading the manuscript.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Darnell, J. E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1421</span><span class="refDoi"> DOI: 10.1126/science.8197455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+J.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins&doi=10.1126%2Fscience.8197455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon α (IFN-α) and interferon γ (IFN-γ), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-α and IFN-γ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0liM-4BppmexcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421%26doi%3D10.1126%2Fscience.8197455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0ljECQB2hNWFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (γc), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit γc.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both γc and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0ljECQB2hNWFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Oakes, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennighausen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaese, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.1016/S1074-7613(00)80274-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2FS1074-7613%2800%2980274-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1996&pages=605-615&author=S.+A.+Oakesauthor=F.+Candottiauthor=J.+A.+Johnstonauthor=Y.+Q.+Chenauthor=J.+J.+Ryanauthor=N.+Taylorauthor=X.+Liuauthor=L.+Hennighausenauthor=L.+D.+Notarangeloauthor=W.+E.+Paulauthor=R.+M.+Blaeseauthor=J.+J.+O%27Shea&title=Signaling+via+IL-2+and+IL-4+in+JAK3-deficient+severe+combined+immunodeficiency+lymphocytes%3A+JAK3-dependent+and+independent+pathways&doi=10.1016%2FS1074-7613%2800%2980274-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980274-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980274-5%26sid%3Dliteratum%253Aachs%26aulast%3DOakes%26aufirst%3DS.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DRyan%26aufirst%3DJ.%2BJ.%26aulast%3DTaylor%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHennighausen%26aufirst%3DL.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DPaul%26aufirst%3DW.%2BE.%26aulast%3DBlaese%26aufirst%3DR.%2BM.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520via%2520IL-2%2520and%2520IL-4%2520in%2520JAK3-deficient%2520severe%2520combined%2520immunodeficiency%2520lymphocytes%253A%2520JAK3-dependent%2520and%2520independent%2520pathways%26jtitle%3DImmunity%26date%3D1996%26volume%3D5%26spage%3D605%26epage%3D615%26doi%3D10.1016%2FS1074-7613%2800%2980274-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">6910</span><span class="NLM_x">–</span> <span class="NLM_lpage">6915</span><span class="refDoi"> DOI: 10.1073/pnas.94.13.6910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1073%2Fpnas.94.13.6910" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=6910-6915&author=M.+Chenauthor=A.+Chengauthor=Y.+Q.+Chenauthor=A.+Hymelauthor=E.+P.+Hansonauthor=L.+Kimmelauthor=Y.+Minamiauthor=T.+Taniguchiauthor=P.+S.+Changelianauthor=J.+J.+O%27Shea&title=The+amino+terminus+of+JAK3+is+necessary+and+sufficient+for+binding+to+the+common+gamma+chain+and+confers+the+ability+to+transmit+interleukin+2-mediated+signals&doi=10.1073%2Fpnas.94.13.6910"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.13.6910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.13.6910%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DHymel%26aufirst%3DA.%26aulast%3DHanson%26aufirst%3DE.%2BP.%26aulast%3DKimmel%26aufirst%3DL.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520amino%2520terminus%2520of%2520JAK3%2520is%2520necessary%2520and%2520sufficient%2520for%2520binding%2520to%2520the%2520common%2520gamma%2520chain%2520and%2520confers%2520the%2520ability%2520to%2520transmit%2520interleukin%25202-mediated%2520signals%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D6910%26epage%3D6915%26doi%3D10.1073%2Fpnas.94.13.6910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">506</span><span class="refDoi"> DOI: 10.1097/00130832-200212000-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14752332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.+J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%27Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis&doi=10.1097%2F00130832-200212000-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2eYZAPUIqeDIJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26spage%3D495%26epage%3D506%26doi%3D10.1097%2F00130832-200212000-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Rochman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spolski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">New insights into the regulation of T cells by γc family cytokines</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1038/nri2580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fnri2580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19543225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=480-490&author=Y.+Rochmanauthor=R.+Spolskiauthor=W.+J.+Leonard&title=New+insights+into+the+regulation+of+T+cells+by+%CE%B3c+family+cytokines&doi=10.1038%2Fnri2580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the regulation of T cells by γc family cytokines</span></div><div class="casAuthors">Rochman, Yrina; Spolski, Rosanne; Leonard, Warren J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">480-490</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Common cytokine receptor γ-chain (γc) family cytokines have crucial roles in the development, proliferation, survival and differentiation of multiple cell lineages of both the innate and adaptive immune systems.  In this Review, the authors focus on the current understanding of the distinct and overlapping effects of interleukin-2 (IL-2), IL-7, IL-9, IL-15 and IL-21, as well as the IL-7-related cytokine thymic stromal lymphopoietin (TSLP), on the survival and proliferation of conventional αβ T cells, γδ T cells and regulatory T cells.  This knowledge potentially allows for the therapeutic manipulation of immune responses for the treatment of cancer, autoimmunity, allergic diseases and immunodeficiency, as well as for vaccine development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GBlSyD8_NLVg90H21EOLACvtfcHk0lhhvcS1xE_8jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D&md5=a6c7285b05193002b89be7233d11f271</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnri2580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2580%26sid%3Dliteratum%253Aachs%26aulast%3DRochman%26aufirst%3DY.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DNew%2520insights%2520into%2520the%2520regulation%2520of%2520T%2520cells%2520by%2520%25CE%25B3c%2520family%2520cytokines%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D480%26epage%3D490%26doi%3D10.1038%2Fnri2580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Macchi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frattini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugazio, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1038/377065a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%27Sheaauthor=P.+Vezzoniauthor=L.+D.+Notarangelo&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29&doi=10.1038%2F377065a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common γ-chain (γc), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the γc-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100→Cys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0lhhvcS1xE_8jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26aulast%3DVezzoni%26aufirst%3DP.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68%26doi%3D10.1038%2F377065a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span><span class="refDoi"> DOI: 10.1016/0092-8674(93)90167-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2F0092-8674%2893%2990167-O" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans&doi=10.1016%2F0092-8674%2893%2990167-O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990167-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990167-O%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157%26doi%3D10.1016%2F0092-8674%2893%2990167-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1126/science.270.5237.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1126%2Fscience.270.5237.797" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%27Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development&doi=10.1126%2Fscience.270.5237.797"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.797%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D797%26epage%3D800%26doi%3D10.1126%2Fscience.270.5237.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">203</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.0105-2896.2005.00220.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1111%2Fj.0105-2896.2005.00220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=15661026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2005&pages=127-142&author=M.+Pesuauthor=F.+Candottiauthor=M.+Husaauthor=S.+R.+Hofmannauthor=L.+D.+Notarangeloauthor=J.+J.+O%27Shea&title=Jak3%2C+severe+combined+immunodeficiency%2C+and+a+new+class+of+immunosuppressive+drugs&doi=10.1111%2Fj.0105-2896.2005.00220.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span></div><div class="casAuthors">Pesu, Marko; Candotti, Fabio; Husa, Matthew; Hofmann, Sigrun R.; Notarangelo, Luigi D.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The recent elucidation of the multiple mol. mechanisms underlying severe combined immunodeficiency (SCID) is an impressive example of the power of mol. medicine.  Anal. of patients and the concomitant generation of animal models mimicking these disorders have quickly provided great insights into the pathophysiol. of these potentially devastating illnesses.  Here, the authors summarize the discoveries that led to the understanding of the role of cytokine receptors and a specific tyrosine kinase, Janus kinase 3 (Jak3), in the pathogenesis of SCID.  The authors discuss how the identification of mutations of Jak3 in autosomal recessive SCID has facilitated the diagnosis of these disorders, offered new insights into the biol. of this kinase, permitted new avenues for therapy, and provided the rationale for a generation of a new class of immunosuppressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYir7OTbMwFbVg90H21EOLACvtfcHk0li4Y_U4yRfugg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D&md5=038b25b97798eda4b6aa1818238e45ba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.0105-2896.2005.00220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0105-2896.2005.00220.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DHusa%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJak3%252C%2520severe%2520combined%2520immunodeficiency%252C%2520and%2520a%2520new%2520class%2520of%2520immunosuppressive%2520drugs%26jtitle%3DImmunol.%2520Rev.%26date%3D2005%26volume%3D203%26spage%3D127%26epage%3D142%26doi%3D10.1111%2Fj.0105-2896.2005.00220.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1126/science.1087061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor&doi=10.1126%2Fscience.1087061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lgVyCmP8p2_Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878%26doi%3D10.1126%2Fscience.1087061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1905</span><span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lgVyCmP8p2_Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span><span class="refDoi"> DOI: 10.1038/ni.1701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%27Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+to+be+or+not+to+be%3F&doi=10.1038%2Fni.1701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0lgVyCmP8p2_Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520to%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360%26doi%3D10.1038%2Fni.1701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Cox, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span> </span><span class="NLM_article-title">JAK3 specific kinase inhibitors: when specificity is not enough</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2011.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.chembiol.2011.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=21439469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=277-278&author=L.+Coxauthor=J.+Cools&title=JAK3+specific+kinase+inhibitors%3A+when+specificity+is+not+enough&doi=10.1016%2Fj.chembiol.2011.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">JAK3 Specific Kinase Inhibitors: When Specificity is not Enough</span></div><div class="casAuthors">Cox, Luk; Cools, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-278</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Janus kinases are important signaling proteins implicated in cytokine signaling.  In particular, Janus kinase 3 (JAK3) has gained attention as a target for inhibition of the immune system, due to its importance for T and B cell development and function.  In this issue however, show that inhibition of JAK3 activity may not be sufficient for this purpose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl5zExXf_b4rVg90H21EOLACvtfcHk0lgos0ln3LGC-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsbs%253D&md5=eeb745f4a8c713f7bd09662346e6d2e4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DL.%26aulast%3DCools%26aufirst%3DJ.%26atitle%3DJAK3%2520specific%2520kinase%2520inhibitors%253A%2520when%2520specificity%2520is%2520not%2520enough%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D277%26epage%3D278%26doi%3D10.1016%2Fj.chembiol.2011.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.l</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Phase IIb dose-ranging study of the oral JAK inhibitor Tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1002/art.33383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.33383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=21952978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=617-629&author=R.+Fleischmannauthor=M.+Cutoloauthor=M.+C.+Genoveseauthor=E.+B.+Leeauthor=K.+S.+Kanikauthor=S.+Sadisauthor=C.+A.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+E.l+Wilkinsonauthor=S.+H.+Zwillich&title=Phase+IIb+dose-ranging+study+of+the+oral+JAK+inhibitor+Tofacitinib+%28CP-690%2C550%29+or+adalimumab+monotherapy+versus+placebo+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+disease-modifying+antirheumatic+drugs&doi=10.1002%2Fart.33383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span></div><div class="casAuthors">Fleischmann, Roy; Cutolo, Maurizio; Genovese, Mark C.; Lee, Eun Bong; Kanik, Keith S.; Sadis, Seth; Connell, Carol A.; Gruben, David; Krishnaswami, Sriram; Wallenstein, Gene; Wilkinson, Bethanie E.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">617-629</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.  Methods : In this 24-wk, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected s.c. every 2 wk (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 wk.  The primary end point was the responder rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) at week 12.  Results : Treatment with tofacitinib at a dose of ≥3 mg twice a day resulted in a rapid response with significant efficacy when compared to placebo, as indicated by the primary end point (ACR20 response at week 12), achieved in 39.2% (3 mg; P ≤ 0.05), 59.2% (5 mg; P < 0.0001), 70.5% (10 mg; P < 0.0001), and 71.9% (15 mg; P < 0.0001) in the tofacitinib group and 35.9% of patients in the adalimumab group (P = 0.105), compared with 22.0% of patients receiving placebo.  Improvements were sustained at week 24, according to the ACR20, ACR50, and ACR70 response rates as well as classifications of remission according to the 3-variable Disease Activity Score in 28 joints (DAS28) using C-reactive protein and the 4-variable DAS28 using the erythrocyte sedimentation rate.  The most common treatment-emergent adverse events (AEs) in patients across all tofacitinib treatment arms (n = 272) were urinary tract infection (7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).  Conclusion : Tofacitinib monotherapy at ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 wk and demonstrated a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuu7Uf_SwBXbVg90H21EOLACvtfcHk0lgos0ln3LGC-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D&md5=99d7be4fd115ffa87410dcbd6c6ea860</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fart.33383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33383%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.l%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DPhase%2520IIb%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520Tofacitinib%2520%2528CP-690%252C550%2529%2520or%2520adalimumab%2520monotherapy%2520versus%2520placebo%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520disease-modifying%2520antirheumatic%2520drugs%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D617%26epage%3D629%26doi%3D10.1002%2Fart.33383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuninger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H.-G.</span><span> </span><span class="NLM_article-title">Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1021/jm101157q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101157q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=284-288&author=G.+Thomaauthor=F.+Nuningerauthor=R.+Falchettoauthor=E.+Hermesauthor=G.+A.+Tavaresauthor=E.+Vangrevelingheauthor=H.-G.+Zerwes&title=Identification+of+a+potent+Janus+kinase+3+inhibitor+with+high+selectivity+within+the+Janus+kinase+family&doi=10.1021%2Fjm101157q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm101157q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101157q%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DNuninger%26aufirst%3DF.%26aulast%3DFalchetto%26aufirst%3DR.%26aulast%3DHermes%26aufirst%3DE.%26aulast%3DTavares%26aufirst%3DG.%2BA.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DZerwes%26aufirst%3DH.-G.%26atitle%3DIdentification%2520of%2520a%2520potent%2520Janus%2520kinase%25203%2520inhibitor%2520with%2520high%2520selectivity%2520within%2520the%2520Janus%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D284%26epage%3D288%26doi%3D10.1021%2Fjm101157q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Lin, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadros, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimble, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewet, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krykbaev, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidl, K. J.</span><span> </span><span class="NLM_article-title">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2283</span><span class="NLM_x">–</span> <span class="NLM_lpage">2293</span><span class="refDoi"> DOI: 10.1002/art.27536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.27536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=20506481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=2283-2293&author=T.+H.+Linauthor=M.+Hegenauthor=E.+Quadrosauthor=C.+L.+Nickerson-Nutterauthor=K.+C.+Appellauthor=A.+G.+Coleauthor=Y.+Shaoauthor=S.+Tamauthor=M.+Ohlmeyerauthor=B.+Wangauthor=D.+G.+Goodwinauthor=E.+F.+Kimbleauthor=J.+Quinteroauthor=M.+Gaoauthor=P.+Symanowiczauthor=C.+Wrocklageauthor=J.+Lussierauthor=S.+H.+Schellingauthor=A.+G.+Hewetauthor=D.+Xuanauthor=R.+Krykbaevauthor=J.+Togiasauthor=X.+Xuauthor=R.+Harrisonauthor=T.+Mansourauthor=M.+Collinsauthor=J.+D.+Clarkauthor=M.+L.+Webbauthor=K.+J.+Seidl&title=Selective+functional+inhibition+of+JAK-3+is+sufficient+for+efficacy+in+collagen-induced+arthritis+in+mice&doi=10.1002%2Fart.27536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span></div><div class="casAuthors">Lin, Tsung H.; Hegen, Martin; Quadros, Elizabeth; Nickerson-Nutter, Cheryl L.; Appell, Kenneth C.; Cole, Andrew G.; Shao, Yuefei; Tam, Steve; Ohlmeyer, Michael; Wang, Bojing; Goodwin, Debra G.; Kimble, Earl F.; Quintero, Jorge; Gao, Min; Symanowicz, Peter; Wrocklage, Christopher; Lussier, Jennifer; Schelling, Scott H.; Hewet, Amha G.; Xuan, Dejun; Krykbaev, Rustem; Togias, Jenny; Xu, Xin; Harrison, Richard; Mansour, Tarek; Collins, Mary; Clark, James D.; Webb, Maria L.; Seidi, Katherine J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2283-2293</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. All γ-chain cytokines signal through JAK-3 and JAK-1 acting in tandem.  We undertook this study to det. whether the JAK-3 selective inhibitor WYE-151650 would be sufficient to disrupt cytokine signaling and to ameliorate autoimmune disease pathol. without inhibiting other pathways mediated by JAK-1, JAK-2, and Tyk-2.  Methods. JAK-3 kinase selective compds. were characterized by kinase assay and JAK-3-dependent (interleukin-2 [IL-2]) and -independent (IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF]) cell-based assays measuring proliferation or STAT phosphorylation.  In vivo, off-target signaling was measured by IL-22- and erythropoietin (EPO)-mediated models, while on-target signaling was measured by IL-2-mediated signaling.  Efficacy of JAK-3 inhibitors was detd. using delayed-type hypersensitivity (DTH) and collagen-induced arthritis (CIA) models in mice.  Results. In vitro, WYE-151650 potently suppressed IL-2-induced STAT-5 phosphorylation and cell proliferation, while exhibiting 10-29-fold less activity against JAK-3-independent IL-6- or GM-CSF-induced STAT phosphorylation.  Ex vivo, WYE-151650 suppressed IL-2-induced STAT phosphorylation, but not IL-6-induced STAT phosphorylation, as measured in whole blood.  In vivo, WYE-151650 inhibited JAK-3-mediated IL-2-induced interferon-γ prodn. and decreased the natural killer cell population in mice, while not affecting IL-22-induced serum amyloid A prodn. or EPO-induced reticulocytosis.  WYE-151650 was efficacious in mouse DTH and CIA models.  Conclusion. In vitro, ex vivo, and in vivo assays demonstrate that WYE-151650 is efficacious in mouse CIA despite JAK-3 selectivity.  These data question the need to broadly inhibit JAK-1-, JAK-2-, or Tyk-2-dependent cytokine pathways for efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogcss6tt3iw7Vg90H21EOLACvtfcHk0lhkrjV9cub2kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP&md5=7fd4f4dae47df1d1a33d3fc0edf5e13d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fart.27536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27536%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DQuadros%26aufirst%3DE.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DOhlmeyer%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGoodwin%26aufirst%3DD.%2BG.%26aulast%3DKimble%26aufirst%3DE.%2BF.%26aulast%3DQuintero%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DSchelling%26aufirst%3DS.%2BH.%26aulast%3DHewet%26aufirst%3DA.%2BG.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DKrykbaev%26aufirst%3DR.%26aulast%3DTogias%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DMansour%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DSeidl%26aufirst%3DK.%2BJ.%26atitle%3DSelective%2520functional%2520inhibition%2520of%2520JAK-3%2520is%2520sufficient%2520for%2520efficacy%2520in%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D2283%26epage%3D2293%26doi%3D10.1002%2Fart.27536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frauchiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hekmat-Nejad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendricks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henningsen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgenkamp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaime-Figueroa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahangir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutach, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span> </span><span class="NLM_article-title">3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1021/jm301646k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301646k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSqtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=345-356&author=M.+Sothauthor=J.+C.+Hermannauthor=C.+Yeeauthor=M.+Alamauthor=J.+W.+Barnettauthor=P.+Berryauthor=M.+F.+Brownerauthor=K.+Frankauthor=S.+Frauchigerauthor=S.+Harrisauthor=Y.+Heauthor=M.+Hekmat-Nejadauthor=T.+Hendricksauthor=R.+Henningsenauthor=R.+Hilgenkampauthor=H.+Hoauthor=A.+Hoffmanauthor=P.+Y.+Hsuauthor=D.+Q.+Huauthor=A.+Itanoauthor=S.+Jaime-Figueroaauthor=A.+Jahangirauthor=S.+Jinauthor=A.+Kuglstatterauthor=A.+K.+Kutachauthor=C.+Liaoauthor=S.+Lynchauthor=J.+Menkeauthor=L.+Niuauthor=V.+Patelauthor=A.+Railkarauthor=D.+Royauthor=A.+Shaoauthor=D.+Shawauthor=S.+Steinerauthor=Y.+Sunauthor=S.+L.+Tanauthor=S.+Wangauthor=M.+D.+Vu&title=3-Amido+Pyrrolopyrazine+JAK+Kinase+Inhibitors%3A+Development+of+a+JAK3+vs+JAK1+Selective+Inhibitor+and+Evaluation+in+Cellular+and+in+Vivo+Models&doi=10.1021%2Fjm301646k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models</span></div><div class="casAuthors">Soth, Michael; Hermann, Johannes C.; Yee, Calvin; Alam, Muzaffar; Barnett, Jim W.; Berry, Pamela; Browner, Michelle F.; Frank, Karl; Frauchiger, Sandra; Harris, Seth; He, Yang; Hekmat-Nejad, Mohammad; Hendricks, Than; Henningsen, Robert; Hilgenkamp, Ramona; Ho, Hoangdung; Hoffman, Ann; Hsu, Pei-Yuan; Hu, Dong-Qing; Itano, Andrea; Jaime-Figueroa, Saul; Jahangir, Alam; Jin, Sue; Kuglstatter, Andreas; Kutach, Alan K.; Liao, Cheng; Lynch, Stephen; Menke, John; Niu, Linghao; Patel, Vaishali; Railkar, Aruna; Roy, Douglas; Shao, Ada; Shaw, David; Steiner, Sandra; Sun, Yongliang; Tan, Seng-Lai; Wang, Sandra; Vu, Minh Diem</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression.  We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 vs. JAK1, and good biopharmaceutical properties.  Evaluation of this analog in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd-C6Aby3wN7Vg90H21EOLACvtfcHk0lhkrjV9cub2kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSqtrrP&md5=026b7d9b52cb5e374617ac2e5863eda4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm301646k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301646k%26sid%3Dliteratum%253Aachs%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DYee%26aufirst%3DC.%26aulast%3DAlam%26aufirst%3DM.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBerry%26aufirst%3DP.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DHendricks%26aufirst%3DT.%26aulast%3DHenningsen%26aufirst%3DR.%26aulast%3DHilgenkamp%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DA.%26aulast%3DHsu%26aufirst%3DP.%2BY.%26aulast%3DHu%26aufirst%3DD.%2BQ.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DJahangir%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKutach%26aufirst%3DA.%2BK.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DS.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DVu%26aufirst%3DM.%2BD.%26atitle%3D3-Amido%2520Pyrrolopyrazine%2520JAK%2520Kinase%2520Inhibitors%253A%2520Development%2520of%2520a%2520JAK3%2520vs%2520JAK1%2520Selective%2520Inhibitor%2520and%2520Evaluation%2520in%2520Cellular%2520and%2520in%2520Vivo%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D345%26epage%3D356%26doi%3D10.1021%2Fjm301646k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><div class="note"><p class="first last">and references therein.</p></div><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0ljWFWmqSdVvKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00644.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%27Shea&title=Therapeutic+targeting+of+Janus+kinases&doi=10.1111%2Fj.1600-065X.2008.00644.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0ljWFWmqSdVvKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142%26doi%3D10.1111%2Fj.1600-065X.2008.00644.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kontzias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span><span class="refDoi"> DOI: 10.1016/j.coph.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%27Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease&doi=10.1016%2Fj.coph.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0ljWFWmqSdVvKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470%26doi%3D10.1016%2Fj.coph.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span><span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lhT8LdfAokp7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span> <span class="citation_source-journal">IDrugs: Invest. Drugs J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=20506062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=394-403&author=R.+A.+Mesa&title=Ruxolitinib%2C+a+selective+JAK1+and+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+neoplasms+and+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span></div><div class="casAuthors">Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.  Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs).  Meaningful redns. in spleen size and constitutional symptoms have been noted in patients with myelofibrosis (both primary and post-essential thrombocythemia/polycythemia vera).  Data from a phase I/II clin. trial led to ongoing registration trials in the US and Europe.  Toxicity (primarily decreased erythropoiesis and thrombocytopoiesis) has been managed by close control of dosing.  The inhibition of inflammatory cytokine signaling through JAK1 inhibition has led to intriguing results in patients with rheumatoid arthritis and psoriasis (using a topical cream formulation).  Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yUMfeRYwE7Vg90H21EOLACvtfcHk0lhT8LdfAokp7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D&md5=9f89b13c71527c112b797375c93ccbff</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DRuxolitinib%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520and%2520psoriasis%26jtitle%3DIDrugs%253A%2520Invest.%2520Drugs%2520J.%26date%3D2010%26volume%3D13%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Ruxolitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><div class="note"><p class="first last">and references therein.</p></div><span class="refDoi"> DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0lhT8LdfAokp7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterling, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaich, C. L.</span><span> </span><span class="NLM_article-title">12- and 24-week patient reported outcomes from a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S214</span><span class="NLM_x">–</span> <span class="NLM_lpage">S220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S214-S220&author=J.+S.+Smolenauthor=D.+E.+Schlichtingauthor=K.+L.+Sterlingauthor=E.+Keystoneauthor=P.+Taylorauthor=M.+C.+Genoveseauthor=L.+Johnsonauthor=J.+C.+R.+Rodriguezauthor=C.+H.+Leeauthor=C.+L.+Gaich&title=12-+and+24-week+patient+reported+outcomes+from+a+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease-modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSterling%26aufirst%3DK.%2BL.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DRodriguez%26aufirst%3DJ.%2BC.%2BR.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DGaich%26aufirst%3DC.%2BL.%26atitle%3D12-%2520and%252024-week%2520patient%2520reported%2520outcomes%2520from%2520a%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS214%26epage%3DS220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span> </span><span class="NLM_article-title">24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">S1050</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S1049-S1050&author=M.+C.+Genoveseauthor=E.+Keystoneauthor=P.+Taylorauthor=E.+Drescherauthor=P.-Y.+Berclazauthor=C.+H.+Leeauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=W.+Macias&title=24-week+results+of+a+blinded+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease+modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DBerclaz%26aufirst%3DP.-Y.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DMacias%26aufirst%3DW.%26atitle%3D24-week%2520results%2520of%2520a%2520blinded%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease%2520modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS1049%26epage%3DS1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Van Rompaey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Aar, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Lacroix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smets, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepescheux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandeghinste, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brys, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van't Klooster, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1 for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">3568</span><span class="NLM_x">–</span> <span class="NLM_lpage">3577</span><span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van+Rompaeyauthor=R.+Galienauthor=E.+M.+Van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+Van%27t+Kloosterauthor=J.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DVan%2527t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Fleischmann, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivitz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legedza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinnman, N.</span><span> </span><span class="NLM_article-title">A Randomized Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral JAK-3 Inhibitor, as Monotherapy in Patients With Rheumatoid Arthritis</span> <span class="citation_source-journal">Arthritis Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span><span class="refDoi"> DOI: 10.1002/art.38949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.38949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=25385260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=334-343&author=R.+M.+Fleischmannauthor=N.+S.+Damjanovauthor=A.+J.+Kivitzauthor=A.+Legedzaauthor=T.+C.+Hoockauthor=N.+Kinnman&title=A+Randomized+Double-Blind%2C+Placebo-Controlled%2C+Twelve-Week%2C+Dose-Ranging+Study+of+Decernotinib%2C+an+Oral+JAK-3+Inhibitor%2C+as+Monotherapy+in+Patients+With+Rheumatoid+Arthritis&doi=10.1002%2Fart.38949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis</span></div><div class="casAuthors">Fleischmann, Roy M.; Damjanov, Nemanja S.; Kivitz, Alan J.; Legedza, Anna; Hoock, Thomas; Kinnman, Nils</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">334-343</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To assess the efficacy and safety of oral decernotinib (VX-509; Vertex Pharmaceuticals) monotherapy in a 12-wk, randomized, double-blind, placebo-controlled, dose-ranging study of patients with rheumatoid arthritis (RA).  Methods : Two hundred four adults with active RA who had been unsuccessfully treated with ≥1 disease-modifying antirheumatic drug were administered placebo tablets or decernotinib twice a day at dosages of 25 mg, 50 mg, 100 mg, or 150 mg.  Primary measures of efficacy at week 12 were the response rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) and mean change from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP).  Results : At week 12, the ACR20 response rates were 39.0%, 61.0%, 65.0%, and 65.9% in the 25-mg, 50-mg, 100-mg, and 150-mg groups, resp., and were significantly higher in the 50-mg group (P = 0.007) and the 100-mg and 150-mg groups (P = 0.002) as compared to the response rates in the placebo group (29.3%).  The mean change from baseline in DAS28-CRP was greater in the 50-mg, 100-mg, and 150-mg groups as compared to the placebo group (P < 0.001).  Decernotinib treatment resulted in higher ACR50 and ACR70 response rates, more patients with DAS28-CRP scores <2.6, and improvements in the Health Assessment Questionnaire disability index as compared to placebo.  The most common adverse events in any decernotinib group were nausea (6.1%), headache (4.3%), an increase in levels of alanine aminotransferase (4.3%), and hypercholesterolemia (3.7%).  In the groups receiving decernotinib, there was an increased risk of infections and increased liver transaminase levels.  Conclusion : Decernotinib was efficacious in improving clin. signs and symptoms of RA at week 12 at dosages of 50-150 mg twice a day.  Infections and increases in liver transaminase and lipid levels were noted as potential safety signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67TXqyDvsjrVg90H21EOLACvtfcHk0lgHtdBi9PUs3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2msrk%253D&md5=cd842d92e391f37cf23c8846a74ceb38</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fart.38949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.38949%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%2BM.%26aulast%3DDamjanov%26aufirst%3DN.%2BS.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DLegedza%26aufirst%3DA.%26aulast%3DHoock%26aufirst%3DT.%2BC.%26aulast%3DKinnman%26aufirst%3DN.%26atitle%3DA%2520Randomized%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Twelve-Week%252C%2520Dose-Ranging%2520Study%2520of%2520Decernotinib%252C%2520an%2520Oral%2520JAK-3%2520Inhibitor%252C%2520as%2520Monotherapy%2520in%2520Patients%2520With%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2015%26volume%3D67%26spage%3D334%26epage%3D343%26doi%3D10.1002%2Fart.38949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Genovese, M. C.; Van Vollenhoven, R. F.; Zhang, Y.; Kinnman, N.</span><span> </span><span class="NLM_article-title">VX-509 (Decernotinib), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Methotrexate in Patients with Rheumatoid Arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span> Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Genovese%2C+M.+C.%3B+Van+Vollenhoven%2C+R.+F.%3B+Zhang%2C+Y.%3B+Kinnman%2C+N.+VX-509+%28Decernotinib%29%2C+an+Oral+Selective+Janus+Kinase+3+Inhibitor%2C+in+Combination+with+Methotrexate+in+Patients+with+Rheumatoid+ArthritisArthritis+Rheum.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DVX-509%2520%2528Decernotinib%2529%252C%2520an%2520Oral%2520Selective%2520Janus%2520Kinase%25203%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Methotrexate%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Rheum." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lgHtdBi9PUs3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H.-G.</span><span> </span><span class="NLM_article-title">Selective inhibitors of the Janus kinase Jak3-Are they effective?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4617</span><span class="NLM_x">–</span> <span class="NLM_lpage">4621</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.bmcl.2014.08.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4617-4621&author=G.+Thomaauthor=P.+Druckesauthor=H.-G.+Zerwes&title=Selective+inhibitors+of+the+Janus+kinase+Jak3-Are+they+effective%3F&doi=10.1016%2Fj.bmcl.2014.08.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.046%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DDruckes%26aufirst%3DP.%26aulast%3DZerwes%26aufirst%3DH.-G.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520Janus%2520kinase%2520Jak3-Are%2520they%2520effective%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4617%26epage%3D4621%26doi%3D10.1016%2Fj.bmcl.2014.08.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakhter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T. C.</span><span> </span><span class="NLM_article-title">VX-509 (Decernotinib) is a Potent and Selective Janus Kinase 3 Inhibitor that Attenuates Inflammation in Animal Models of Autoimmune Disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1124/jpet.114.221176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1124%2Fjpet.114.221176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=25762693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFaiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=405-414&author=S.+Mahajanauthor=J.+K.+Hoganauthor=D.+Shlyakhterauthor=L.+Ohauthor=F.+G.+Salituroauthor=L.+Farmerauthor=T.+C.+Hoock&title=VX-509+%28Decernotinib%29+is+a+Potent+and+Selective+Janus+Kinase+3+Inhibitor+that+Attenuates+Inflammation+in+Animal+Models+of+Autoimmune+Disease&doi=10.1124%2Fjpet.114.221176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease</span></div><div class="casAuthors">Mahajan, Sudipta; Hogan, James K.; Shlyakhter, Dina; Oh, Luke; Salituro, Francesco G.; Farmer, Luc; Hoock, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-414</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytokines, growth factors, and other chem. messengers rely on a class of intracellular nonreceptor tyrosine kinases known as Janus kinases (JAKs) to rapidly transduce intracellular signals.  A no. of these cytokines are crit. for lymphocyte development and mediating immune responses.  JAK3 is of particular interest due to its importance in immune function and its expression, which is largely confined to lymphocytes, thus limiting the potential impact of JAK3 inhibition on nonimmune physiol.  The aim of this study was to evaluate the potency and selectivity of the investigational JAK3 inhibitor VX-509 (decernotinib) [(R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide] against JAK3 kinase activity and inhibition of JAK3-mediated signaling in vitro and JAK3-dependent physiol. processes in vivo.  These results demonstrate that VX-509 potently inhibits JAK3 in enzyme assays (Ki = 2.5 nM + 0.7 nM) and cellular assays dependent on JAK3 activity (IC50 range, 50-170 nM), with limited or no measurable potency against other JAK isotypes or non-JAK kinases.  VX-509 also showed activity in two animal models of aberrant immune function.  VX-509 treatment resulted in dose-dependent redn. in ankle swelling and paw wt. and improved paw histopathol. scores in the rat collagen-induced arthritis model.  In a mouse model of oxazolone-induced delayed-type hypersensitivity, VX-509 reduced the T cell-mediated inflammatory response in skin.  These findings demonstrate that VX-509 is a selective and potent inhibitor of JAK3 in vitro and modulates proinflammatory response in models of immune-mediated diseases, such as collagen-induced arthritis and delayed-type hypersensitivity.  The data support evaluation of VX-509 for treatment of patients with autoimmune and inflammatory diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd7OHX-kRf97Vg90H21EOLACvtfcHk0lig5S0uyY2MAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFaiur4%253D&md5=f4d384e23966e8305537bac4f5ab2918</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221176%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DShlyakhter%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DL.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DFarmer%26aufirst%3DL.%26aulast%3DHoock%26aufirst%3DT.%2BC.%26atitle%3DVX-509%2520%2528Decernotinib%2529%2520is%2520a%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%25203%2520Inhibitor%2520that%2520Attenuates%2520Inflammation%2520in%2520Animal%2520Models%2520of%2520Autoimmune%2520Disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D405%26epage%3D414%26doi%3D10.1124%2Fjpet.114.221176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ledeboer, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messersmith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanthakumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Come, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccola, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zessis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazhanisamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span> </span><span class="NLM_article-title">2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6529</span><span class="NLM_x">–</span> <span class="NLM_lpage">6533</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.bmcl.2009.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19857967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6529-6533&author=M.+W.+Ledeboerauthor=A.+C.+Pierceauthor=J.+P.+Duffyauthor=H.+Gaoauthor=D.+Messersmithauthor=F.+G.+Salituroauthor=S.+Nanthakumarauthor=J.+Comeauthor=H.+J.+Zuccolaauthor=L.+Swensonauthor=D.+Shlyakterauthor=S.+Mahajanauthor=T.+Hoockauthor=B.+Fanauthor=W.-J.+Tsaiauthor=E.+Kolaczkowskiauthor=S.+Carrierauthor=J.+K.+Hoganauthor=R.+Zessisauthor=S.+Pazhanisamyauthor=Y.+L.+Bennani&title=2-Aminopyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+and+selective+inhibitors+of+JAK2&doi=10.1016%2Fj.bmcl.2009.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2</span></div><div class="casAuthors">Ledeboer, Mark W.; Pierce, Albert C.; Duffy, John P.; Gao, Huai; Messersmith, David; Salituro, Francesco G.; Nanthakumar, Suganthini; Come, Jon; Zuccola, Harmon J.; Swenson, Lora; Shlyakter, Dina; Mahajan, Sudipta; Hoock, Thomas; Fan, Bin; Tsai, Wan-Jung; Kolaczkowski, Elaine; Carrier, Scott; Hogan, James K.; Zessis, Richard; Pazhanisamy, S.; Bennani, Youssef L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6529-6533</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis.  In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2.  Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3c3ghCDfXrVg90H21EOLACvtfcHk0lig5S0uyY2MAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvF&md5=6f9c11b5214398c0cf6b41569cf5bb99</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DCome%26aufirst%3DJ.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DW.-J.%26aulast%3DKolaczkowski%26aufirst%3DE.%26aulast%3DCarrier%26aufirst%3DS.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DZessis%26aufirst%3DR.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26atitle%3D2-Aminopyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520JAK2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6529%26epage%3D6533%26doi%3D10.1016%2Fj.bmcl.2009.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccola, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jepson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauffenbach, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledeboer, M. W.</span><span> </span><span class="NLM_article-title">Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7938</span><span class="NLM_x">–</span> <span class="NLM_lpage">7941</span><span class="refDoi"> DOI: 10.1021/jm901383u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901383u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7938-7941&author=T.+Wangauthor=J.+P.+Duffyauthor=J.+Wangauthor=S.+Halasauthor=F.+G.+Salituroauthor=A.+C.+Pierceauthor=H.+J.+Zuccolaauthor=J.+R.+Blackauthor=J.+K.+Hoganauthor=S.+Jepsonauthor=D.+Shlyakterauthor=S.+Mahajanauthor=Y.+Guauthor=T.+Hoockauthor=M.+Woodauthor=B.+F.+Fureyauthor=J.+D.+Frantzauthor=L.+M.+Dauffenbachauthor=U.+A.+Germannauthor=B.+Fanauthor=M.+Namchukauthor=Y.+L.+Bennaniauthor=M.+W.+Ledeboer&title=Janus+Kinase+2+Inhibitors.+Synthesis+and+Characterization+of+a+Novel+Polycyclic+Azaindole&doi=10.1021%2Fjm901383u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Fjm901383u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901383u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHalas%26aufirst%3DS.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26aulast%3DBlack%26aufirst%3DJ.%2BR.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DJepson%26aufirst%3DS.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DFurey%26aufirst%3DB.%2BF.%26aulast%3DFrantz%26aufirst%3DJ.%2BD.%26aulast%3DDauffenbach%26aufirst%3DL.%2BM.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26atitle%3DJanus%2520Kinase%25202%2520Inhibitors.%2520Synthesis%2520and%2520Characterization%2520of%2520a%2520Novel%2520Polycyclic%2520Azaindole%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7938%26epage%3D7941%26doi%3D10.1021%2Fjm901383u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="note"><p class="first last">The MSR (minimum significant ratio) was determined for each of the enzyme assays: JAK3 (2.5), JAK2 (3.3), AURA (1.3), FLT3 (2.5), SYK (1.5). This number was retrospectively derived from historical data in which the assay had been run at least twice using a data set that included from 14 to >20 individual compounds. A meaningful difference in <i>K</i><sub>i</sub> between compounds is given by the MSR; e.g.. in the JAK2 assay compounds must differ by at least 3.3-fold to be considered to have different potencies.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Pierce, A. C.; Zuccola, H. J.</span>; <span class="NLM_etal"></span> Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pierce%2C+A.+C.%3B+Zuccola%2C+H.+J.%3B+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">For reviews on Jak2 inhibitors in potential treatment of myeloproliferative disorders, see:</p></div><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Atallah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1586/era.09.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1586%2Fera.09.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19445582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVWgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=663-670&author=E.+Atallahauthor=S.+Verstovsek&title=Prospect+of+JAK2+inhibitor+therapy+in+myeloproliferative+neoplasms&doi=10.1586%2Fera.09.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms</span></div><div class="casAuthors">Atallah, Ehab; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-670</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biol. of those disorders.  Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: almost all patients with polycythemia vera harbor the mutation and about 50% of patients with essential thrombocythemia and primary myelofibrosis have the mutation, making the development of JAK2 tyrosine kinase inhibitors an attractive therapeutic goal.  In addn., inhibition of JAK2 kinase may have a therapeutic role in other hematol. malignancies, such as chronic myeloid leukemia or lymphoma.  A no. of mols. that inhibit JAK2 kinase have been described in the literature, and several are being evaluated in a clin. setting.  Here, we summarize current clin. experience with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPRYwnmb4_5LVg90H21EOLACvtfcHk0lg7dozf2SRXqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVWgt70%253D&md5=f8e0dad252de172a3c08286b824784ba</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1586%2Fera.09.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.09.14%26sid%3Dliteratum%253Aachs%26aulast%3DAtallah%26aufirst%3DE.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DProspect%2520of%2520JAK2%2520inhibitor%2520therapy%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D663%26epage%3D670%26doi%3D10.1586%2Fera.09.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pardanani, A.</span><span> </span><span class="NLM_article-title">JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1038/sj.leu.2404948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fsj.leu.2404948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=23-30&author=A.+Pardanani&title=JAK2+inhibitor+therapy+in+myeloproliferative+disorders%3A+rationale%2C+preclinical+studies+and+ongoing+clinical+trials&doi=10.1038%2Fsj.leu.2404948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404948%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26atitle%3DJAK2%2520inhibitor%2520therapy%2520in%2520myeloproliferative%2520disorders%253A%2520rationale%252C%2520preclinical%2520studies%2520and%2520ongoing%2520clinical%2520trials%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D23%26epage%3D30%26doi%3D10.1038%2Fsj.leu.2404948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Skoda, R. C.</span><span> </span><span class="NLM_article-title">Can we control JAK?</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5419</span><span class="NLM_x">–</span> <span class="NLM_lpage">5420</span><span class="refDoi"> DOI: 10.1182/blood-2007-11-123810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1182%2Fblood-2007-11-123810" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=5419-5420&author=R.+C.+Skoda&title=Can+we+control+JAK%3F&doi=10.1182%2Fblood-2007-11-123810"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-11-123810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-11-123810%26sid%3Dliteratum%253Aachs%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DCan%2520we%2520control%2520JAK%253F%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D5419%26epage%3D5420%26doi%3D10.1182%2Fblood-2007-11-123810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Morgan, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">A role for JAK2 mutations in myeloproliferative diseases</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1146/annurev.med.59.061506.154159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1146%2Fannurev.med.59.061506.154159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2008&pages=213-222&author=K.+J.+Morganauthor=D.+G.+Gilliland&title=A+role+for+JAK2+mutations+in+myeloproliferative+diseases&doi=10.1146%2Fannurev.med.59.061506.154159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.59.061506.154159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.59.061506.154159%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DK.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DA%2520role%2520for%2520JAK2%2520mutations%2520in%2520myeloproliferative%2520diseases%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2008%26volume%3D59%26spage%3D213%26epage%3D222%26doi%3D10.1146%2Fannurev.med.59.061506.154159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Sayyah, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span> </span><span class="NLM_article-title">Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1007/s11912-009-0018-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1007%2Fs11912-009-0018-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19216843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVSlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=117-124&author=J.+Sayyahauthor=P.+P.+Sayeski&title=Jak2+inhibitors%3A+rationale+and+role+as+therapeutic+agents+in+hematologic+malignancies&doi=10.1007%2Fs11912-009-0018-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies</span></div><div class="casAuthors">Sayyah, Jacqueline; Sayeski, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Oncology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">CORUAT</span>;
        ISSN:<span class="NLM_cas:issn">1534-6269</span>.
    
            (<span class="NLM_cas:orgname">Current Medicine Group LLC</span>)
        </div><div class="casAbstract">A review.  Although the Jak2-V617F mutation has generated strong awareness because of its causative role in myeloproliferative disorders, reports of Jak2 gene aberrations linked to hematol. malignancies have preceded those of V617F by nearly a decade.  These malignant mutations include Jak2 amino acid substitutions, deletions, insertions, and chromosomal translocations.  As a consequence, researchers are increasingly focused on identifying Jak2 inhibitors that suppress aberrant Jak2 kinase activity.  Some of these inhibitors may one day become therapeutically beneficial for individuals with Jak2-related hematol. malignancies.  This review summarizes various Jak2 mutations assocd. with hematol. malignancies and assesses some of the Jak2 inhibitors in the preclin. phase or in clin. trials.  By reviewing these specific areas, we hope to have a better understanding of Jak2's role in hematol. malignancies and to shed light on the utility of Jak2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0al6RszSt77Vg90H21EOLACvtfcHk0ljL4U8ZOGXRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVSlurk%253D&md5=b6b38c2aa8fb44f8cef6b0738426317a</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1007%2Fs11912-009-0018-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-009-0018-2%26sid%3Dliteratum%253Aachs%26aulast%3DSayyah%26aufirst%3DJ.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26atitle%3DJak2%2520inhibitors%253A%2520rationale%2520and%2520role%2520as%2520therapeutic%2520agents%2520in%2520hematologic%2520malignancies%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2009%26volume%3D11%26spage%3D117%26epage%3D124%26doi%3D10.1007%2Fs11912-009-0018-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">47954</span><span class="NLM_x">–</span> <span class="NLM_lpage">47963</span><span class="refDoi"> DOI: 10.1074/jbc.M205156200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1074%2Fjbc.M205156200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=47954-47963&author=P.+Saharinenauthor=O.+Silvennoinen&title=The+Pseudokinase+Domain+Is+Required+for+Suppression+of+Basal+Activity+of+Jak2+and+Jak3+Tyrosine+Kinases+and+for+Cytokine-inducible+Activation+of+Signal+Transduction&doi=10.1074%2Fjbc.M205156200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M205156200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M205156200%26sid%3Dliteratum%253Aachs%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520Pseudokinase%2520Domain%2520Is%2520Required%2520for%2520Suppression%2520of%2520Basal%2520Activity%2520of%2520Jak2%2520and%2520Jak3%2520Tyrosine%2520Kinases%2520and%2520for%2520Cytokine-inducible%2520Activation%2520of%2520Signal%2520Transduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D47954%26epage%3D47963%26doi%3D10.1074%2Fjbc.M205156200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1128/MCB.20.3.947-956.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1128%2FMCB.20.3.947-956.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10629052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1SntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=947-956&author=M.+Chenauthor=A.+Chengauthor=F.+Candottiauthor=Y.-J.+Zhouauthor=A.+Hymelauthor=A.+Fasthauthor=L.+D.+Notarangeloauthor=J.+J.+O%27Shea&title=Complex+effects+of+naturally+occurring+mutations+in+the+JAK3+pseudokinase+domain%3A+evidence+for+interactions+between+the+kinase+and+pseudokinase+domains&doi=10.1128%2FMCB.20.3.947-956.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains</span></div><div class="casAuthors">Chen, Min; Cheng, Alan; Candotti, Fabio; Zhou, Yong-Jie; Hymel, Anka; Fasth, Anders; Notarangelo, Luigi D.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">947-956</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The structure of Janus kinases (JAKs) is unique among protein tyrosine kinases in having tandem, non-identical kinase and pseudokinase domains.  Despite its conservation in evolution, however, the function of the pseudokinase domain remains poorly understood.  Lack of JAK3 expression results in severe combined immunodeficiency (SCID).  In this study, we analyze two SCID patients with mutations in the JAK3 pseudokinase domain, which allows for protein expression but disrupts the regulation of the kinase activity.  Specifically, these mutant forms of JAK3 had undetectable kinase activity in vitro but were hyperphosphorylated both in patients' Epstein-Barr virus-transformed B cells and when over-expressed in COS7 cells.  Moreover, reconstitution of cells with these mutants demonstrated that, although they were constitutively phosphorylated basally, they were unable to transmit cytokine-dependent signals.  Further anal. showed that the isolated catalytic domain of JAK3 was functional whereas either the addn. of the pseudokinase domain or its deletion from the full-length mol. reduced catalytic activity.  Through co-immunopptn. of the isolated pseudokinase domain with the isolated catalytic domain, we provide the first evidence that these two domains interact.  Furthermore, whereas the wild-type pseudokinase domain modestly inhibited kinase domain-mediated STAT5 phosphorylation, the patient-derived mutants markedly inhibited this phosphorylation.  We thus conclude that the JAK3 pseudokinase domain is essential for JAK3 function by regulating its catalytic activity and autophosphorylation.  We propose a model in which this occurs via intramol. interaction with the kinase domain and that increased inhibition of kinase activity by the pseudokinase domain likely contributes to the disease pathogenesis in these two patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2EGEAjO-ALVg90H21EOLACvtfcHk0ljL4U8ZOGXRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1SntA%253D%253D&md5=fc7535a1a1c9812d8ab896add11f1028</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.3.947-956.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.3.947-956.2000%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DHymel%26aufirst%3DA.%26aulast%3DFasth%26aufirst%3DA.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DComplex%2520effects%2520of%2520naturally%2520occurring%2520mutations%2520in%2520the%2520JAK3%2520pseudokinase%2520domain%253A%2520evidence%2520for%2520interactions%2520between%2520the%2520kinase%2520and%2520pseudokinase%2520domains%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D947%26epage%3D956%26doi%3D10.1128%2FMCB.20.3.947-956.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/S1097-2765(03)00505-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain&doi=10.1016%2FS1097-2765%2803%2900505-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0ljL4U8ZOGXRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178%26doi%3D10.1016%2FS1097-2765%2803%2900505-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajose-Adeogun, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diu-Hercend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golec, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span><span class="refDoi"> DOI: 10.1038/nm1003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fnm1003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14981513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+Aurora+kinases%2C+suppresses+tumor+growth+in+vivo&doi=10.1038%2Fnm1003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span></div><div class="casAuthors">Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis.  Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis.  Here we report the discovery of a highly potent and selective small-mol. inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types.  This compd. causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses.  Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgm1YUgqkWLVg90H21EOLACvtfcHk0limrEfGHnmwEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D&md5=954ba274e280d8d08a7f2e331011432d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnm1003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1003%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520Aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D262%26epage%3D267%26doi%3D10.1038%2Fnm1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="note"><p class="first last">For full details regarding JAK2 and JAK3 <i>K</i><sub>i</sub> determinations, refer to the <a href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf" class="ext-link">Supporting Information</a> and the following references:</p></div><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazhanisamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galullo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2249</span><span class="NLM_x">–</span> <span class="NLM_lpage">2255</span><span class="refDoi"> DOI: 10.1002/pro.5560071102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fpro.5560071102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=9827991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1GrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1998&pages=2249-2255&author=T.+Foxauthor=J.+T.+Collauthor=X.+Xieauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=M.+D.+Porterauthor=S.+Pazhanisamyauthor=M.+A.+Flemingauthor=V.+Galulloauthor=M.-S.+Suauthor=K.+P.+Wilson&title=A+single+amino+acid+substitution+makes+ERK2+susceptible+to+pyridinyl+imidazole+inhibitors+of+p38+MAP+kinase&doi=10.1002%2Fpro.5560071102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase</span></div><div class="casAuthors">Fox, Ted; Coll, Joyce T.; Xie, Xiaoling; Ford, Pamella J.; Germann, Ursula A.; Porter, Margaret D.; Pazhanisamy, S.; Fleming, Mark A.; Galullo, Vincent; Su, Michael S. S.; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2249-2255</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Mitogen-activated protein (MAP) kinases are serine/threonine kinases that mediate intracellular signal transduction pathways.  Pyridinyl imidazole compds. block pro-inflammatory cytokine prodn. and are specific p38 kinase inhibitors.  ERK2 is related to p38 in sequence and structure, but is not inhibited by pyridinyl imidazole inhibitors.  Crystal structures of two pyridinyl imidazoles complexed with p38 revealed these compds. bind in the ATP site.  Mutagenesis data suggested a single residue difference at threonine 106 between p38 and other MAP kinases is sufficient to confer selectivity of pyridinyl imidazoles.  We have changed the equiv. residue in human ERK2, Q105, into threonine and alanine, and substituted four addnl. ATP binding site residues.  The single residue change Q105A in ERK2 enhances the binding of SB202190 at least 25,000-fold compared to wild-type ERK2.  We report enzymic analyses of wild-type ERK2 and the mutant proteins, and the crystal structure of a pyridinyl imidazole, SB203580, bound to an ERK2 pentamutant, I103L, Q105T, D106H, E109G, T110A.  These ATP binding site substitutions induce low nanomolar sensitivity to pyridinyl imidazoles.  Furthermore, we identified 5-iodotubercidin as a potent ERK2 inhibitor, which may help reveal the role of ERK2 in cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrlKBLv_uYKLVg90H21EOLACvtfcHk0limrEfGHnmwEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1GrsLs%253D&md5=fccebbc08468e60512d2598440f64b25</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560071102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560071102%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DT.%26aulast%3DColl%26aufirst%3DJ.%2BT.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DPorter%26aufirst%3DM.%2BD.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DFleming%26aufirst%3DM.%2BA.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DSu%26aufirst%3DM.-S.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DA%2520single%2520amino%2520acid%2520substitution%2520makes%2520ERK2%2520susceptible%2520to%2520pyridinyl%2520imidazole%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%26jtitle%3DProtein%2520Sci.%26date%3D1998%26volume%3D7%26spage%3D2249%26epage%3D2255%26doi%3D10.1002%2Fpro.5560071102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morrison, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, S. R.</span><span> </span><span class="NLM_article-title">Approaches to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors</span> <span class="citation_source-journal">Comments Mol. Cell. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaL2MXkvVert7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1985&pages=347-368&author=J.+F.+Morrisonauthor=S.+R.+Stone&title=Approaches+to+the+study+and+analysis+of+the+inhibition+of+enzymes+by+slow-+and+tight-binding+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors</span></div><div class="casAuthors">Morrison, John F.; Stone, Stuart R.</div><div class="citationInfo"><span class="NLM_cas:title">Comments on Molecular and Cellular Biophysics</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">347-68</span>CODEN:
                <span class="NLM_cas:coden">CMCBDM</span>;
        ISSN:<span class="NLM_cas:issn">0143-8123</span>.
    </div><div class="casAbstract">A review and discussion with 25 refs. on the mechanism and kinetic anal. of enzyme slow- and tight-binding inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83f4j5LgZN7Vg90H21EOLACvtfcHk0limrEfGHnmwEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXkvVert7o%253D&md5=26df0f1503bc3d749128b2e2ecd42eea</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26aulast%3DStone%26aufirst%3DS.%2BR.%26atitle%3DApproaches%2520to%2520the%2520study%2520and%2520analysis%2520of%2520the%2520inhibition%2520of%2520enzymes%2520by%2520slow-%2520and%2520tight-binding%2520inhibitors%26jtitle%3DComments%2520Mol.%2520Cell.%2520Biophys.%26date%3D1985%26volume%3D2%26spage%3D347%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Vonrhein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flensburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smart, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paciorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bricogne, G.</span><span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0ljteCcINFFVpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Bricogne, G.; Blanc, E.; Brandl, M.; C, F.; Keller, P.; Paciorek, W.; P, R.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T.</span> <span class="citation_source-book">BUSTER</span>, version 2.11.4; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=F.+C&author=P.+Keller&author=W.+Paciorek&author=R.+P&author=A.+Sharff&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26btitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljteCcINFFVpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':[],'ref34':['cit34'],'ref35':['cit35a','cit35b','cit35c','cit35d','cit35e'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 50 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shi-Fei Li, Xue Liang, Xing-Kang Wu, Xiang Gao, <span class="NLM_string-name hlFld-ContribAuthor">Li-Wei Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovering the Mechanisms of Wikstroelide E as a Potential HIV-Latency-Reversing Agent by Transcriptome Profiling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2021,</strong> <em>84 </em>
                                    (4)
                                     , 1022-1033. <a href="https://doi.org/10.1021/acs.jnatprod.0c01039" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.0c01039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.0c01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.0c01039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DDiscovering%252Bthe%252BMechanisms%252Bof%252BWikstroelide%252BE%252Bas%252Ba%252BPotential%252BHIV-Latency-Reversing%252BAgent%252Bby%252BTranscriptome%252BProfiling%26aulast%3DLi%26aufirst%3DShi-Fei%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D03102020%26date%3D16032021%26volume%3D84%26issue%3D4%26spage%3D1022%26epage%3D1033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">J. Henry Blackwell, Roopender Kumar, <span class="NLM_string-name hlFld-ContribAuthor">Matthew J. Gaunt</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-Light-Mediated Carbonyl Alkylative Amination to All-Alkyl α-Tertiary Amino Acid Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (3)
                                     , 1598-1609. <a href="https://doi.org/10.1021/jacs.0c12162" title="DOI URL">https://doi.org/10.1021/jacs.0c12162</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c12162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c12162%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DVisible-Light-Mediated%252BCarbonyl%252BAlkylative%252BAmination%252Bto%252BAll-Alkyl%252B%2525CE%2525B1-Tertiary%252BAmino%252BAcid%252BDerivatives%26aulast%3DBlackwell%26aufirst%3DJ.%2BHenry%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D20112020%26date%3D11012021%26volume%3D143%26issue%3D3%26spage%3D1598%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andreas Tosstorff, Jason C. Cole, Robin Taylor, Seth F. Harris, <span class="NLM_string-name hlFld-ContribAuthor">Bernd Kuhn</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Noncompetitive Protein–Ligand Interactions for Structural Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (12)
                                     , 6595-6611. <a href="https://doi.org/10.1021/acs.jcim.0c00858" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00858%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Bof%252BNoncompetitive%252BProtein%2525E2%252580%252593Ligand%252BInteractions%252Bfor%252BStructural%252BOptimization%26aulast%3DTosstorff%26aufirst%3DAndreas%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28072020%26date%3D21102020%26volume%3D60%26issue%3D12%26spage%3D6595%26epage%3D6611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Roshan Y Nimje, Devaiah Vytla, Prakasam Kuppusamy, Rajeswari Velayuthaperumal, Lokesh Babu Jarugu, China Anki Reddy, Nanjundaswamy Kanikahalli Chikkananjaiah, Richard A. Rampulla, Cullen L. Cavallaro, Jianqing Li, Arvind Mathur, Anuradha Gupta, <span class="NLM_string-name hlFld-ContribAuthor">Amrita Roy</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Differentially Protected Azatryptophan Analogs via Pd2(dba)3/XPhos Catalyzed Negishi Coupling of N-Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected tert-Butyl (R)-2-Amino-3-iodopropanoate. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (17)
                                     , 11519-11530. <a href="https://doi.org/10.1021/acs.joc.0c00973" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00973</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00973%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BDifferentially%252BProtected%252BAzatryptophan%252BAnalogs%252Bvia%252BPd2%252528dba%2525293%25252FXPhos%252BCatalyzed%252BNegishi%252BCoupling%252Bof%252BN-Ts%252BAzaindole%252BHalides%252Bwith%252BZinc%252BDerivative%252Bfrom%252BFmoc-Protected%252Btert-Butyl%252B%252528R%252529-2-Amino-3-iodopropanoate%26aulast%3DNimje%26aufirst%3DRoshan%2BY%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20042020%26date%3D25082020%26date%3D10082020%26volume%3D85%26issue%3D17%26spage%3D11519%26epage%3D11530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pavel Štarha, Zdeněk Trávníček, Hana Crlíková, Ján Vančo, Jana Kašpárková, <span class="NLM_string-name hlFld-ContribAuthor">Zdeněk Dvořák</span>. </span><span class="cited-content_cbyCitation_article-title">Half-Sandwich Ir(III) Complex of N1-Pyridyl-7-azaindole Exceeds Cytotoxicity of Cisplatin at Various Human Cancer Cells and 3D Multicellular Tumor Spheroids. </span><span class="cited-content_cbyCitation_journal-name">Organometallics</span><span> <strong>2018,</strong> <em>37 </em>
                                    (16)
                                     , 2749-2759. <a href="https://doi.org/10.1021/acs.organomet.8b00415" title="DOI URL">https://doi.org/10.1021/acs.organomet.8b00415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.organomet.8b00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.organomet.8b00415%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganometallics%26atitle%3DHalf-Sandwich%252BIr%252528III%252529%252BComplex%252Bof%252BN1-Pyridyl-7-azaindole%252BExceeds%252BCytotoxicity%252Bof%252BCisplatin%252Bat%252BVarious%252BHuman%252BCancer%252BCells%252Band%252B3D%252BMulticellular%252BTumor%252BSpheroids%26aulast%3D%25C5%25A0tarha%26aufirst%3DPavel%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15062018%26date%3D14082018%26volume%3D37%26issue%3D16%26spage%3D2749%26epage%3D2759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucas A.  Santos</span>, <span class="hlFld-ContribAuthor ">Elaine F. F.  da Cunha</span>, and <span class="hlFld-ContribAuthor ">Teodorico C.  Ramalho</span>  . </span><span class="cited-content_cbyCitation_article-title">Toward the Classical Description of Halogen Bonds: A Quantum Based Generalized Empirical Potential for Fluorine, Chlorine, and Bromine. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry A</span><span> <strong>2017,</strong> <em>121 </em>
                                    (12)
                                     , 2442-2451. <a href="https://doi.org/10.1021/acs.jpca.6b13112" title="DOI URL">https://doi.org/10.1021/acs.jpca.6b13112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpca.6b13112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpca.6b13112%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520A%26atitle%3DToward%252Bthe%252BClassical%252BDescription%252Bof%252BHalogen%252BBonds%25253A%252BA%252BQuantum%252BBased%252BGeneralized%252BEmpirical%252BPotential%252Bfor%252BFluorine%25252C%252BChlorine%25252C%252Band%252BBromine%26aulast%3DSantos%26aufirst%3DLucas%2BA.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2017%26date%3D31122016%26date%3D13032017%26date%3D21032017%26date%3D30032017%26date%3D14032017%26volume%3D121%26issue%3D12%26spage%3D2442%26epage%3D2451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark A. T.  Blaskovich</span>  . </span><span class="cited-content_cbyCitation_article-title">Unusual Amino Acids in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (24)
                                     , 10807-10836. <a href="https://doi.org/10.1021/acs.jmedchem.6b00319" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00319%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUnusual%252BAmino%252BAcids%252Bin%252BMedicinal%252BChemistry%26aulast%3DBlaskovich%26aufirst%3DMark%2BA.%2BT.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D02032016%26date%3D30092016%26date%3D22122016%26date%3D02092016%26volume%3D59%26issue%3D24%26spage%3D10807%26epage%3D10836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">Tsung  Lin</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Erick  Moy</span>, <span class="hlFld-ContribAuthor ">Paul  Balbo</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Yajuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Kimberly  Crouse</span>, <span class="hlFld-ContribAuthor ">Caitlyn  Dickinson</span>, <span class="hlFld-ContribAuthor ">Peter  Symanowicz</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Ray  Unwalla</span>, <span class="hlFld-ContribAuthor ">Sidney  Liang</span>, <span class="hlFld-ContribAuthor ">Adam M.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Matthew  Hayward</span>, <span class="hlFld-ContribAuthor ">Justin  Montgomery</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>, <span class="hlFld-ContribAuthor ">Jonathan  Bauman</span>, <span class="hlFld-ContribAuthor ">John I.  Trujillo</span>, <span class="hlFld-ContribAuthor ">Agustin  Casimiro-Garcia</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>, <span class="hlFld-ContribAuthor ">Louis  Leung</span>, <span class="hlFld-ContribAuthor ">Kieran F.  Geoghegan</span>, <span class="hlFld-ContribAuthor ">Amira  Quazi</span>, <span class="hlFld-ContribAuthor ">Dejun  Xuan</span>, <span class="hlFld-ContribAuthor ">Lyn  Jones</span>, <span class="hlFld-ContribAuthor ">Erik  Hett</span>, <span class="hlFld-ContribAuthor ">Katherine  Wright</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, and <span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (12)
                                     , 3442-3451. <a href="https://doi.org/10.1021/acschembio.6b00677" title="DOI URL">https://doi.org/10.1021/acschembio.6b00677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.6b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.6b00677%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252BJAK3-Selective%252BInhibitor%25253A%252BFunctional%252BDifferentiation%252Bof%252BJAK3-Selective%252BInhibition%252Bover%252Bpan-JAK%252Bor%252BJAK1-Selective%252BInhibition%26aulast%3DTelliez%26aufirst%3DJean-Baptiste%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05082016%26date%3D28102016%26date%3D10112016%26date%3D16122016%26date%3D28102016%26volume%3D11%26issue%3D12%26spage%3D3442%26epage%3D3451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalie  Palaychuk</span>, <span class="hlFld-ContribAuthor ">Travis J.  DeLano</span>, <span class="hlFld-ContribAuthor ">Michael J.  Boyd</span>, <span class="hlFld-ContribAuthor ">Jeremy  Green</span>, and <span class="hlFld-ContribAuthor ">Upul K.  Bandarage</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Cycloalkyl Substituted 7-Azaindoles via Photoredox Nickel Dual Catalytic Cross-Coupling in Batch and Continuous Flow. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2016,</strong> <em>18 </em>
                                    (23)
                                     , 6180-6183. <a href="https://doi.org/10.1021/acs.orglett.6b03223" title="DOI URL">https://doi.org/10.1021/acs.orglett.6b03223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.6b03223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.6b03223%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BCycloalkyl%252BSubstituted%252B7-Azaindoles%252Bvia%252BPhotoredox%252BNickel%252BDual%252BCatalytic%252BCross-Coupling%252Bin%252BBatch%252Band%252BContinuous%252BFlow%26aulast%3DPalaychuk%26aufirst%3DNatalie%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D27102016%26date%3D18112016%26date%3D02122016%26volume%3D18%26issue%3D23%26spage%3D6180%26epage%3D6183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.M.S.  Krishna</span>, <span class="hlFld-ContribAuthor ">Hima Bindu  Gandham</span>, <span class="hlFld-ContribAuthor ">Krishna Reddy  Valluru</span>, <span class="hlFld-ContribAuthor ">N.S. Kameswara  Rao</span>, <span class="hlFld-ContribAuthor ">Gattu  Sridhar</span>, <span class="hlFld-ContribAuthor ">Venkateswara Rao  Battula</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anticancer activity of arylketo alkyne derivatives of 7-azaindole-oxazole. </span><span class="cited-content_cbyCitation_journal-name">Chemical Data Collections</span><span> <strong>2021,</strong> <em>34 </em>, 100743. <a href="https://doi.org/10.1016/j.cdc.2021.100743" title="DOI URL">https://doi.org/10.1016/j.cdc.2021.100743</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cdc.2021.100743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cdc.2021.100743%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Data%2520Collections%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banticancer%252Bactivity%252Bof%252Barylketo%252Balkyne%252Bderivatives%252Bof%252B7-azaindole-oxazole%26aulast%3DKrishna%26aufirst%3DA.M.S.%26date%3D2021%26volume%3D34%26spage%3D100743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna  Wątły</span>, <span class="hlFld-ContribAuthor ">Adriana  Miller</span>, <span class="hlFld-ContribAuthor ">Henryk  Kozłowski</span>, <span class="hlFld-ContribAuthor ">Magdalena  Rowińska-Żyrek</span>. </span><span class="cited-content_cbyCitation_article-title">Peptidomimetics – An infinite reservoir of metal binding motifs in metabolically stable and biologically active molecules. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2021,</strong> <em>217 </em>, 111386. <a href="https://doi.org/10.1016/j.jinorgbio.2021.111386" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2021.111386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2021.111386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2021.111386%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DPeptidomimetics%252B%2525E2%252580%252593%252BAn%252Binfinite%252Breservoir%252Bof%252Bmetal%252Bbinding%252Bmotifs%252Bin%252Bmetabolically%252Bstable%252Band%252Bbiologically%252Bactive%252Bmolecules%26aulast%3DW%25C4%2585t%25C5%2582y%26aufirst%3DJoanna%26date%3D2021%26volume%3D217%26spage%3D111386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karima  Alim</span>, <span class="hlFld-ContribAuthor ">Arnaud  Bruyère</span>, <span class="hlFld-ContribAuthor ">Alain  Lescoat</span>, <span class="hlFld-ContribAuthor ">Elodie  Jouan</span>, <span class="hlFld-ContribAuthor ">Valérie  Lecureur</span>, <span class="hlFld-ContribAuthor ">Marc  Le Vée</span>, <span class="hlFld-ContribAuthor ">Olivier  Fardel</span>. </span><span class="cited-content_cbyCitation_article-title">Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (3)
                                     , 259-271. <a href="https://doi.org/10.1080/17425255.2021.1862084" title="DOI URL">https://doi.org/10.1080/17425255.2021.1862084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2021.1862084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2021.1862084%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DInteractions%252Bof%252Bjanus%252Bkinase%252Binhibitors%252Bwith%252Bdrug%252Btransporters%252Band%252Bconsequences%252Bfor%252Bpharmacokinetics%252Band%252Btoxicity%26aulast%3DAlim%26aufirst%3DKarima%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D3%26spage%3D259%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nabil  Al-Zaqri</span>, <span class="hlFld-ContribAuthor ">T.  Pooventhiran</span>, <span class="hlFld-ContribAuthor ">D. Jagadeeswara  Rao</span>, <span class="hlFld-ContribAuthor ">Ali  Alsalme</span>, <span class="hlFld-ContribAuthor ">Ismail  Warad</span>, <span class="hlFld-ContribAuthor ">Renjith  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Structure, conformational dynamics, quantum mechanical studies and potential biological activity analysis of multiple sclerosis medicine ozanimod. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1227 </em>, 129685. <a href="https://doi.org/10.1016/j.molstruc.2020.129685" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.129685</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.129685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.129685%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DStructure%25252C%252Bconformational%252Bdynamics%25252C%252Bquantum%252Bmechanical%252Bstudies%252Band%252Bpotential%252Bbiological%252Bactivity%252Banalysis%252Bof%252Bmultiple%252Bsclerosis%252Bmedicine%252Bozanimod%26aulast%3DAl-Zaqri%26aufirst%3DNabil%26date%3D2021%26volume%3D1227%26spage%3D129685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rita A.  Moura</span>, <span class="hlFld-ContribAuthor ">João Eurico  Fonseca</span>. </span><span class="cited-content_cbyCitation_article-title">JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Medicine</span><span> <strong>2021,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmed.2020.607725" title="DOI URL">https://doi.org/10.3389/fmed.2020.607725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmed.2020.607725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmed.2020.607725%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Medicine%26atitle%3DJAK%252BInhibitors%252Band%252BModulation%252Bof%252BB%252BCell%252BImmune%252BResponses%252Bin%252BRheumatoid%252BArthritis%26aulast%3DMoura%26aufirst%3DRita%2BA.%26date%3D2021%26date%3D2021%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  El Jammal</span>, <span class="hlFld-ContribAuthor ">Pascal  Sève</span>, <span class="hlFld-ContribAuthor ">Mathieu  Gerfaud-Valentin</span>, <span class="hlFld-ContribAuthor ">Yvan  Jamilloux</span>. </span><span class="cited-content_cbyCitation_article-title">State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2021,</strong> <em>22 </em>
                                    (2)
                                     , 205-218. <a href="https://doi.org/10.1080/14656566.2020.1822325" title="DOI URL">https://doi.org/10.1080/14656566.2020.1822325</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2020.1822325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2020.1822325%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DState%252Bof%252Bthe%252Bart%25253A%252Bapproved%252Band%252Bemerging%252BJAK%252Binhibitors%252Bfor%252Brheumatoid%252Barthritis%26aulast%3DEl%2BJammal%26aufirst%3DThomas%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D2%26spage%3D205%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaurav  Raina</span>, <span class="hlFld-ContribAuthor ">Prakash  Kannaboina</span>, <span class="hlFld-ContribAuthor ">Qazi Naveed  Ahmed</span>, <span class="hlFld-ContribAuthor ">Krishanu  Mondal</span>, <span class="hlFld-ContribAuthor ">Parthasarathi  Das</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium‐Catalyzed Barluenga‐Valdes Type Cross‐Coupling Reaction: Alkenylation of 7‐Azaindole
              s. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>10 </em>
                                    (1)
                                     , 251-256. <a href="https://doi.org/10.1002/ajoc.202000516" title="DOI URL">https://doi.org/10.1002/ajoc.202000516</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.202000516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.202000516%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPalladium%2525E2%252580%252590Catalyzed%252BBarluenga%2525E2%252580%252590Valdes%252BType%252BCross%2525E2%252580%252590Coupling%252BReaction%25253A%252BAlkenylation%252Bof%252B7%2525E2%252580%252590Azaindole%252Bs%26aulast%3DRaina%26aufirst%3DGaurav%26date%3D2021%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D251%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael F.  Robinson</span>, <span class="hlFld-ContribAuthor ">Nemanja  Damjanov</span>, <span class="hlFld-ContribAuthor ">Bojana  Stamenkovic</span>, <span class="hlFld-ContribAuthor ">Goran  Radunovic</span>, <span class="hlFld-ContribAuthor ">Alan  Kivitz</span>, <span class="hlFld-ContribAuthor ">Lori  Cox</span>, <span class="hlFld-ContribAuthor ">Zorayr  Manukyan</span>, <span class="hlFld-ContribAuthor ">Christopher  Banfield</span>, <span class="hlFld-ContribAuthor ">Michael  Saunders</span>, <span class="hlFld-ContribAuthor ">Deepa  Chandra</span>, <span class="hlFld-ContribAuthor ">Michael S.  Vincent</span>, <span class="hlFld-ContribAuthor ">Jessica  Mancuso</span>, <span class="hlFld-ContribAuthor ">Elena  Peeva</span>, <span class="hlFld-ContribAuthor ">Jean S.  Beebe</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. </span><span class="cited-content_cbyCitation_journal-name">Arthritis & Rheumatology</span><span> <strong>2020,</strong> <em>72 </em>
                                    (10)
                                     , 1621-1631. <a href="https://doi.org/10.1002/art.41316" title="DOI URL">https://doi.org/10.1002/art.41316</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/art.41316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fart.41316%26sid%3Dliteratum%253Aachs%26jtitle%3DArthritis%2520%2526%2520Rheumatology%26atitle%3DEfficacy%252Band%252BSafety%252Bof%252BPF%2525E2%252580%25259006651600%252B%252528Ritlecitinib%252529%25252C%252Ba%252BNovel%252BJAK3%25252FTEC%252BInhibitor%25252C%252Bin%252BPatients%252BWith%252BModerate%2525E2%252580%252590to%2525E2%252580%252590Severe%252BRheumatoid%252BArthritis%252Band%252Ban%252BInadequate%252BResponse%252Bto%252BMethotrexate%26aulast%3DRobinson%26aufirst%3DMichael%2BF.%26date%3D2020%26date%3D2020%26volume%3D72%26issue%3D10%26spage%3D1621%26epage%3D1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arezoo  Hosseini</span>, <span class="hlFld-ContribAuthor ">Tohid  Gharibi</span>, <span class="hlFld-ContribAuthor ">Faroogh  Marofi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Javadian</span>, <span class="hlFld-ContribAuthor ">Zohreh  Babaloo</span>, <span class="hlFld-ContribAuthor ">Behzad  Baradaran</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2020,</strong> <em>235 </em>
                                    (9)
                                     , 5903-5924. <a href="https://doi.org/10.1002/jcp.29593" title="DOI URL">https://doi.org/10.1002/jcp.29593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.29593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.29593%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DJanus%252Bkinase%252Binhibitors%25253A%252BA%252Btherapeutic%252Bstrategy%252Bfor%252Bcancer%252Band%252Bautoimmune%252Bdiseases%26aulast%3DHosseini%26aufirst%3DArezoo%26date%3D2020%26date%3D2020%26volume%3D235%26issue%3D9%26spage%3D5903%26epage%3D5924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanjiv  Singh</span>, <span class="hlFld-ContribAuthor ">Shantanu  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2020,</strong> <em>86 </em>, 106731. <a href="https://doi.org/10.1016/j.intimp.2020.106731" title="DOI URL">https://doi.org/10.1016/j.intimp.2020.106731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2020.106731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2020.106731%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DJAK-STAT%252Binhibitors%25253A%252BImmersing%252Btherapeutic%252Bapproach%252Bfor%252Bmanagement%252Bof%252Brheumatoid%252Barthritis%26aulast%3DSingh%26aufirst%3DSanjiv%26date%3D2020%26volume%3D86%26spage%3D106731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju  Wang</span>, <span class="hlFld-ContribAuthor ">Chen-Fu  Liu</span>, <span class="hlFld-ContribAuthor ">Quan  Zheng</span>, <span class="hlFld-ContribAuthor ">Guo-Wu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">C-H Functionalization of Biaryl Compounds. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (25)
                                     , 3737-3765. <a href="https://doi.org/10.1002/ejoc.202000071" title="DOI URL">https://doi.org/10.1002/ejoc.202000071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202000071%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DC-H%252BFunctionalization%252Bof%252BBiaryl%252BCompounds%26aulast%3DWang%26aufirst%3DJu%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D25%26spage%3D3737%26epage%3D3765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacopo  Angelini</span>, <span class="hlFld-ContribAuthor ">Rossella  Talotta</span>, <span class="hlFld-ContribAuthor ">Rossana  Roncato</span>, <span class="hlFld-ContribAuthor ">Giulia  Fornasier</span>, <span class="hlFld-ContribAuthor ">Giorgia  Barbiero</span>, <span class="hlFld-ContribAuthor ">Lisa  Dal Cin</span>, <span class="hlFld-ContribAuthor ">Serena  Brancati</span>, <span class="hlFld-ContribAuthor ">Francesco  Scaglione</span>. </span><span class="cited-content_cbyCitation_article-title">JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (7)
                                     , 1002. <a href="https://doi.org/10.3390/biom10071002" title="DOI URL">https://doi.org/10.3390/biom10071002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10071002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10071002%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DJAK-Inhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%25253A%252BA%252BFocus%252Bon%252Bthe%252BPresent%252Band%252Ban%252BOutlook%252Bon%252Bthe%252BFuture%26aulast%3DAngelini%26aufirst%3DJacopo%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D7%26spage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Qianqian  Yu</span>, <span class="hlFld-ContribAuthor ">Yanfei  Cai</span>, <span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Wenqing  Liang</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00083" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00083%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DTheoretical%252BExploring%252BSelective-Binding%252BMechanisms%252Bof%252BJAK3%252Bby%252B3D-QSAR%25252C%252BMolecular%252BDynamics%252BSimulation%252Band%252BFree%252BEnergy%252BCalculation%26aulast%3DZhu%26aufirst%3DJingyu%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>, <span class="hlFld-ContribAuthor ">Michael  Forster</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Janus Kinase 3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 225-256. <a href="https://doi.org/10.1007/7355_2020_96" title="DOI URL">https://doi.org/10.1007/7355_2020_96</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_96%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BJanus%252BKinase%252B3%252BInhibitors%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D225%26epage%3D256%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Karel D.  Klika</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Tatsunori  Sato</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of fluorine-containing amino acids for drug design. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111826. <a href="https://doi.org/10.1016/j.ejmech.2019.111826" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111826</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111826%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplications%252Bof%252Bfluorine-containing%252Bamino%252Bacids%252Bfor%252Bdrug%252Bdesign%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2020%26volume%3D186%26spage%3D111826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Chiara  Greco</span>, <span class="hlFld-ContribAuthor ">Ilaria  Giacchello</span>, <span class="hlFld-ContribAuthor ">Anna Lucia  Fallacara</span>, <span class="hlFld-ContribAuthor ">Munjed M.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Giancarlo  Grossi</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>. </span><span class="cited-content_cbyCitation_article-title">An Update on JAK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (10)
                                     , 1806-1832. <a href="https://doi.org/10.2174/0929867325666180327093502" title="DOI URL">https://doi.org/10.2174/0929867325666180327093502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180327093502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180327093502%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DAn%252BUpdate%252Bon%252BJAK%252BInhibitors%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2019%26volume%3D26%26issue%3D10%26spage%3D1806%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaru  Wei</span>, <span class="hlFld-ContribAuthor ">Zhiyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Nai  She</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Jinglai  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Atomistic insight into the inhibition mechanisms of suppressors of cytokine signaling on Janus kinase. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2019,</strong> <em>21 </em>
                                    (24)
                                     , 12905-12915. <a href="https://doi.org/10.1039/C9CP02257K" title="DOI URL">https://doi.org/10.1039/C9CP02257K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CP02257K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CP02257K%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DAtomistic%252Binsight%252Binto%252Bthe%252Binhibition%252Bmechanisms%252Bof%252Bsuppressors%252Bof%252Bcytokine%252Bsignaling%252Bon%252BJanus%252Bkinase%26aulast%3DWei%26aufirst%3DYaru%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D24%26spage%3D12905%26epage%3D12915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anja  Dullius</span>, <span class="hlFld-ContribAuthor ">Claudia Monfroni  Rocha</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Claucia Fernanda Volken  de Souza</span>, <span class="hlFld-ContribAuthor ">Márcia Inês  Goettert</span>. </span><span class="cited-content_cbyCitation_article-title">Are peptides a solution for the treatment of hyperactivated JAK3 pathways?. </span><span class="cited-content_cbyCitation_journal-name">Inflammopharmacology</span><span> <strong>2019,</strong> <em>27 </em>
                                    (3)
                                     , 433-452. <a href="https://doi.org/10.1007/s10787-019-00589-2" title="DOI URL">https://doi.org/10.1007/s10787-019-00589-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10787-019-00589-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10787-019-00589-2%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammopharmacology%26atitle%3DAre%252Bpeptides%252Ba%252Bsolution%252Bfor%252Bthe%252Btreatment%252Bof%252Bhyperactivated%252BJAK3%252Bpathways%25253F%26aulast%3DDullius%26aufirst%3DAnja%26date%3D2019%26date%3D2019%26volume%3D27%26issue%3D3%26spage%3D433%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanja  Narancic</span>, <span class="hlFld-ContribAuthor ">Sarah A.  Almahboub</span>, <span class="hlFld-ContribAuthor ">Kevin E.  O’Connor</span>. </span><span class="cited-content_cbyCitation_article-title">Unnatural amino acids: production and biotechnological potential. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Microbiology and Biotechnology</span><span> <strong>2019,</strong> <em>35 </em>
                                    (4)
                                     <a href="https://doi.org/10.1007/s11274-019-2642-9" title="DOI URL">https://doi.org/10.1007/s11274-019-2642-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11274-019-2642-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11274-019-2642-9%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Microbiology%2520and%2520Biotechnology%26atitle%3DUnnatural%252Bamino%252Bacids%25253A%252Bproduction%252Band%252Bbiotechnological%252Bpotential%26aulast%3DNarancic%26aufirst%3DTanja%26date%3D2019%26date%3D2019%26volume%3D35%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deng</span>, <span class="hlFld-ContribAuthor ">Bellanti</span>, <span class="hlFld-ContribAuthor ">Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Essential Kinases and Transcriptional Regulators and Their Roles in Autoimmunity. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (4)
                                     , 145. <a href="https://doi.org/10.3390/biom9040145" title="DOI URL">https://doi.org/10.3390/biom9040145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9040145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9040145%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DEssential%252BKinases%252Band%252BTranscriptional%252BRegulators%252Band%252BTheir%252BRoles%252Bin%252BAutoimmunity%26aulast%3DDeng%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D4%26spage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anniina  T. Virtanen</span>, <span class="hlFld-ContribAuthor ">Teemu  Haikarainen</span>, <span class="hlFld-ContribAuthor ">Juuli  Raivola</span>, <span class="hlFld-ContribAuthor ">Olli  Silvennoinen</span>. </span><span class="cited-content_cbyCitation_article-title">Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">BioDrugs</span><span> <strong>2019,</strong> <em>33 </em>
                                    (1)
                                     , 15-32. <a href="https://doi.org/10.1007/s40259-019-00333-w" title="DOI URL">https://doi.org/10.1007/s40259-019-00333-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40259-019-00333-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40259-019-00333-w%26sid%3Dliteratum%253Aachs%26jtitle%3DBioDrugs%26atitle%3DSelective%252BJAKinibs%25253A%252BProspects%252Bin%252BInflammatory%252Band%252BAutoimmune%252BDiseases%26aulast%3DT.%2BVirtanen%26aufirst%3DAnniina%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D1%26spage%3D15%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yifan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiao  Liu</span>, <span class="hlFld-ContribAuthor ">Youzhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Long  Peng</span>, <span class="hlFld-ContribAuthor ">John Z. H.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Residue-specific free energy analysis in ligand bindings to JAK2. </span><span class="cited-content_cbyCitation_journal-name">Molecular Physics</span><span> <strong>2018,</strong> <em>116 </em>
                                    (19-20)
                                     , 2633-2641. <a href="https://doi.org/10.1080/00268976.2018.1442596" title="DOI URL">https://doi.org/10.1080/00268976.2018.1442596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00268976.2018.1442596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00268976.2018.1442596%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Physics%26atitle%3DResidue-specific%252Bfree%252Benergy%252Banalysis%252Bin%252Bligand%252Bbindings%252Bto%252BJAK2%26aulast%3DZhou%26aufirst%3DYifan%26date%3D2018%26date%3D2018%26volume%3D116%26issue%3D19-20%26spage%3D2633%26epage%3D2641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Shao</span>, <span class="hlFld-ContribAuthor ">Taijin  Wang</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2018,</strong> <em>22 </em>
                                    (2)
                                     , 343-358. <a href="https://doi.org/10.1007/s11030-017-9803-2" title="DOI URL">https://doi.org/10.1007/s11030-017-9803-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9803-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9803-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252BSAR%252Bstudy%252Bof%252Bhighly%252Bpotent%25252C%252Bselective%25252C%252Birreversible%252Bcovalent%252BJAK3%252Binhibitors%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2018%26date%3D2018%26volume%3D22%26issue%3D2%26spage%3D343%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matilde  Iorizzo</span>, <span class="hlFld-ContribAuthor ">Antonella  Tosti</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging drugs for alopecia areata: JAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Emerging Drugs</span><span> <strong>2018,</strong> <em>23 </em>
                                    (1)
                                     , 77-81. <a href="https://doi.org/10.1080/14728214.2018.1444750" title="DOI URL">https://doi.org/10.1080/14728214.2018.1444750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728214.2018.1444750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728214.2018.1444750%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Emerging%2520Drugs%26atitle%3DEmerging%252Bdrugs%252Bfor%252Balopecia%252Bareata%25253A%252BJAK%252Binhibitors%26aulast%3DIorizzo%26aufirst%3DMatilde%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D1%26spage%3D77%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Kim</span>, <span class="hlFld-ContribAuthor ">Bruce  Strober</span>. </span><span class="cited-content_cbyCitation_article-title">Janus Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 187-198. <a href="https://doi.org/10.1007/978-3-319-66884-0_19" title="DOI URL">https://doi.org/10.1007/978-3-319-66884-0_19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-66884-0_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-66884-0_19%26sid%3Dliteratum%253Aachs%26atitle%3DJanus%252BKinase%252BInhibitors%26aulast%3DKim%26aufirst%3DAndrew%26date%3D2018%26date%3D2017%26spage%3D187%26epage%3D198%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DBiologic%252Band%252BSystemic%252BAgents%252Bin%252BDermatology%26aulast%3DYamauchi%26aufirst%3DPaul%2BS.%26date%3D2018%26volume%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takayuki  Irie</span>, <span class="hlFld-ContribAuthor ">Masaaki  Sawa</span>. </span><span class="cited-content_cbyCitation_article-title">7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">CHEMICAL & PHARMACEUTICAL BULLETIN</span><span> <strong>2018,</strong> <em>66 </em>
                                    (1)
                                     , 29-36. <a href="https://doi.org/10.1248/cpb.c17-00380" title="DOI URL">https://doi.org/10.1248/cpb.c17-00380</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c17-00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c17-00380%26sid%3Dliteratum%253Aachs%26jtitle%3DCHEMICAL%2520%2526%2520PHARMACEUTICAL%2520BULLETIN%26atitle%3D7-Azaindole%25253A%252BA%252BVersatile%252BScaffold%252Bfor%252BDeveloping%252BKinase%252BInhibitors%26aulast%3DIrie%26aufirst%3DTakayuki%26date%3D2018%26volume%3D66%26issue%3D1%26spage%3D29%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniella M.  Schwartz</span>, <span class="hlFld-ContribAuthor ">Yuka  Kanno</span>, <span class="hlFld-ContribAuthor ">Alejandro  Villarino</span>, <span class="hlFld-ContribAuthor ">Michael  Ward</span>, <span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2017,</strong> <em>16 </em>
                                    (12)
                                     , 843-862. <a href="https://doi.org/10.1038/nrd.2017.201" title="DOI URL">https://doi.org/10.1038/nrd.2017.201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DJAK%252Binhibition%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Bimmune%252Band%252Binflammatory%252Bdiseases%26aulast%3DSchwartz%26aufirst%3DDaniella%2BM.%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D12%26spage%3D843%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2017,</strong> <em>350 </em>
                                    (11)
                                     , 1700194. <a href="https://doi.org/10.1002/ardp.201700194" title="DOI URL">https://doi.org/10.1002/ardp.201700194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201700194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201700194%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252Ba%252BHighly%252BSelective%252BJAK3%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2017%26date%3D2017%26volume%3D350%26issue%3D11%26spage%3D1700194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (18)
                                     , 4229-4237. <a href="https://doi.org/10.1016/j.bmcl.2017.07.079" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.07.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.07.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.07.079%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Badvances%252Bin%252BJAK3%252Binhibition%25253A%252BIsoform%252Bselectivity%252Bby%252Bcovalent%252Bcysteine%252Btargeting%26aulast%3DForster%26aufirst%3DMichael%26date%3D2017%26volume%3D27%26issue%3D18%26spage%3D4229%26epage%3D4237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kelly M.  DeMars</span>, <span class="hlFld-ContribAuthor ">Sean C.  Pacheco</span>, <span class="hlFld-ContribAuthor ">Changjun  Yang</span>, <span class="hlFld-ContribAuthor ">David M.  Siwarski</span>, <span class="hlFld-ContribAuthor ">Eduardo  Candelario-Jalil</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neurology</span><span> <strong>2017,</strong> <em>8 </em><a href="https://doi.org/10.3389/fneur.2017.00363" title="DOI URL">https://doi.org/10.3389/fneur.2017.00363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fneur.2017.00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffneur.2017.00363%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neurology%26atitle%3DSelective%252BInhibition%252Bof%252BJanus%252BKinase%252B3%252BHas%252BNo%252BImpact%252Bon%252BInfarct%252BSize%252Bor%252BNeurobehavioral%252BOutcomes%252Bin%252BPermanent%252BIschemic%252BStroke%252Bin%252BMice%26aulast%3DDeMars%26aufirst%3DKelly%2BM.%26date%3D2017%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katharina  Welsch</span>, <span class="hlFld-ContribAuthor ">Julia  Holstein</span>, <span class="hlFld-ContribAuthor ">Arian  Laurence</span>, <span class="hlFld-ContribAuthor ">Kamran  Ghoreschi</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Immunology</span><span> <strong>2017,</strong> <em>47 </em>
                                    (7)
                                     , 1096-1107. <a href="https://doi.org/10.1002/eji.201646680" title="DOI URL">https://doi.org/10.1002/eji.201646680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/eji.201646680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Feji.201646680%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Immunology%26atitle%3DTargeting%252BJAK%25252FSTAT%252Bsignalling%252Bin%252Binflammatory%252Bskin%252Bdiseases%252Bwith%252Bsmall%252Bmolecule%252Binhibitors%26aulast%3DWelsch%26aufirst%3DKatharina%26date%3D2017%26date%3D2017%26volume%3D47%26issue%3D7%26spage%3D1096%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  Damsky</span>, <span class="hlFld-ContribAuthor ">Brett A.  King</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors in dermatology: The promise of a new drug class. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Academy of Dermatology</span><span> <strong>2017,</strong> <em>76 </em>
                                    (4)
                                     , 736-744. <a href="https://doi.org/10.1016/j.jaad.2016.12.005" title="DOI URL">https://doi.org/10.1016/j.jaad.2016.12.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaad.2016.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaad.2016.12.005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Academy%2520of%2520Dermatology%26atitle%3DJAK%252Binhibitors%252Bin%252Bdermatology%25253A%252BThe%252Bpromise%252Bof%252Ba%252Bnew%252Bdrug%252Bclass%26aulast%3DDamsky%26aufirst%3DWilliam%26date%3D2017%26volume%3D76%26issue%3D4%26spage%3D736%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jason G.  Kettle</span>, <span class="hlFld-ContribAuthor ">Annika  Åstrand</span>, <span class="hlFld-ContribAuthor ">Matthew  Catley</span>, <span class="hlFld-ContribAuthor ">Neil P.  Grimster</span>, <span class="hlFld-ContribAuthor ">Magnus  Nilsson</span>, <span class="hlFld-ContribAuthor ">Qibin  Su</span>, <span class="hlFld-ContribAuthor ">Richard  Woessner</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (2)
                                     , 145-161. <a href="https://doi.org/10.1080/13543776.2017.1252754" title="DOI URL">https://doi.org/10.1080/13543776.2017.1252754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1252754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1252754%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DInhibitors%252Bof%252BJAK-family%252Bkinases%25253A%252Ban%252Bupdate%252Bon%252Bthe%252Bpatent%252Bliterature%252B2013-2015%25252C%252Bpart%252B2%26aulast%3DKettle%26aufirst%3DJason%2BG.%26date%3D2017%26date%3D2016%26volume%3D27%26issue%3D2%26spage%3D145%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Pan  Chen</span>, <span class="hlFld-ContribAuthor ">Li  Gui</span>, <span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Fei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (1)
                                     , 75-83. <a href="https://doi.org/10.1016/j.bmc.2016.10.011" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.10.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.10.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B4-%2525282-furanyl%252529pyrimidin-2-amines%252Bas%252BJanus%252Bkinase%252B2%252Binhibitors%26aulast%3DWang%26aufirst%3DYazhou%26date%3D2017%26volume%3D25%26issue%3D1%26spage%3D75%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2016,</strong> <em>111 </em>, 784-803. <a href="https://doi.org/10.1016/j.phrs.2016.07.038" title="DOI URL">https://doi.org/10.1016/j.phrs.2016.07.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DJanus%252Bkinase%252B%252528JAK%252529%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Binflammatory%252Band%252Bneoplastic%252Bdiseases%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaojiao  Xu</span>, <span class="hlFld-ContribAuthor ">Jin  Cai</span>, <span class="hlFld-ContribAuthor ">Junqing  Chen</span>, <span class="hlFld-ContribAuthor ">Xi  Zong</span>, <span class="hlFld-ContribAuthor ">Xuan  Wu</span>, <span class="hlFld-ContribAuthor ">Min  Ji</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">An Efficient Synthesis of Baricitinib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2016,</strong> <em>40 </em>
                                    (4)
                                     , 205-208. <a href="https://doi.org/10.3184/174751916X14569294811333" title="DOI URL">https://doi.org/10.3184/174751916X14569294811333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3184/174751916X14569294811333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3184%2F174751916X14569294811333%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DAn%252BEfficient%252BSynthesis%252Bof%252BBaricitinib%26aulast%3DXu%26aufirst%3DJiaojiao%26date%3D2016%26date%3D2016%26volume%3D40%26issue%3D4%26spage%3D205%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samra  Sardar</span>, <span class="hlFld-ContribAuthor ">Åsa  Andersson</span>. </span><span class="cited-content_cbyCitation_article-title">Old and new therapeutics for Rheumatoid Arthritis:
              in vivo
              models and drug development. </span><span class="cited-content_cbyCitation_journal-name">Immunopharmacology and Immunotoxicology</span><span> <strong>2016,</strong> <em>38 </em>
                                    (1)
                                     , 2-13. <a href="https://doi.org/10.3109/08923973.2015.1125917" title="DOI URL">https://doi.org/10.3109/08923973.2015.1125917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/08923973.2015.1125917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F08923973.2015.1125917%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunopharmacology%2520and%2520Immunotoxicology%26atitle%3DOld%252Band%252Bnew%252Btherapeutics%252Bfor%252BRheumatoid%252BArthritis%25253A%252Bin%252Bvivo%252Bmodels%252Band%252Bdrug%252Bdevelopment%26aulast%3DSardar%26aufirst%3DSamra%26date%3D2016%26date%3D2016%26volume%3D38%26issue%3D1%26spage%3D2%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">Daniella M.  Schwartz</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>. </span><span class="cited-content_cbyCitation_article-title">Editorial: Decernotinib: A Next-Generation Jakinib. </span><span class="cited-content_cbyCitation_journal-name">Arthritis & Rheumatology</span><span> <strong>2016,</strong> <em>68 </em>
                                    (1)
                                     , 31-34. <a href="https://doi.org/10.1002/art.39463" title="DOI URL">https://doi.org/10.1002/art.39463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/art.39463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fart.39463%26sid%3Dliteratum%253Aachs%26jtitle%3DArthritis%2520%2526%2520Rheumatology%26atitle%3DEditorial%25253A%252BDecernotinib%25253A%252BA%252BNext-Generation%252BJakinib%26aulast%3DGadina%26aufirst%3DMassimo%26date%3D2016%26date%3D2015%26volume%3D68%26issue%3D1%26spage%3D31%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. Alison  Rinderspacher</span>. </span><span class="cited-content_cbyCitation_article-title">Six-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 439-492. <a href="https://doi.org/10.1016/B978-0-08-100755-6.00013-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-100755-6.00013-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-100755-6.00013-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-100755-6.00013-2%26sid%3Dliteratum%253Aachs%26atitle%3DSix-Membered%252BRing%252BSystems%26aulast%3DRinderspacher%26aufirst%3DK.%2BAlison%26date%3D2016%26spage%3D439%26epage%3D492%26pub%3DElsevier%26date%3D2016%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0014.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. JAK-STAT signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0015.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selected clinically approved or experimental JAK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0016.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>1</b> and <b>2</b> overlaid in the JAK2 structure. Superposition created by overlaying the hinge regions of the ERK2 and JAK2 crystal structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0017.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure co-complex of <b>22</b> in JAK2. Hinge hydrogen bonds to Leu 932 highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0018.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of <b>44</b> in JAK2. Hinge hydrogen bonds to Leu 932 and Glu 930 highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structure of VX-509 in JAK2. Hinge hydrogen bonds to Leu 932 highlighted in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose-dependent inhibition of popletial lymph node (PLN) hyperplasia by VX-509 in the rat HvG model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose-dependent decrease in ex vivo stimulated biomarker CD25 by VX-509 in the rat HvG model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) NaH, TsCl, THF; (b) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (c) bis(pinacolato)diboron, Pd(PPh<sub>3</sub>)<sub>4</sub>, KOAc, 1,4-dioxane.</p></p></figure><figure data-id="sch2a" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0005.jpeg" id="rightTab-GRAPHIC-d4011e3113-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=sch2a"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions for part a: (a) PhCH<sub>2</sub>NH<sub>2</sub>, DIPEA, THF, reflux, 1–2 h or IPA, 90 °, (54–79%); (b) PhCH<sub>2</sub>NH<sub>2</sub>, neat (79%); (c) PhCH<sub>2</sub>NH<sub>2</sub>, 150 °C (microwave) (40–55%); (d) (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, reflux; (ii) NaO<i>t</i>Bu, 130–160 °C, 10–20 min (microwave) (25–89%). Conditions for part b: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, reflux (51%; X = CCl); (b) Oxone, CH<sub>3</sub>OH–H<sub>2</sub>O (1:1) (32%; X = CCl); (c) (i) PhCH<sub>2</sub>NH<sub>2</sub>, EtOH, reflux, 16 h (94%; X = CCl); (ii) 3 N NaOH, CH<sub>3</sub>OH (75%; X = CCl) or NaO<i>t</i>Bu, 130–160 °C, 10–20 min (microwave).</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/medium/jm-2015-00301k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-18/acs.jmedchem.5b00301/20150918/images/large/jm-2015-00301k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00301&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) HATU or EDC, HOBt, DIEA, DMF, CF<sub>3</sub>CH<sub>2</sub>NH<sub>2</sub>–HCl, rt (60–92%); (b) 1:1 TFA–CH<sub>2</sub>Cl<sub>2</sub> or 2 M HCl, Et<sub>2</sub>O–CH<sub>3</sub>OH (quantitative); (c) DIEA, IPA or THF (29–80%); (d) (i) <b>50a</b>–<b>e</b>, 2 M Na<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DME, 150 °C, 10 min (microwave) or reflux; 16 h; (ii) LiOH, THF, H<sub>2</sub>O, rt or CH<sub>3</sub>OH, 25% NaOCH<sub>3</sub> in CH<sub>3</sub>OH, 60 °C, 1 h (30–65%, two steps).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Darnell, J. E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1421</span><span class="refDoi"> DOI: 10.1126/science.8197455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+J.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins&doi=10.1126%2Fscience.8197455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon α (IFN-α) and interferon γ (IFN-γ), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-α and IFN-γ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0ljRk4wfjBDCOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421%26doi%3D10.1126%2Fscience.8197455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0ljRk4wfjBDCOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (γc), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit γc.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both γc and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0ljnqQtc5MwyAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Oakes, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennighausen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaese, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.1016/S1074-7613(00)80274-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2FS1074-7613%2800%2980274-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1996&pages=605-615&author=S.+A.+Oakesauthor=F.+Candottiauthor=J.+A.+Johnstonauthor=Y.+Q.+Chenauthor=J.+J.+Ryanauthor=N.+Taylorauthor=X.+Liuauthor=L.+Hennighausenauthor=L.+D.+Notarangeloauthor=W.+E.+Paulauthor=R.+M.+Blaeseauthor=J.+J.+O%27Shea&title=Signaling+via+IL-2+and+IL-4+in+JAK3-deficient+severe+combined+immunodeficiency+lymphocytes%3A+JAK3-dependent+and+independent+pathways&doi=10.1016%2FS1074-7613%2800%2980274-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980274-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980274-5%26sid%3Dliteratum%253Aachs%26aulast%3DOakes%26aufirst%3DS.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DRyan%26aufirst%3DJ.%2BJ.%26aulast%3DTaylor%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHennighausen%26aufirst%3DL.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DPaul%26aufirst%3DW.%2BE.%26aulast%3DBlaese%26aufirst%3DR.%2BM.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520via%2520IL-2%2520and%2520IL-4%2520in%2520JAK3-deficient%2520severe%2520combined%2520immunodeficiency%2520lymphocytes%253A%2520JAK3-dependent%2520and%2520independent%2520pathways%26jtitle%3DImmunity%26date%3D1996%26volume%3D5%26spage%3D605%26epage%3D615%26doi%3D10.1016%2FS1074-7613%2800%2980274-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">6910</span><span class="NLM_x">–</span> <span class="NLM_lpage">6915</span><span class="refDoi"> DOI: 10.1073/pnas.94.13.6910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1073%2Fpnas.94.13.6910" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=6910-6915&author=M.+Chenauthor=A.+Chengauthor=Y.+Q.+Chenauthor=A.+Hymelauthor=E.+P.+Hansonauthor=L.+Kimmelauthor=Y.+Minamiauthor=T.+Taniguchiauthor=P.+S.+Changelianauthor=J.+J.+O%27Shea&title=The+amino+terminus+of+JAK3+is+necessary+and+sufficient+for+binding+to+the+common+gamma+chain+and+confers+the+ability+to+transmit+interleukin+2-mediated+signals&doi=10.1073%2Fpnas.94.13.6910"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.13.6910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.13.6910%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DHymel%26aufirst%3DA.%26aulast%3DHanson%26aufirst%3DE.%2BP.%26aulast%3DKimmel%26aufirst%3DL.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520amino%2520terminus%2520of%2520JAK3%2520is%2520necessary%2520and%2520sufficient%2520for%2520binding%2520to%2520the%2520common%2520gamma%2520chain%2520and%2520confers%2520the%2520ability%2520to%2520transmit%2520interleukin%25202-mediated%2520signals%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D6910%26epage%3D6915%26doi%3D10.1073%2Fpnas.94.13.6910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">506</span><span class="refDoi"> DOI: 10.1097/00130832-200212000-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14752332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.+J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%27Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis&doi=10.1097%2F00130832-200212000-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2ebv9CM96DESALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26spage%3D495%26epage%3D506%26doi%3D10.1097%2F00130832-200212000-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Rochman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spolski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">New insights into the regulation of T cells by γc family cytokines</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1038/nri2580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fnri2580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19543225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=480-490&author=Y.+Rochmanauthor=R.+Spolskiauthor=W.+J.+Leonard&title=New+insights+into+the+regulation+of+T+cells+by+%CE%B3c+family+cytokines&doi=10.1038%2Fnri2580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the regulation of T cells by γc family cytokines</span></div><div class="casAuthors">Rochman, Yrina; Spolski, Rosanne; Leonard, Warren J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">480-490</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Common cytokine receptor γ-chain (γc) family cytokines have crucial roles in the development, proliferation, survival and differentiation of multiple cell lineages of both the innate and adaptive immune systems.  In this Review, the authors focus on the current understanding of the distinct and overlapping effects of interleukin-2 (IL-2), IL-7, IL-9, IL-15 and IL-21, as well as the IL-7-related cytokine thymic stromal lymphopoietin (TSLP), on the survival and proliferation of conventional αβ T cells, γδ T cells and regulatory T cells.  This knowledge potentially allows for the therapeutic manipulation of immune responses for the treatment of cancer, autoimmunity, allergic diseases and immunodeficiency, as well as for vaccine development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GBlSyD8_NLVg90H21EOLACvtfcHk0lhINHoq7rld3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D&md5=a6c7285b05193002b89be7233d11f271</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnri2580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2580%26sid%3Dliteratum%253Aachs%26aulast%3DRochman%26aufirst%3DY.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DNew%2520insights%2520into%2520the%2520regulation%2520of%2520T%2520cells%2520by%2520%25CE%25B3c%2520family%2520cytokines%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D480%26epage%3D490%26doi%3D10.1038%2Fnri2580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Macchi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frattini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugazio, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1038/377065a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%27Sheaauthor=P.+Vezzoniauthor=L.+D.+Notarangelo&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29&doi=10.1038%2F377065a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common γ-chain (γc), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the γc-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100→Cys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0lhINHoq7rld3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26aulast%3DVezzoni%26aufirst%3DP.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68%26doi%3D10.1038%2F377065a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span><span class="refDoi"> DOI: 10.1016/0092-8674(93)90167-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2F0092-8674%2893%2990167-O" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans&doi=10.1016%2F0092-8674%2893%2990167-O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990167-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990167-O%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157%26doi%3D10.1016%2F0092-8674%2893%2990167-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1126/science.270.5237.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1126%2Fscience.270.5237.797" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%27Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development&doi=10.1126%2Fscience.270.5237.797"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.797%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D797%26epage%3D800%26doi%3D10.1126%2Fscience.270.5237.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">203</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.0105-2896.2005.00220.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1111%2Fj.0105-2896.2005.00220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=15661026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2005&pages=127-142&author=M.+Pesuauthor=F.+Candottiauthor=M.+Husaauthor=S.+R.+Hofmannauthor=L.+D.+Notarangeloauthor=J.+J.+O%27Shea&title=Jak3%2C+severe+combined+immunodeficiency%2C+and+a+new+class+of+immunosuppressive+drugs&doi=10.1111%2Fj.0105-2896.2005.00220.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</span></div><div class="casAuthors">Pesu, Marko; Candotti, Fabio; Husa, Matthew; Hofmann, Sigrun R.; Notarangelo, Luigi D.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The recent elucidation of the multiple mol. mechanisms underlying severe combined immunodeficiency (SCID) is an impressive example of the power of mol. medicine.  Anal. of patients and the concomitant generation of animal models mimicking these disorders have quickly provided great insights into the pathophysiol. of these potentially devastating illnesses.  Here, the authors summarize the discoveries that led to the understanding of the role of cytokine receptors and a specific tyrosine kinase, Janus kinase 3 (Jak3), in the pathogenesis of SCID.  The authors discuss how the identification of mutations of Jak3 in autosomal recessive SCID has facilitated the diagnosis of these disorders, offered new insights into the biol. of this kinase, permitted new avenues for therapy, and provided the rationale for a generation of a new class of immunosuppressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYir7OTbMwFbVg90H21EOLACvtfcHk0lj5ge1kx4e2vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFyns7o%253D&md5=038b25b97798eda4b6aa1818238e45ba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.0105-2896.2005.00220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0105-2896.2005.00220.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DHusa%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJak3%252C%2520severe%2520combined%2520immunodeficiency%252C%2520and%2520a%2520new%2520class%2520of%2520immunosuppressive%2520drugs%26jtitle%3DImmunol.%2520Rev.%26date%3D2005%26volume%3D203%26spage%3D127%26epage%3D142%26doi%3D10.1111%2Fj.0105-2896.2005.00220.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1126/science.1087061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor&doi=10.1126%2Fscience.1087061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lj5ge1kx4e2vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878%26doi%3D10.1126%2Fscience.1087061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1905</span><span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lgKnVom_bsnUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span><span class="refDoi"> DOI: 10.1038/ni.1701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%27Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+to+be+or+not+to+be%3F&doi=10.1038%2Fni.1701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0lgKnVom_bsnUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520to%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360%26doi%3D10.1038%2Fni.1701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Cox, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span> </span><span class="NLM_article-title">JAK3 specific kinase inhibitors: when specificity is not enough</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2011.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.chembiol.2011.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=21439469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=277-278&author=L.+Coxauthor=J.+Cools&title=JAK3+specific+kinase+inhibitors%3A+when+specificity+is+not+enough&doi=10.1016%2Fj.chembiol.2011.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">JAK3 Specific Kinase Inhibitors: When Specificity is not Enough</span></div><div class="casAuthors">Cox, Luk; Cools, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-278</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Janus kinases are important signaling proteins implicated in cytokine signaling.  In particular, Janus kinase 3 (JAK3) has gained attention as a target for inhibition of the immune system, due to its importance for T and B cell development and function.  In this issue however, show that inhibition of JAK3 activity may not be sufficient for this purpose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl5zExXf_b4rVg90H21EOLACvtfcHk0lgKnVom_bsnUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsbs%253D&md5=eeb745f4a8c713f7bd09662346e6d2e4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DL.%26aulast%3DCools%26aufirst%3DJ.%26atitle%3DJAK3%2520specific%2520kinase%2520inhibitors%253A%2520when%2520specificity%2520is%2520not%2520enough%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D277%26epage%3D278%26doi%3D10.1016%2Fj.chembiol.2011.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.l</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Phase IIb dose-ranging study of the oral JAK inhibitor Tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1002/art.33383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.33383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=21952978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=617-629&author=R.+Fleischmannauthor=M.+Cutoloauthor=M.+C.+Genoveseauthor=E.+B.+Leeauthor=K.+S.+Kanikauthor=S.+Sadisauthor=C.+A.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+E.l+Wilkinsonauthor=S.+H.+Zwillich&title=Phase+IIb+dose-ranging+study+of+the+oral+JAK+inhibitor+Tofacitinib+%28CP-690%2C550%29+or+adalimumab+monotherapy+versus+placebo+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+disease-modifying+antirheumatic+drugs&doi=10.1002%2Fart.33383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span></div><div class="casAuthors">Fleischmann, Roy; Cutolo, Maurizio; Genovese, Mark C.; Lee, Eun Bong; Kanik, Keith S.; Sadis, Seth; Connell, Carol A.; Gruben, David; Krishnaswami, Sriram; Wallenstein, Gene; Wilkinson, Bethanie E.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">617-629</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.  Methods : In this 24-wk, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected s.c. every 2 wk (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 wk.  The primary end point was the responder rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) at week 12.  Results : Treatment with tofacitinib at a dose of ≥3 mg twice a day resulted in a rapid response with significant efficacy when compared to placebo, as indicated by the primary end point (ACR20 response at week 12), achieved in 39.2% (3 mg; P ≤ 0.05), 59.2% (5 mg; P < 0.0001), 70.5% (10 mg; P < 0.0001), and 71.9% (15 mg; P < 0.0001) in the tofacitinib group and 35.9% of patients in the adalimumab group (P = 0.105), compared with 22.0% of patients receiving placebo.  Improvements were sustained at week 24, according to the ACR20, ACR50, and ACR70 response rates as well as classifications of remission according to the 3-variable Disease Activity Score in 28 joints (DAS28) using C-reactive protein and the 4-variable DAS28 using the erythrocyte sedimentation rate.  The most common treatment-emergent adverse events (AEs) in patients across all tofacitinib treatment arms (n = 272) were urinary tract infection (7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).  Conclusion : Tofacitinib monotherapy at ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 wk and demonstrated a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuu7Uf_SwBXbVg90H21EOLACvtfcHk0liuRvipNOHVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D&md5=99d7be4fd115ffa87410dcbd6c6ea860</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fart.33383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33383%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.l%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DPhase%2520IIb%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520Tofacitinib%2520%2528CP-690%252C550%2529%2520or%2520adalimumab%2520monotherapy%2520versus%2520placebo%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520disease-modifying%2520antirheumatic%2520drugs%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D617%26epage%3D629%26doi%3D10.1002%2Fart.33383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuninger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H.-G.</span><span> </span><span class="NLM_article-title">Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1021/jm101157q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101157q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=284-288&author=G.+Thomaauthor=F.+Nuningerauthor=R.+Falchettoauthor=E.+Hermesauthor=G.+A.+Tavaresauthor=E.+Vangrevelingheauthor=H.-G.+Zerwes&title=Identification+of+a+potent+Janus+kinase+3+inhibitor+with+high+selectivity+within+the+Janus+kinase+family&doi=10.1021%2Fjm101157q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm101157q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101157q%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DNuninger%26aufirst%3DF.%26aulast%3DFalchetto%26aufirst%3DR.%26aulast%3DHermes%26aufirst%3DE.%26aulast%3DTavares%26aufirst%3DG.%2BA.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DZerwes%26aufirst%3DH.-G.%26atitle%3DIdentification%2520of%2520a%2520potent%2520Janus%2520kinase%25203%2520inhibitor%2520with%2520high%2520selectivity%2520within%2520the%2520Janus%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D284%26epage%3D288%26doi%3D10.1021%2Fjm101157q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Lin, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadros, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimble, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewet, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krykbaev, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidl, K. J.</span><span> </span><span class="NLM_article-title">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2283</span><span class="NLM_x">–</span> <span class="NLM_lpage">2293</span><span class="refDoi"> DOI: 10.1002/art.27536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.27536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=20506481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=2283-2293&author=T.+H.+Linauthor=M.+Hegenauthor=E.+Quadrosauthor=C.+L.+Nickerson-Nutterauthor=K.+C.+Appellauthor=A.+G.+Coleauthor=Y.+Shaoauthor=S.+Tamauthor=M.+Ohlmeyerauthor=B.+Wangauthor=D.+G.+Goodwinauthor=E.+F.+Kimbleauthor=J.+Quinteroauthor=M.+Gaoauthor=P.+Symanowiczauthor=C.+Wrocklageauthor=J.+Lussierauthor=S.+H.+Schellingauthor=A.+G.+Hewetauthor=D.+Xuanauthor=R.+Krykbaevauthor=J.+Togiasauthor=X.+Xuauthor=R.+Harrisonauthor=T.+Mansourauthor=M.+Collinsauthor=J.+D.+Clarkauthor=M.+L.+Webbauthor=K.+J.+Seidl&title=Selective+functional+inhibition+of+JAK-3+is+sufficient+for+efficacy+in+collagen-induced+arthritis+in+mice&doi=10.1002%2Fart.27536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span></div><div class="casAuthors">Lin, Tsung H.; Hegen, Martin; Quadros, Elizabeth; Nickerson-Nutter, Cheryl L.; Appell, Kenneth C.; Cole, Andrew G.; Shao, Yuefei; Tam, Steve; Ohlmeyer, Michael; Wang, Bojing; Goodwin, Debra G.; Kimble, Earl F.; Quintero, Jorge; Gao, Min; Symanowicz, Peter; Wrocklage, Christopher; Lussier, Jennifer; Schelling, Scott H.; Hewet, Amha G.; Xuan, Dejun; Krykbaev, Rustem; Togias, Jenny; Xu, Xin; Harrison, Richard; Mansour, Tarek; Collins, Mary; Clark, James D.; Webb, Maria L.; Seidi, Katherine J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2283-2293</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. All γ-chain cytokines signal through JAK-3 and JAK-1 acting in tandem.  We undertook this study to det. whether the JAK-3 selective inhibitor WYE-151650 would be sufficient to disrupt cytokine signaling and to ameliorate autoimmune disease pathol. without inhibiting other pathways mediated by JAK-1, JAK-2, and Tyk-2.  Methods. JAK-3 kinase selective compds. were characterized by kinase assay and JAK-3-dependent (interleukin-2 [IL-2]) and -independent (IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF]) cell-based assays measuring proliferation or STAT phosphorylation.  In vivo, off-target signaling was measured by IL-22- and erythropoietin (EPO)-mediated models, while on-target signaling was measured by IL-2-mediated signaling.  Efficacy of JAK-3 inhibitors was detd. using delayed-type hypersensitivity (DTH) and collagen-induced arthritis (CIA) models in mice.  Results. In vitro, WYE-151650 potently suppressed IL-2-induced STAT-5 phosphorylation and cell proliferation, while exhibiting 10-29-fold less activity against JAK-3-independent IL-6- or GM-CSF-induced STAT phosphorylation.  Ex vivo, WYE-151650 suppressed IL-2-induced STAT phosphorylation, but not IL-6-induced STAT phosphorylation, as measured in whole blood.  In vivo, WYE-151650 inhibited JAK-3-mediated IL-2-induced interferon-γ prodn. and decreased the natural killer cell population in mice, while not affecting IL-22-induced serum amyloid A prodn. or EPO-induced reticulocytosis.  WYE-151650 was efficacious in mouse DTH and CIA models.  Conclusion. In vitro, ex vivo, and in vivo assays demonstrate that WYE-151650 is efficacious in mouse CIA despite JAK-3 selectivity.  These data question the need to broadly inhibit JAK-1-, JAK-2-, or Tyk-2-dependent cytokine pathways for efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogcss6tt3iw7Vg90H21EOLACvtfcHk0liuRvipNOHVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP&md5=7fd4f4dae47df1d1a33d3fc0edf5e13d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fart.27536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27536%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DQuadros%26aufirst%3DE.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DOhlmeyer%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGoodwin%26aufirst%3DD.%2BG.%26aulast%3DKimble%26aufirst%3DE.%2BF.%26aulast%3DQuintero%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DSchelling%26aufirst%3DS.%2BH.%26aulast%3DHewet%26aufirst%3DA.%2BG.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DKrykbaev%26aufirst%3DR.%26aulast%3DTogias%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DMansour%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DSeidl%26aufirst%3DK.%2BJ.%26atitle%3DSelective%2520functional%2520inhibition%2520of%2520JAK-3%2520is%2520sufficient%2520for%2520efficacy%2520in%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D2283%26epage%3D2293%26doi%3D10.1002%2Fart.27536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frauchiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hekmat-Nejad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendricks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henningsen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgenkamp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaime-Figueroa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahangir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutach, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span> </span><span class="NLM_article-title">3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1021/jm301646k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301646k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSqtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=345-356&author=M.+Sothauthor=J.+C.+Hermannauthor=C.+Yeeauthor=M.+Alamauthor=J.+W.+Barnettauthor=P.+Berryauthor=M.+F.+Brownerauthor=K.+Frankauthor=S.+Frauchigerauthor=S.+Harrisauthor=Y.+Heauthor=M.+Hekmat-Nejadauthor=T.+Hendricksauthor=R.+Henningsenauthor=R.+Hilgenkampauthor=H.+Hoauthor=A.+Hoffmanauthor=P.+Y.+Hsuauthor=D.+Q.+Huauthor=A.+Itanoauthor=S.+Jaime-Figueroaauthor=A.+Jahangirauthor=S.+Jinauthor=A.+Kuglstatterauthor=A.+K.+Kutachauthor=C.+Liaoauthor=S.+Lynchauthor=J.+Menkeauthor=L.+Niuauthor=V.+Patelauthor=A.+Railkarauthor=D.+Royauthor=A.+Shaoauthor=D.+Shawauthor=S.+Steinerauthor=Y.+Sunauthor=S.+L.+Tanauthor=S.+Wangauthor=M.+D.+Vu&title=3-Amido+Pyrrolopyrazine+JAK+Kinase+Inhibitors%3A+Development+of+a+JAK3+vs+JAK1+Selective+Inhibitor+and+Evaluation+in+Cellular+and+in+Vivo+Models&doi=10.1021%2Fjm301646k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models</span></div><div class="casAuthors">Soth, Michael; Hermann, Johannes C.; Yee, Calvin; Alam, Muzaffar; Barnett, Jim W.; Berry, Pamela; Browner, Michelle F.; Frank, Karl; Frauchiger, Sandra; Harris, Seth; He, Yang; Hekmat-Nejad, Mohammad; Hendricks, Than; Henningsen, Robert; Hilgenkamp, Ramona; Ho, Hoangdung; Hoffman, Ann; Hsu, Pei-Yuan; Hu, Dong-Qing; Itano, Andrea; Jaime-Figueroa, Saul; Jahangir, Alam; Jin, Sue; Kuglstatter, Andreas; Kutach, Alan K.; Liao, Cheng; Lynch, Stephen; Menke, John; Niu, Linghao; Patel, Vaishali; Railkar, Aruna; Roy, Douglas; Shao, Ada; Shaw, David; Steiner, Sandra; Sun, Yongliang; Tan, Seng-Lai; Wang, Sandra; Vu, Minh Diem</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression.  We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 vs. JAK1, and good biopharmaceutical properties.  Evaluation of this analog in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd-C6Aby3wN7Vg90H21EOLACvtfcHk0lgDnd2stJ_Ijg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSqtrrP&md5=026b7d9b52cb5e374617ac2e5863eda4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm301646k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301646k%26sid%3Dliteratum%253Aachs%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DYee%26aufirst%3DC.%26aulast%3DAlam%26aufirst%3DM.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBerry%26aufirst%3DP.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DHendricks%26aufirst%3DT.%26aulast%3DHenningsen%26aufirst%3DR.%26aulast%3DHilgenkamp%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DA.%26aulast%3DHsu%26aufirst%3DP.%2BY.%26aulast%3DHu%26aufirst%3DD.%2BQ.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DJahangir%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKutach%26aufirst%3DA.%2BK.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DS.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DVu%26aufirst%3DM.%2BD.%26atitle%3D3-Amido%2520Pyrrolopyrazine%2520JAK%2520Kinase%2520Inhibitors%253A%2520Development%2520of%2520a%2520JAK3%2520vs%2520JAK1%2520Selective%2520Inhibitor%2520and%2520Evaluation%2520in%2520Cellular%2520and%2520in%2520Vivo%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D345%26epage%3D356%26doi%3D10.1021%2Fjm301646k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><div class="note"><p class="first last">and references therein.</p></div><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lgDnd2stJ_Ijg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00644.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%27Shea&title=Therapeutic+targeting+of+Janus+kinases&doi=10.1111%2Fj.1600-065X.2008.00644.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0ljr8wFexnk1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142%26doi%3D10.1111%2Fj.1600-065X.2008.00644.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kontzias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span><span class="refDoi"> DOI: 10.1016/j.coph.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%27Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease&doi=10.1016%2Fj.coph.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0ljr8wFexnk1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470%26doi%3D10.1016%2Fj.coph.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span><span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0ljr8wFexnk1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span> <span class="citation_source-journal">IDrugs: Invest. Drugs J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=20506062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=394-403&author=R.+A.+Mesa&title=Ruxolitinib%2C+a+selective+JAK1+and+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+neoplasms+and+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span></div><div class="casAuthors">Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.  Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs).  Meaningful redns. in spleen size and constitutional symptoms have been noted in patients with myelofibrosis (both primary and post-essential thrombocythemia/polycythemia vera).  Data from a phase I/II clin. trial led to ongoing registration trials in the US and Europe.  Toxicity (primarily decreased erythropoiesis and thrombocytopoiesis) has been managed by close control of dosing.  The inhibition of inflammatory cytokine signaling through JAK1 inhibition has led to intriguing results in patients with rheumatoid arthritis and psoriasis (using a topical cream formulation).  Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yUMfeRYwE7Vg90H21EOLACvtfcHk0ljsdeT-tjAlYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D&md5=9f89b13c71527c112b797375c93ccbff</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DRuxolitinib%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520and%2520psoriasis%26jtitle%3DIDrugs%253A%2520Invest.%2520Drugs%2520J.%26date%3D2010%26volume%3D13%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Ruxolitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><div class="note"><p class="first last">and references therein.</p></div><span class="refDoi"> DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0ljsdeT-tjAlYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterling, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaich, C. L.</span><span> </span><span class="NLM_article-title">12- and 24-week patient reported outcomes from a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S214</span><span class="NLM_x">–</span> <span class="NLM_lpage">S220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S214-S220&author=J.+S.+Smolenauthor=D.+E.+Schlichtingauthor=K.+L.+Sterlingauthor=E.+Keystoneauthor=P.+Taylorauthor=M.+C.+Genoveseauthor=L.+Johnsonauthor=J.+C.+R.+Rodriguezauthor=C.+H.+Leeauthor=C.+L.+Gaich&title=12-+and+24-week+patient+reported+outcomes+from+a+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease-modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSterling%26aufirst%3DK.%2BL.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DRodriguez%26aufirst%3DJ.%2BC.%2BR.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DGaich%26aufirst%3DC.%2BL.%26atitle%3D12-%2520and%252024-week%2520patient%2520reported%2520outcomes%2520from%2520a%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS214%26epage%3DS220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span> </span><span class="NLM_article-title">24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">S1050</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S1049-S1050&author=M.+C.+Genoveseauthor=E.+Keystoneauthor=P.+Taylorauthor=E.+Drescherauthor=P.-Y.+Berclazauthor=C.+H.+Leeauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=W.+Macias&title=24-week+results+of+a+blinded+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease+modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DBerclaz%26aufirst%3DP.-Y.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DMacias%26aufirst%3DW.%26atitle%3D24-week%2520results%2520of%2520a%2520blinded%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease%2520modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS1049%26epage%3DS1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Van Rompaey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Aar, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Lacroix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smets, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepescheux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandeghinste, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brys, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van't Klooster, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1 for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">3568</span><span class="NLM_x">–</span> <span class="NLM_lpage">3577</span><span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van+Rompaeyauthor=R.+Galienauthor=E.+M.+Van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+Van%27t+Kloosterauthor=J.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DVan%2527t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Fleischmann, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivitz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legedza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinnman, N.</span><span> </span><span class="NLM_article-title">A Randomized Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral JAK-3 Inhibitor, as Monotherapy in Patients With Rheumatoid Arthritis</span> <span class="citation_source-journal">Arthritis Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span><span class="refDoi"> DOI: 10.1002/art.38949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fart.38949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=25385260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=334-343&author=R.+M.+Fleischmannauthor=N.+S.+Damjanovauthor=A.+J.+Kivitzauthor=A.+Legedzaauthor=T.+C.+Hoockauthor=N.+Kinnman&title=A+Randomized+Double-Blind%2C+Placebo-Controlled%2C+Twelve-Week%2C+Dose-Ranging+Study+of+Decernotinib%2C+an+Oral+JAK-3+Inhibitor%2C+as+Monotherapy+in+Patients+With+Rheumatoid+Arthritis&doi=10.1002%2Fart.38949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis</span></div><div class="casAuthors">Fleischmann, Roy M.; Damjanov, Nemanja S.; Kivitz, Alan J.; Legedza, Anna; Hoock, Thomas; Kinnman, Nils</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">334-343</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To assess the efficacy and safety of oral decernotinib (VX-509; Vertex Pharmaceuticals) monotherapy in a 12-wk, randomized, double-blind, placebo-controlled, dose-ranging study of patients with rheumatoid arthritis (RA).  Methods : Two hundred four adults with active RA who had been unsuccessfully treated with ≥1 disease-modifying antirheumatic drug were administered placebo tablets or decernotinib twice a day at dosages of 25 mg, 50 mg, 100 mg, or 150 mg.  Primary measures of efficacy at week 12 were the response rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) and mean change from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP).  Results : At week 12, the ACR20 response rates were 39.0%, 61.0%, 65.0%, and 65.9% in the 25-mg, 50-mg, 100-mg, and 150-mg groups, resp., and were significantly higher in the 50-mg group (P = 0.007) and the 100-mg and 150-mg groups (P = 0.002) as compared to the response rates in the placebo group (29.3%).  The mean change from baseline in DAS28-CRP was greater in the 50-mg, 100-mg, and 150-mg groups as compared to the placebo group (P < 0.001).  Decernotinib treatment resulted in higher ACR50 and ACR70 response rates, more patients with DAS28-CRP scores <2.6, and improvements in the Health Assessment Questionnaire disability index as compared to placebo.  The most common adverse events in any decernotinib group were nausea (6.1%), headache (4.3%), an increase in levels of alanine aminotransferase (4.3%), and hypercholesterolemia (3.7%).  In the groups receiving decernotinib, there was an increased risk of infections and increased liver transaminase levels.  Conclusion : Decernotinib was efficacious in improving clin. signs and symptoms of RA at week 12 at dosages of 50-150 mg twice a day.  Infections and increases in liver transaminase and lipid levels were noted as potential safety signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67TXqyDvsjrVg90H21EOLACvtfcHk0ligj4_Zb8ZHkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2msrk%253D&md5=cd842d92e391f37cf23c8846a74ceb38</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fart.38949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.38949%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%2BM.%26aulast%3DDamjanov%26aufirst%3DN.%2BS.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DLegedza%26aufirst%3DA.%26aulast%3DHoock%26aufirst%3DT.%2BC.%26aulast%3DKinnman%26aufirst%3DN.%26atitle%3DA%2520Randomized%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Twelve-Week%252C%2520Dose-Ranging%2520Study%2520of%2520Decernotinib%252C%2520an%2520Oral%2520JAK-3%2520Inhibitor%252C%2520as%2520Monotherapy%2520in%2520Patients%2520With%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2015%26volume%3D67%26spage%3D334%26epage%3D343%26doi%3D10.1002%2Fart.38949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Genovese, M. C.; Van Vollenhoven, R. F.; Zhang, Y.; Kinnman, N.</span><span> </span><span class="NLM_article-title">VX-509 (Decernotinib), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Methotrexate in Patients with Rheumatoid Arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span> Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Genovese%2C+M.+C.%3B+Van+Vollenhoven%2C+R.+F.%3B+Zhang%2C+Y.%3B+Kinnman%2C+N.+VX-509+%28Decernotinib%29%2C+an+Oral+Selective+Janus+Kinase+3+Inhibitor%2C+in+Combination+with+Methotrexate+in+Patients+with+Rheumatoid+ArthritisArthritis+Rheum.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DVX-509%2520%2528Decernotinib%2529%252C%2520an%2520Oral%2520Selective%2520Janus%2520Kinase%25203%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Methotrexate%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Rheum." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0ligj4_Zb8ZHkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H.-G.</span><span> </span><span class="NLM_article-title">Selective inhibitors of the Janus kinase Jak3-Are they effective?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4617</span><span class="NLM_x">–</span> <span class="NLM_lpage">4621</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.bmcl.2014.08.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4617-4621&author=G.+Thomaauthor=P.+Druckesauthor=H.-G.+Zerwes&title=Selective+inhibitors+of+the+Janus+kinase+Jak3-Are+they+effective%3F&doi=10.1016%2Fj.bmcl.2014.08.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.046%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DDruckes%26aufirst%3DP.%26aulast%3DZerwes%26aufirst%3DH.-G.%26atitle%3DSelective%2520inhibitors%2520of%2520the%2520Janus%2520kinase%2520Jak3-Are%2520they%2520effective%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4617%26epage%3D4621%26doi%3D10.1016%2Fj.bmcl.2014.08.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakhter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T. C.</span><span> </span><span class="NLM_article-title">VX-509 (Decernotinib) is a Potent and Selective Janus Kinase 3 Inhibitor that Attenuates Inflammation in Animal Models of Autoimmune Disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1124/jpet.114.221176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1124%2Fjpet.114.221176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=25762693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFaiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=405-414&author=S.+Mahajanauthor=J.+K.+Hoganauthor=D.+Shlyakhterauthor=L.+Ohauthor=F.+G.+Salituroauthor=L.+Farmerauthor=T.+C.+Hoock&title=VX-509+%28Decernotinib%29+is+a+Potent+and+Selective+Janus+Kinase+3+Inhibitor+that+Attenuates+Inflammation+in+Animal+Models+of+Autoimmune+Disease&doi=10.1124%2Fjpet.114.221176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease</span></div><div class="casAuthors">Mahajan, Sudipta; Hogan, James K.; Shlyakhter, Dina; Oh, Luke; Salituro, Francesco G.; Farmer, Luc; Hoock, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-414</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytokines, growth factors, and other chem. messengers rely on a class of intracellular nonreceptor tyrosine kinases known as Janus kinases (JAKs) to rapidly transduce intracellular signals.  A no. of these cytokines are crit. for lymphocyte development and mediating immune responses.  JAK3 is of particular interest due to its importance in immune function and its expression, which is largely confined to lymphocytes, thus limiting the potential impact of JAK3 inhibition on nonimmune physiol.  The aim of this study was to evaluate the potency and selectivity of the investigational JAK3 inhibitor VX-509 (decernotinib) [(R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide] against JAK3 kinase activity and inhibition of JAK3-mediated signaling in vitro and JAK3-dependent physiol. processes in vivo.  These results demonstrate that VX-509 potently inhibits JAK3 in enzyme assays (Ki = 2.5 nM + 0.7 nM) and cellular assays dependent on JAK3 activity (IC50 range, 50-170 nM), with limited or no measurable potency against other JAK isotypes or non-JAK kinases.  VX-509 also showed activity in two animal models of aberrant immune function.  VX-509 treatment resulted in dose-dependent redn. in ankle swelling and paw wt. and improved paw histopathol. scores in the rat collagen-induced arthritis model.  In a mouse model of oxazolone-induced delayed-type hypersensitivity, VX-509 reduced the T cell-mediated inflammatory response in skin.  These findings demonstrate that VX-509 is a selective and potent inhibitor of JAK3 in vitro and modulates proinflammatory response in models of immune-mediated diseases, such as collagen-induced arthritis and delayed-type hypersensitivity.  The data support evaluation of VX-509 for treatment of patients with autoimmune and inflammatory diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd7OHX-kRf97Vg90H21EOLACvtfcHk0lgJ5VHInjIJkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFaiur4%253D&md5=f4d384e23966e8305537bac4f5ab2918</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221176%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DShlyakhter%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DL.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DFarmer%26aufirst%3DL.%26aulast%3DHoock%26aufirst%3DT.%2BC.%26atitle%3DVX-509%2520%2528Decernotinib%2529%2520is%2520a%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%25203%2520Inhibitor%2520that%2520Attenuates%2520Inflammation%2520in%2520Animal%2520Models%2520of%2520Autoimmune%2520Disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D405%26epage%3D414%26doi%3D10.1124%2Fjpet.114.221176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ledeboer, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messersmith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanthakumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Come, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccola, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zessis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazhanisamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span> </span><span class="NLM_article-title">2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6529</span><span class="NLM_x">–</span> <span class="NLM_lpage">6533</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2Fj.bmcl.2009.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19857967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6529-6533&author=M.+W.+Ledeboerauthor=A.+C.+Pierceauthor=J.+P.+Duffyauthor=H.+Gaoauthor=D.+Messersmithauthor=F.+G.+Salituroauthor=S.+Nanthakumarauthor=J.+Comeauthor=H.+J.+Zuccolaauthor=L.+Swensonauthor=D.+Shlyakterauthor=S.+Mahajanauthor=T.+Hoockauthor=B.+Fanauthor=W.-J.+Tsaiauthor=E.+Kolaczkowskiauthor=S.+Carrierauthor=J.+K.+Hoganauthor=R.+Zessisauthor=S.+Pazhanisamyauthor=Y.+L.+Bennani&title=2-Aminopyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+and+selective+inhibitors+of+JAK2&doi=10.1016%2Fj.bmcl.2009.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2</span></div><div class="casAuthors">Ledeboer, Mark W.; Pierce, Albert C.; Duffy, John P.; Gao, Huai; Messersmith, David; Salituro, Francesco G.; Nanthakumar, Suganthini; Come, Jon; Zuccola, Harmon J.; Swenson, Lora; Shlyakter, Dina; Mahajan, Sudipta; Hoock, Thomas; Fan, Bin; Tsai, Wan-Jung; Kolaczkowski, Elaine; Carrier, Scott; Hogan, James K.; Zessis, Richard; Pazhanisamy, S.; Bennani, Youssef L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6529-6533</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis.  In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2.  Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3c3ghCDfXrVg90H21EOLACvtfcHk0lgJ5VHInjIJkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvF&md5=6f9c11b5214398c0cf6b41569cf5bb99</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DCome%26aufirst%3DJ.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DW.-J.%26aulast%3DKolaczkowski%26aufirst%3DE.%26aulast%3DCarrier%26aufirst%3DS.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DZessis%26aufirst%3DR.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26atitle%3D2-Aminopyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520JAK2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6529%26epage%3D6533%26doi%3D10.1016%2Fj.bmcl.2009.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccola, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jepson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shlyakter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauffenbach, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledeboer, M. W.</span><span> </span><span class="NLM_article-title">Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7938</span><span class="NLM_x">–</span> <span class="NLM_lpage">7941</span><span class="refDoi"> DOI: 10.1021/jm901383u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901383u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7938-7941&author=T.+Wangauthor=J.+P.+Duffyauthor=J.+Wangauthor=S.+Halasauthor=F.+G.+Salituroauthor=A.+C.+Pierceauthor=H.+J.+Zuccolaauthor=J.+R.+Blackauthor=J.+K.+Hoganauthor=S.+Jepsonauthor=D.+Shlyakterauthor=S.+Mahajanauthor=Y.+Guauthor=T.+Hoockauthor=M.+Woodauthor=B.+F.+Fureyauthor=J.+D.+Frantzauthor=L.+M.+Dauffenbachauthor=U.+A.+Germannauthor=B.+Fanauthor=M.+Namchukauthor=Y.+L.+Bennaniauthor=M.+W.+Ledeboer&title=Janus+Kinase+2+Inhibitors.+Synthesis+and+Characterization+of+a+Novel+Polycyclic+Azaindole&doi=10.1021%2Fjm901383u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Fjm901383u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901383u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHalas%26aufirst%3DS.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DZuccola%26aufirst%3DH.%2BJ.%26aulast%3DBlack%26aufirst%3DJ.%2BR.%26aulast%3DHogan%26aufirst%3DJ.%2BK.%26aulast%3DJepson%26aufirst%3DS.%26aulast%3DShlyakter%26aufirst%3DD.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHoock%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DFurey%26aufirst%3DB.%2BF.%26aulast%3DFrantz%26aufirst%3DJ.%2BD.%26aulast%3DDauffenbach%26aufirst%3DL.%2BM.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26atitle%3DJanus%2520Kinase%25202%2520Inhibitors.%2520Synthesis%2520and%2520Characterization%2520of%2520a%2520Novel%2520Polycyclic%2520Azaindole%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7938%26epage%3D7941%26doi%3D10.1021%2Fjm901383u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="note"><p class="first last">The MSR (minimum significant ratio) was determined for each of the enzyme assays: JAK3 (2.5), JAK2 (3.3), AURA (1.3), FLT3 (2.5), SYK (1.5). This number was retrospectively derived from historical data in which the assay had been run at least twice using a data set that included from 14 to >20 individual compounds. A meaningful difference in <i>K</i><sub>i</sub> between compounds is given by the MSR; e.g.. in the JAK2 assay compounds must differ by at least 3.3-fold to be considered to have different potencies.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Pierce, A. C.; Zuccola, H. J.</span>; <span class="NLM_etal"></span> Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pierce%2C+A.+C.%3B+Zuccola%2C+H.+J.%3B+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">For reviews on Jak2 inhibitors in potential treatment of myeloproliferative disorders, see:</p></div><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Atallah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1586/era.09.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1586%2Fera.09.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19445582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVWgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=663-670&author=E.+Atallahauthor=S.+Verstovsek&title=Prospect+of+JAK2+inhibitor+therapy+in+myeloproliferative+neoplasms&doi=10.1586%2Fera.09.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms</span></div><div class="casAuthors">Atallah, Ehab; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-670</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biol. of those disorders.  Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: almost all patients with polycythemia vera harbor the mutation and about 50% of patients with essential thrombocythemia and primary myelofibrosis have the mutation, making the development of JAK2 tyrosine kinase inhibitors an attractive therapeutic goal.  In addn., inhibition of JAK2 kinase may have a therapeutic role in other hematol. malignancies, such as chronic myeloid leukemia or lymphoma.  A no. of mols. that inhibit JAK2 kinase have been described in the literature, and several are being evaluated in a clin. setting.  Here, we summarize current clin. experience with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPRYwnmb4_5LVg90H21EOLACvtfcHk0lhvPsWghDwaxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVWgt70%253D&md5=f8e0dad252de172a3c08286b824784ba</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1586%2Fera.09.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.09.14%26sid%3Dliteratum%253Aachs%26aulast%3DAtallah%26aufirst%3DE.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DProspect%2520of%2520JAK2%2520inhibitor%2520therapy%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D663%26epage%3D670%26doi%3D10.1586%2Fera.09.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pardanani, A.</span><span> </span><span class="NLM_article-title">JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1038/sj.leu.2404948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fsj.leu.2404948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=23-30&author=A.+Pardanani&title=JAK2+inhibitor+therapy+in+myeloproliferative+disorders%3A+rationale%2C+preclinical+studies+and+ongoing+clinical+trials&doi=10.1038%2Fsj.leu.2404948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404948%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26atitle%3DJAK2%2520inhibitor%2520therapy%2520in%2520myeloproliferative%2520disorders%253A%2520rationale%252C%2520preclinical%2520studies%2520and%2520ongoing%2520clinical%2520trials%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D23%26epage%3D30%26doi%3D10.1038%2Fsj.leu.2404948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Skoda, R. C.</span><span> </span><span class="NLM_article-title">Can we control JAK?</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5419</span><span class="NLM_x">–</span> <span class="NLM_lpage">5420</span><span class="refDoi"> DOI: 10.1182/blood-2007-11-123810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1182%2Fblood-2007-11-123810" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=5419-5420&author=R.+C.+Skoda&title=Can+we+control+JAK%3F&doi=10.1182%2Fblood-2007-11-123810"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-11-123810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-11-123810%26sid%3Dliteratum%253Aachs%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DCan%2520we%2520control%2520JAK%253F%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D5419%26epage%3D5420%26doi%3D10.1182%2Fblood-2007-11-123810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Morgan, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">A role for JAK2 mutations in myeloproliferative diseases</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1146/annurev.med.59.061506.154159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1146%2Fannurev.med.59.061506.154159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2008&pages=213-222&author=K.+J.+Morganauthor=D.+G.+Gilliland&title=A+role+for+JAK2+mutations+in+myeloproliferative+diseases&doi=10.1146%2Fannurev.med.59.061506.154159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.59.061506.154159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.59.061506.154159%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DK.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DA%2520role%2520for%2520JAK2%2520mutations%2520in%2520myeloproliferative%2520diseases%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2008%26volume%3D59%26spage%3D213%26epage%3D222%26doi%3D10.1146%2Fannurev.med.59.061506.154159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Sayyah, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span> </span><span class="NLM_article-title">Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1007/s11912-009-0018-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1007%2Fs11912-009-0018-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=19216843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVSlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=117-124&author=J.+Sayyahauthor=P.+P.+Sayeski&title=Jak2+inhibitors%3A+rationale+and+role+as+therapeutic+agents+in+hematologic+malignancies&doi=10.1007%2Fs11912-009-0018-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies</span></div><div class="casAuthors">Sayyah, Jacqueline; Sayeski, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Oncology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">CORUAT</span>;
        ISSN:<span class="NLM_cas:issn">1534-6269</span>.
    
            (<span class="NLM_cas:orgname">Current Medicine Group LLC</span>)
        </div><div class="casAbstract">A review.  Although the Jak2-V617F mutation has generated strong awareness because of its causative role in myeloproliferative disorders, reports of Jak2 gene aberrations linked to hematol. malignancies have preceded those of V617F by nearly a decade.  These malignant mutations include Jak2 amino acid substitutions, deletions, insertions, and chromosomal translocations.  As a consequence, researchers are increasingly focused on identifying Jak2 inhibitors that suppress aberrant Jak2 kinase activity.  Some of these inhibitors may one day become therapeutically beneficial for individuals with Jak2-related hematol. malignancies.  This review summarizes various Jak2 mutations assocd. with hematol. malignancies and assesses some of the Jak2 inhibitors in the preclin. phase or in clin. trials.  By reviewing these specific areas, we hope to have a better understanding of Jak2's role in hematol. malignancies and to shed light on the utility of Jak2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0al6RszSt77Vg90H21EOLACvtfcHk0lhvPsWghDwaxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVSlurk%253D&md5=b6b38c2aa8fb44f8cef6b0738426317a</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1007%2Fs11912-009-0018-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-009-0018-2%26sid%3Dliteratum%253Aachs%26aulast%3DSayyah%26aufirst%3DJ.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26atitle%3DJak2%2520inhibitors%253A%2520rationale%2520and%2520role%2520as%2520therapeutic%2520agents%2520in%2520hematologic%2520malignancies%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2009%26volume%3D11%26spage%3D117%26epage%3D124%26doi%3D10.1007%2Fs11912-009-0018-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">47954</span><span class="NLM_x">–</span> <span class="NLM_lpage">47963</span><span class="refDoi"> DOI: 10.1074/jbc.M205156200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1074%2Fjbc.M205156200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=47954-47963&author=P.+Saharinenauthor=O.+Silvennoinen&title=The+Pseudokinase+Domain+Is+Required+for+Suppression+of+Basal+Activity+of+Jak2+and+Jak3+Tyrosine+Kinases+and+for+Cytokine-inducible+Activation+of+Signal+Transduction&doi=10.1074%2Fjbc.M205156200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M205156200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M205156200%26sid%3Dliteratum%253Aachs%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520Pseudokinase%2520Domain%2520Is%2520Required%2520for%2520Suppression%2520of%2520Basal%2520Activity%2520of%2520Jak2%2520and%2520Jak3%2520Tyrosine%2520Kinases%2520and%2520for%2520Cytokine-inducible%2520Activation%2520of%2520Signal%2520Transduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D47954%26epage%3D47963%26doi%3D10.1074%2Fjbc.M205156200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1128/MCB.20.3.947-956.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1128%2FMCB.20.3.947-956.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10629052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1SntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=947-956&author=M.+Chenauthor=A.+Chengauthor=F.+Candottiauthor=Y.-J.+Zhouauthor=A.+Hymelauthor=A.+Fasthauthor=L.+D.+Notarangeloauthor=J.+J.+O%27Shea&title=Complex+effects+of+naturally+occurring+mutations+in+the+JAK3+pseudokinase+domain%3A+evidence+for+interactions+between+the+kinase+and+pseudokinase+domains&doi=10.1128%2FMCB.20.3.947-956.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains</span></div><div class="casAuthors">Chen, Min; Cheng, Alan; Candotti, Fabio; Zhou, Yong-Jie; Hymel, Anka; Fasth, Anders; Notarangelo, Luigi D.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">947-956</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The structure of Janus kinases (JAKs) is unique among protein tyrosine kinases in having tandem, non-identical kinase and pseudokinase domains.  Despite its conservation in evolution, however, the function of the pseudokinase domain remains poorly understood.  Lack of JAK3 expression results in severe combined immunodeficiency (SCID).  In this study, we analyze two SCID patients with mutations in the JAK3 pseudokinase domain, which allows for protein expression but disrupts the regulation of the kinase activity.  Specifically, these mutant forms of JAK3 had undetectable kinase activity in vitro but were hyperphosphorylated both in patients' Epstein-Barr virus-transformed B cells and when over-expressed in COS7 cells.  Moreover, reconstitution of cells with these mutants demonstrated that, although they were constitutively phosphorylated basally, they were unable to transmit cytokine-dependent signals.  Further anal. showed that the isolated catalytic domain of JAK3 was functional whereas either the addn. of the pseudokinase domain or its deletion from the full-length mol. reduced catalytic activity.  Through co-immunopptn. of the isolated pseudokinase domain with the isolated catalytic domain, we provide the first evidence that these two domains interact.  Furthermore, whereas the wild-type pseudokinase domain modestly inhibited kinase domain-mediated STAT5 phosphorylation, the patient-derived mutants markedly inhibited this phosphorylation.  We thus conclude that the JAK3 pseudokinase domain is essential for JAK3 function by regulating its catalytic activity and autophosphorylation.  We propose a model in which this occurs via intramol. interaction with the kinase domain and that increased inhibition of kinase activity by the pseudokinase domain likely contributes to the disease pathogenesis in these two patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2EGEAjO-ALVg90H21EOLACvtfcHk0lhFL23NpLJeKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1SntA%253D%253D&md5=fc7535a1a1c9812d8ab896add11f1028</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.3.947-956.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.3.947-956.2000%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DHymel%26aufirst%3DA.%26aulast%3DFasth%26aufirst%3DA.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DComplex%2520effects%2520of%2520naturally%2520occurring%2520mutations%2520in%2520the%2520JAK3%2520pseudokinase%2520domain%253A%2520evidence%2520for%2520interactions%2520between%2520the%2520kinase%2520and%2520pseudokinase%2520domains%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D947%26epage%3D956%26doi%3D10.1128%2FMCB.20.3.947-956.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/S1097-2765(03)00505-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain&doi=10.1016%2FS1097-2765%2803%2900505-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lhFL23NpLJeKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178%26doi%3D10.1016%2FS1097-2765%2803%2900505-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajose-Adeogun, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diu-Hercend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golec, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span><span class="refDoi"> DOI: 10.1038/nm1003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1038%2Fnm1003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=14981513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+Aurora+kinases%2C+suppresses+tumor+growth+in+vivo&doi=10.1038%2Fnm1003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span></div><div class="casAuthors">Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis.  Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis.  Here we report the discovery of a highly potent and selective small-mol. inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types.  This compd. causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses.  Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgm1YUgqkWLVg90H21EOLACvtfcHk0lhFL23NpLJeKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D&md5=954ba274e280d8d08a7f2e331011432d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnm1003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1003%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520Aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D262%26epage%3D267%26doi%3D10.1038%2Fnm1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="note"><p class="first last">For full details regarding JAK2 and JAK3 <i>K</i><sub>i</sub> determinations, refer to the <a href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf" class="ext-link">Supporting Information</a> and the following references:</p></div><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazhanisamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galullo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2249</span><span class="NLM_x">–</span> <span class="NLM_lpage">2255</span><span class="refDoi"> DOI: 10.1002/pro.5560071102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1002%2Fpro.5560071102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=9827991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1GrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1998&pages=2249-2255&author=T.+Foxauthor=J.+T.+Collauthor=X.+Xieauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=M.+D.+Porterauthor=S.+Pazhanisamyauthor=M.+A.+Flemingauthor=V.+Galulloauthor=M.-S.+Suauthor=K.+P.+Wilson&title=A+single+amino+acid+substitution+makes+ERK2+susceptible+to+pyridinyl+imidazole+inhibitors+of+p38+MAP+kinase&doi=10.1002%2Fpro.5560071102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase</span></div><div class="casAuthors">Fox, Ted; Coll, Joyce T.; Xie, Xiaoling; Ford, Pamella J.; Germann, Ursula A.; Porter, Margaret D.; Pazhanisamy, S.; Fleming, Mark A.; Galullo, Vincent; Su, Michael S. S.; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2249-2255</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Mitogen-activated protein (MAP) kinases are serine/threonine kinases that mediate intracellular signal transduction pathways.  Pyridinyl imidazole compds. block pro-inflammatory cytokine prodn. and are specific p38 kinase inhibitors.  ERK2 is related to p38 in sequence and structure, but is not inhibited by pyridinyl imidazole inhibitors.  Crystal structures of two pyridinyl imidazoles complexed with p38 revealed these compds. bind in the ATP site.  Mutagenesis data suggested a single residue difference at threonine 106 between p38 and other MAP kinases is sufficient to confer selectivity of pyridinyl imidazoles.  We have changed the equiv. residue in human ERK2, Q105, into threonine and alanine, and substituted four addnl. ATP binding site residues.  The single residue change Q105A in ERK2 enhances the binding of SB202190 at least 25,000-fold compared to wild-type ERK2.  We report enzymic analyses of wild-type ERK2 and the mutant proteins, and the crystal structure of a pyridinyl imidazole, SB203580, bound to an ERK2 pentamutant, I103L, Q105T, D106H, E109G, T110A.  These ATP binding site substitutions induce low nanomolar sensitivity to pyridinyl imidazoles.  Furthermore, we identified 5-iodotubercidin as a potent ERK2 inhibitor, which may help reveal the role of ERK2 in cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrlKBLv_uYKLVg90H21EOLACvtfcHk0ljrLHNSaX2Trg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1GrsLs%253D&md5=fccebbc08468e60512d2598440f64b25</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560071102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560071102%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DT.%26aulast%3DColl%26aufirst%3DJ.%2BT.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DPorter%26aufirst%3DM.%2BD.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DFleming%26aufirst%3DM.%2BA.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DSu%26aufirst%3DM.-S.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DA%2520single%2520amino%2520acid%2520substitution%2520makes%2520ERK2%2520susceptible%2520to%2520pyridinyl%2520imidazole%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%26jtitle%3DProtein%2520Sci.%26date%3D1998%26volume%3D7%26spage%3D2249%26epage%3D2255%26doi%3D10.1002%2Fpro.5560071102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morrison, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, S. R.</span><span> </span><span class="NLM_article-title">Approaches to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors</span> <span class="citation_source-journal">Comments Mol. Cell. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADyaL2MXkvVert7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1985&pages=347-368&author=J.+F.+Morrisonauthor=S.+R.+Stone&title=Approaches+to+the+study+and+analysis+of+the+inhibition+of+enzymes+by+slow-+and+tight-binding+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors</span></div><div class="casAuthors">Morrison, John F.; Stone, Stuart R.</div><div class="citationInfo"><span class="NLM_cas:title">Comments on Molecular and Cellular Biophysics</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">347-68</span>CODEN:
                <span class="NLM_cas:coden">CMCBDM</span>;
        ISSN:<span class="NLM_cas:issn">0143-8123</span>.
    </div><div class="casAbstract">A review and discussion with 25 refs. on the mechanism and kinetic anal. of enzyme slow- and tight-binding inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83f4j5LgZN7Vg90H21EOLACvtfcHk0ljrLHNSaX2Trg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXkvVert7o%253D&md5=26df0f1503bc3d749128b2e2ecd42eea</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26aulast%3DStone%26aufirst%3DS.%2BR.%26atitle%3DApproaches%2520to%2520the%2520study%2520and%2520analysis%2520of%2520the%2520inhibition%2520of%2520enzymes%2520by%2520slow-%2520and%2520tight-binding%2520inhibitors%26jtitle%3DComments%2520Mol.%2520Cell.%2520Biophys.%26date%3D1985%26volume%3D2%26spage%3D347%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Vonrhein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flensburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smart, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paciorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bricogne, G.</span><span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0ljrLHNSaX2Trg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Bricogne, G.; Blanc, E.; Brandl, M.; C, F.; Keller, P.; Paciorek, W.; P, R.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T.</span> <span class="citation_source-book">BUSTER</span>, version 2.11.4; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=F.+C&author=P.+Keller&author=W.+Paciorek&author=R.+P&author=A.+Sharff&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26btitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lg2oZ42eHdydQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=AAD22741" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=AAD22741','Genbank','AAD22741'); return false;">Genbank: AAD22741</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=L28824" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=L28824','Genbank','L28824'); return false;">Genbank: L28824</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d4011e8365-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i103"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00301">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26661"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b00301">10.1021/acs.jmedchem.5b00301</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Data collection and refinement statistics, <sup>1</sup>H and <sup>13</sup>C NMR spectra, VX-509 plasma and lymph node exposures, dose-dependent inhibition of PLN hyperplasia by tofacitanib, dose-dependent decrease in stimulated biomarker CD25 by tofacitinib, and VX-509 dog and rat concentration vs time plots (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Simplified molecular input line entry system (SMILES) notation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_001.pdf">jm5b00301_si_001.pdf (1.72 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00301/suppl_file/jm5b00301_si_002.csv">jm5b00301_si_002.csv (5.03 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00301&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00301%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-18%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00301" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0f2d77c00d197","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
